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ABSTRACT 
 Regulation of the in vivo half-lives of intracellular proteins is an important 
cellular process. Many intracellular proteins are short-lived, owing to their regulated and 
processive degradation by the Ubiquitin (Ub)-Proteasome System (UPS). In eukaryotes, 
the N-end rule pathway is one specific pathway within the UPS. The N-end rule pathway 
relates the identity of the N-terminal residue of a protein, or a protein fragment, to its in 
vivo half-life. Substrates of the N-end rule pathway are recognized by the presence of 
degradation signals, termed N-degrons. Recognition components of the N-end rule 
pathway are E3 ubiquitin ligases that are capable of binding to N-degrons. The N-end 
rule pathway consists of two distinct branches: the Arg/N-end rule pathway and the 
Ac/N-end rule pathway.  
 In the present studies, we demonstrate a complementary targeting of the rat 
serotonin N-acetyltransferase (AANAT), an important mediator of circadian physiology, 
by both branches of the N-end rule pathway. The co-targeting results from incomplete N-
terminal (Nt-) acetylation of a Met-$  motif at the N-terminus of AANAT in vivo. In the 
same study, we demonstrate that human AANAT is substantially longer-lived than its rat 
counterpart, owing to differences in their N-terminal sequences. This molecular genetic 
investigation of  the degradation of a physiological N-end rule substrate followed an 
analogous earlier study, in which we reported that a clinically-relevant (blood pressure-
increasing) Q2L mutant of human RGS2 (termed ML-RGS2), a regulator of G proteins, 
could likewise be co-targeted by both branches of the N-end rule pathway. Together, 
AANAT and RGS2 are the first identified and characterized physiological substrates of 
the Ac/N-end rule pathway in mammals.    
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 We also report on the development and use of in vitro N-terminal arginylation 
(Nt-arginylation) assays using CelluSpots peptide arrays, in conjunction with pulse-chase 
assays in rabbit reticulocyte extract, for the systematic investigation of the effects of N-
terminus-proximal sequence context on the Nt-arginylation activity of the Ate1 
arginyltransferase, a component of the Arg/N-end rule pathway. These experiments help 
to define the sequence requirements for efficient Nt-arginylation by Ate1. Finally, we 
demonstrate that Rec8, a subunit of the cohesin protein complex during meiosis, is a 
natural short-lived substrate of the mammalian Arg/N-end rule pathway. 
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CHAPTER 1: 
INTRODUCTION TO THE N-END RULE PATHWAY 
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INTRODUCTION 
The Ubiquitin-Proteasome System 
 The regulated and processive degradation of intracellular proteins is carried out 
largely by the ubiquitin-proteasome system, in conjunction with molecular chaperones, 
autophagy, and lysosomal proteolysis. The half-lives of proteins in a cell range from as 
brief as a few seconds to many days. The functions of protein regulation through 
proteolysis include the destruction of regulatory proteins whose concentrations must vary 
with time and changes in the state of a cell, the generation of protein fragments that can 
act as hormones, antigens, or other effectors, the maintenance of amino acid pools in 
cells, the elimination of abnormal proteins, and the control of subunit stoichiometries 
within protein complexes (1-3).  
In eukaryotes, proteins are targeted for degradation by conjugation of the 76-
residue ubiquitin (Ub) protein to a protein substrate that contains a degradation signal, 
termed a degron (4). Following ubiquitylation, proteins are targeted to and recognized by 
the 26S proteasome, a processive, ATP-dependent protease (5). In the canonical 
mechanism of substrate ubiquitylation, Ub is conjugated to a specific Lys residue in a 
substrate protein, and then polyubiquitin chains are assembled on the substrate through 
linkage of the C-terminal Gly76 of one Ub to the Lys48 residue of the preceding Ub, thus 
forming a Lys48-linked polyUb Chain (6). Conjugation of Ub to another protein requires 
three sequential reactions. In the first step, the C-terminal Gly76 residue of Ub is joined 
via a thioester linkage to a Cys residue of an E1 Ub-activating enzyme, in an ATP-
dependent reaction. In the second step, the “activated” Ub is transferred to a Cys residue 
in an E2 Ub-conjugating enzyme. In the third step, the Ub is transferred by an E3 
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ubiquitin ligase to (most commonly) a Lys residue in the target substrate, where it is 
linked to an µ-amino group of the Lys via an isopeptide bond (7) (Fig. 1.1).   
A polyubiquitylated protein is targeted to the 26S proteasome, a multisubunit, 
ATP-dependent protease that recognizes, unfolds, deubiquitylates, and processively 
degrades the ubiquitylated substrate. The 26S proteasome is comprised of a 20S core 
particle (CP) and a 19S particle (also known as the regulatory particle (RP)). Recognition 
of substrates by the proteasome is mediated through binding of the 19S RP to the 
substrate’s poly-Ub chain. After binding of the substrate to the 19S RP, its polyubiquitin 
linkage is disassembled by deubiquitylase activity, the protein is at least partially 
unfolded, and it is then translocated into the 20S CP (5,8). The hollow 20S CP chamber 
contains proteolytic activities that degrade substrates to short peptides, which can then be 
further degraded to amino acids by cytosolic peptidases, following the release of short 
peptides from the proteasome (9,10). 
In addition to the canonical Lys48-linked polyubiquitin chains, Ub can also be 
conjugated to a substrate as a mono-Ub moiety, or polyubiquitin chains assembled 
through the use of other (non-Lys48) Lys residues in Ub. In addition, polyubiquitin 
chains can also be linked to specific Thr, Ser, or Cys residues in the substrate protein, or 
through the conjugation of Ub to the N-terminus of a substrate protein (11). Although 
polyubiquitin chains formed through nearly any of the seven Lys residues in Ub can 
target proteins for degradation, these (non-Lys-48) substrate-liked polyubiquitin chains 
also have diverse non-proteolytic functions (11-14).    
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The N-end Rule Pathway 
 In 1986, the N-end rule pathway became the first specific pathway of the Ub-
proteasome system to be discovered (15,16). The N-end rule pathway relates the identity 
of a protein’s N-terminal residue to its in vivo half-life. N-terminal degradation signals of 
the N-end rule pathway are called N-degrons, and recognition components of the N-end 
rule pathway are called N-recognins (1). The primary determinant of an N-degron is a 
destabilizing N-terminal residue of a protein. In eukaryotes, E3 Ub ligases that bind to 
specific N-degrons function as N-recognins, whereas in prokaryotes the 12-kDa protein 
ClpS functions as an N-recognin (17). The eukaryotic N-end rule pathway consists of two 
branches, the Arg/N-end rule pathway (discovered in 1986), and the Ac/N-end rule 
pathway (discovered in 2010).  
 
The Arg/N-end Rule Pathway 
 The Arg/N-end rule pathway targets proteins for degradation through the 
recognition of specific unacetylated N-terminal residues by E3 N-recognins, termed 
Arg/N-recognins. Unacetylated N-terminal Arg, Lys, His, Leu, Ile, Phe, Trp, Tyr, Asp, 
Glu, Asn, Gln, and Cys comprise the main determinants of N-degrons in the Arg/N-end 
rule pathway. These residues become N-terminal through either the cotranslational 
removal of Met by Met-aminopeptidase (MetAPs), or following the posttranslational and 
conditional cleavage by nonprocessive proteases, such as, for example, calpains, 
caspases, and separases. Additionally, it was recently shown that the unacetylated N-
terminal Met residue, when followed by a bulky hydrophobic ($ ) residue, can also act as 
a primary destabilizing residue (18).   
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 E3 ligases that function as Arg/N-recognins contain highly spalogous (spatially 
similar (19))  ~80-residue regions called UBR domains or Type-1 binding sites (20-23). 
A UBR domain binds to the Type-1 primary destabilizing N-terminal residues Arg, Lys, 
or His. A second, usually adjacent, region of Arg/N-recognins, called the Type-2 binding 
site, recognizes N-terminal Leu, Ile, Phe, Trp, and Tyr. Together, the directly recognized 
N-terminal basic (Arg, Lys, His) and bulky hydrophobic (Leu, Ile, Phe, Trp, and Tyr) 
residues are denoted as “primary” destabilizing residues.  
 In contrast to the primary destabilizing residues, N-terminal Asp, Asn, Glu, Gln, 
and Cys function as destabilizing residues following their preliminary modifications, and 
are thus denoted as “secondary” or “tertiary” destabilizing residues, depending on the 
number of modifications required before targeting by N-recognins. One of the 
preliminary modifications is N-terminal arginylation (Nt-arginylation), in which the Arg-
tRNA-protein transferase (R-transferase) conjugates Arg to N-terminal Asp, Glu, or 
oxidized Cys of proteins or peptides. R-transferases, which are apparently confined to 
eukaryotes, are encoded by the Ate1 gene and utilize Arg-tRNA as the cosubstrate and 
donor of Arg (24-27).  Although R-transferases cannot directly arginylate N-terminal Asn 
or Gln, the Arg/N-end rule pathway contains specific N-terminal amidases (Nt-amidases) 
that enzymatically convert N-terminal Asn and Gln (tertiary destabilizing residues) to 
Asp and Glu, respectively, which can then be Nt-arginylated (28-32) (Fig. 4.4).  
 An unmodified N-terminal Cys residue of a protein is yet another tertiary 
destabilizing residue, as it must undergo two modifications (oxidation and then 
arginylation) prior to recognition and binding of the substrate by an N-recognin. If the N-
terminal Cys can be oxidized, through either enzymatic reactions mediated by N-terminal 
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Cys oxidases or non-enzymatic reactions that require nitric oxide (NO) and oxygen, the 
resulting Cys-sulfinate or Cys-sulfonate can then be Nt-arginylated by the Ate1 R-
transferase (33,34). The requirement for NO- and oxygen-dependent oxidation of N-
terminal Cys-containing substrates makes the Arg/N-end rule pathway a mechanistically 
distinct sensor of both NO and oxygen (34,35).  
 Early studies of the S. cerevisiae Arg/N-end rule pathway indicated that 
polyubiquitylation of substrates was mediated by a dimer comprised of the 225 kDa Ubr1 
E3 ubiquitin ligase and the Ubr1-bound 20 kDa Rad6 E2 ubiquitin-conjugating enzyme 
(1,36-38). More recently, the targeting apparatus was discovered to be more elaborate, 
comprising a physical complex of the RING-type Ubr1 E3 N-recognin and the HECT-
type Ufd4 E3, in association with their cognate E2s Rad6 and Ubc4/Ubc5, respectively 
(39,40). Ufd4 is the E3 of the Ub-fusion degradation (UFD) pathway that recognizes a 
“non-removable” N-terminal Ub moiety of a Ub fusion as a primary degron, and 
polyubiquitylates the moiety, leading to the fusion’s proteasome-dependent degradation 
(41,42). The UFD4 pathway is present in both yeast and mammals, suggesting that the 
double-E3 organization (Ubr1-Ufd4) of the S. cerevisiae Arg/N-end rule pathway is 
universal among eukaryotes (39).  
 In contrast to S. cerevisiae, in which Ubr1 is the sole N-recognin of the Arg/N-
end rule pathway, the genomes of multicellular eukaryotes, such as mammals, encode at 
least four UBR domain-containing E3 N-recognins, termed Ubr1, Ubr2, Ubr4, and Ubr5 
(also known as Edd). Mammalian Ubr1 and Ubr2 are highly sequelogous N-recognins, 
whereas the sequelogy between Ubr1 and Ubr4 or Ubr5 is confined largely to their ~80 
residue UBR domains. Mammalian Ubr1, Ubr2, and Ubr4 N-recognins contain both 
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Type-1 and Type-2 binding sites, whereas Ubr5/Edd N-recognin lacks the Type-2 
binding site.  
 Regulated degradation of proteins or their fragments by the N-end rule pathway 
mediates a strikingly broad range of functions, including the sensing of heme, NO, 
oxygen, and short peptides; the selective elimination of misfolded proteins; the regulation 
of DNA repair through the degradation of the Mgt1 DNA repair protein; the 
cohesion/segregation of chromosomes through the degradation of a subunit of cohesin; 
signaling by transmembrane receptors through the degradation of the G-protein regulators 
Rgs2, Rgs4, Rgs5, and Rgs16; the control of peptide import through the degradation of 
Cup9; the regulation of apoptosis, meiosis, viral and bacterial infections, fat metabolism, 
cell migration, actin filaments, cardiovascular development, spermatogenesis, 
neurogenesis, and memory; the function of adult organs, including the brain, muscle, 
testis, and pancreas; and the regulation of leaf and shoot development, leaf senescence, 
and seed germination in plants (3,35,43-60).  
            In Chapter 2 of this thesis we further expand the functions of the Arg/N-end rule 
pathway to include the degradation of the AANAT enzyme, an important regulator of 
circadian physiology, and in Chapter 5 we expand these functions to include the 
degradation of the separase-cleaved mouse REC8, a subunit of cohesin complexes during 
meiosis. Mutational inactivation of human UBR1 causes Johanson-Blizzard syndrome, a 
set of severe birth defects (JBS). Ubr1-lacking mice exhibit phenotypes that partially 
overlap with those of human JBS patients (52). Ubr2-lacking mice have a variety of 
defects, including genomic instability and impaired spermatogenesis (as well as 
infertility) in males (61,62). 
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The Ac/N-end Rule Pathway 
 The second branch of the N-end rule pathway, termed the Ac/N-end rule pathway, 
was discovered by our laboratory in 2010, 24 years after discovery of the Arg/N-end rule 
pathway (63). This branch involves the cotranslational N±-acetylation (Nt-acetylation) of 
nascent proteins whose N-termini bear either Met or the small, uncharged residues Ala, 
Cys, Ser, Thr, or Val. These residues become N-terminal after the cotranslational removal 
of the N-terminal Met residue by Met-aminopeptidases (MetAPs), and can be 
cotranslationally Nt-acetylated by specific ribosome Nt-acetylases, thereby forming 
degradation signals that can be recognized by the Ac/N-end rule pathway (64-68). 
 The Nt-acetylated Met, Ala, Cys, Ser, Thr, and Val residues comprise a class of 
N-degrons termed Ac/N-degrons (63). The cotranslational Nt-acetylation of nascent 
proteins is both mechanistically and functionally distinct from the largely 
posttranslational acetylation of internal Lys residues in many proteins (65,69-79). 
Furthermore, in contrast to acetylation of internal lysines, Nt-acetylation is apparently 
irreversible (there are, apparently, no N-terminus-specific deacetylases). Previous studies 
of Nt-acetylation have characterized the specificity and activity of Nt-acetyltransferases 
that catalyze this enzymatic reaction, but the biological function of Nt-acetylation 
remained largely unknown. The discovery of the Ac/N-end rule pathway revealed a 
major physiological role of both Nt-acetylases and MetAPs (2,63).  
 In S. cerevisiae, the Ac/N-end rule pathway is mediated by, at least, the RING-
type Doa10 and Not4 E3 ligases. Doa10, an endoplasmic reticulum (ER)-embedded E3, 
functions together with the Ubc6/Ubc7 E2 enzymes, and is capable of targeting both 
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“soluble” (nuclear and cytosolic) and transmembrane proteins (80). In mammalian cells, 
this pathway is mediated by, at least, Teb4 (see Chapter 3), which is sequelogous to the 
yeast Doa10 E3 Ub ligase (81).  
 Together, the Arg/N-end rule pathway and the Ac/N-end rule pathway are capable 
of targeting a majority of cellular proteins for regulated degradation. More than 80% of 
human proteins are cotranslationally Nt-acetylated by ribosome-associated Nt-acetylases. 
Consequently, most proteins are likely to harbor an Ac/N-degron from the moment of 
their birth. (This statement is still inferential, awaiting more extensive, proteome-scale 
analyses that would determine how many of Nt-acetylated proteins actually bear an at 
least transiently active Ac/N-degron. The current assumption, based on already existing 
lines of evidence (refs. of 2010-2015), is that many, possibly most, Nt-acetylated proteins 
contain Ac/N-degrons.)  
Interestingly, the Arg/N-end rule and Ac/N-end rule pathways are not mutually 
exclusive for many substrates, as many proteins that can be Nt-acetylated are only 
partially Nt-acetylated in vivo, even under normal (unstressful) conditions. As a result 
(and for a subset of N-terminal residues), a partial Nt-acetylation of a protein can still 
allow its complete destruction through its complementary targeting by both Arg/N-
recognins and Ac/N-recognins (Fig 1.5). 
 One example of an N-terminal residue susceptible to “complementary” targeting 
by both branches of the N-end rule is N-terminal Cys, which can be Nt-acetylated (in 
proteins that contain the initially present N-terminal Met-Cys sequence) after the 
cotranslational removal of N-terminal Met by Met-aminopeptidases. However, some 
sequence contexts, for example, a basic residue at position 2 (following the removal of 
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Nt-Met), inhibit the Nt-acetylation of N-terminal Cys. The mammalian proteins Rgs4, 
Rgs5, and Rgs16 are one example of this inhibition. In each of these proteins, the N-
terminal Cys residue is followed by a basic residue, which inhibits Nt-acetylation and 
thereby facilitates for Ate1 R-transferase-dependent Nt-arginylation of these proteins, 
following the conditional oxidation of their N-terminal Cys), and subsequent recognition 
of the N-terminal Arg residue by the Ubr1 E3 ligase.  
Despite the current understanding of the sequence specificity of the Ate1 R-
transferase (Fig. 1.2), a more complete understanding remained to be attained. For 
example, it remained unclear exactly how the Nt-arginylation of activity of Ate1 is 
influenced by specific sequence and conformational features of proteins bearing N-
terminal Asp, Gly, and Cys residues, the “canonical” sequence determinants recognized 
by Ate1. Moreover, over the last decade there were several, still extant, lines of (non-
definitive) evidence in the published literature that claimed the ability of Ate1 to Nt-
arginylate “non-canonical” Nt-sequences as well. In Chapter 4, we utilize an in vitro 
arginylation assay and Celluspots peptide arrays, in combination with rabbit reticulocyte-
based pulse-chase degradation assays, to systematically investigate the effects of 
sequence context on the Nt-arginylation of peptides containing N-terminal Asp, Glu, and 
Cys.  
A second example of N-terminal residues that are susceptible to complementary 
targeting by both branches of the N-end rule pathway is N-terminal Met when it is 
followed by a hydrophobic residue ($ ). As mentioned above, the N-terminal Met residue 
is permissive for Nt-acetylation, thus making it possible for proteins that retain N-
terminal Met and become Nt-acetylated to be targeted for degradation by the Ac/N-end 
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rule pathway. However, in cases where Nt-acetylation of N-terminal Met is incomplete, 
the unmodified N-terminal Met can be recognized by the Ubr1 Arg/N-recognin of the 
Arg/N-end rule pathway, if Nt-Met if followed by a bulky hydrophobic residue (18).  
In Chapter 2 we show that the rat serotonin N-acetyltransferase (AANAT), an 
important mediator of circadian physiology, is targeted for degradation via 
complementary recognition of its partially-acetylated N-terminal M $  (Met-Leu-) 
sequence by both branches of the N-end rule pathway. In Chapter 3, we demonstrate that 
a clinically-relevant Q2L mutant of human RGS2 (termed ML-RGS2) is also co-targeted 
for degradation by both the Arg/N-end rule and Ac/N-end rule pathways, owing to its 
incomplete Nt-acetylation (55,82). Together, these studies advance our knowledge of 
how both branches of the N-end rule pathway can work together to ensure efficient 
overall degradation of at least a subset of incompletely Nt-acetylated protein substrates. 
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Fig. 1.1. The ubiquitin-proteasome system (UPS).  The ubiquitin-proteasome system 
(Ub system). The conjugation of Ub to other proteins involves a preliminary ATP-
dependent step in which the last residue of Ub (Gly76) is joined, via a thioester bond, to a 
Cys residue of the E1 (Ub-activating) enzyme. The “activated” Ub moiety is transferred 
to a Cys residue in one of several Ub-conjugating (E2) enzymes, and from there, through 
an isopeptide bond, to a Lys residue of an ultimate acceptor, denoted as “protein”. E2 
enzymes function as subunits of E2-E3 Ub ligase complexes that can produce substrate-
linked poly-Ub chains. Such chains have specific Ub-Ub topologies, depending on the 
identity of a Lys residue of Ub (which contains several lysines) that forms an isopeptide 
bond with C-terminal Gly76 of the adjacent Ub moiety in a chain. Specific poly-Ub chains 
can confer the degradation of a substrate by the 26S proteasome or other metabolic fates. 
Monoubiquitylation of some protein substrates can also occur, and has specific functions. 
One role of E3 is the recognition of a substrate's degradation signal (degron). Individual 
mammalian genomes encode at least 1,000 distinct E3 Ub ligases. 
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Fig. 1.2. The mammalian Arg/N-end rule pathway. N-terminal residues are indicated 
by single-letter abbreviations for amino acids. Yellow ovals denote the rest of a protein 
substrate. “Primary”, “secondary”, and “tertiary” denote mechanistically distinct subsets 
of destabilizing N-terminal residues. C* denotes oxidized N-terminal Cys, either Cys-
sulfinate or Cys-sulfonate, produced in vivo through reactions that require both nitric 
oxide (NO) and oxygen. The mammalian N-recognins Ubr1, Ubr2, Ubr4, and Ubr5 (Edd) 
have multiple substrate binding sites that also recognize internal (non-N-terminal) 
degrons in other substrates of the Arg/N-end rule pathway, the ones that lack N-degrons. 
A question mark after Trip12 (which mediates the mammalian UFD pathway) and is a 
sequelog of the S. cerevisiae Ufd4 E3) denotes the untested possibility that mammalian 
Ubr1 and/or Ubr2 form complexes with Trip12, by analogy with the Ubr1–Ufd4 complex 
in S. cerevisiae. 
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Fig. 1.3. The N-end rule pathway in Saccharomyces cerevisiae. A. The Arg/N-end rule 
pathway. Yellow ovals denote the rest of a protein substrate. “Primary”, “secondary” and 
“tertiary” denote mechanistically distinct subsets of destabilizing N-terminal residues. 
The physically associated Ubr1 (N-recognin) and Ufd4 E3s have substrate-binding sites 
that recognize internal (non-N-terminal) degrons in substrates of the Arg/N-end rule 
pathway that lack N-degrons. Ubr1 (but not Ufd4) recognizes N-degrons as well.  B. The 
Ac/N-end rule pathway. Red arrow on the left indicates the removal of N-terminal Met 
by Met-aminopeptidases (MetAPs). This Met residue is retained if a residue at Position 2 
is nonpermissive (too large) for Met-aminopeptidases. If the (retained) N-terminal Met or 
N-terminal Ala, Val, Ser, Thr and Cys are followed by residues that allow Nt-acetylation 
(see the main text), these N-terminal residues are usually Nt-acetylated. The resulting N-
degrons are called AcN-degrons. The term “secondary” refers to the necessity of 
modification (Nt-acetylation) of a destabilizing N-terminal residue before a protein can 
be recognized by a cognate Ub ligase. Proteins containing AcN-degrons are targeted for 
ubiquitylation and proteasome-mediated degradation by the Doa10 E3 N-recognin, in 
conjunction with the Ubc6 and Ubc7 E2 enzymes. Although Gly and Pro can be made N-
terminal by MetAPs, and although Doa10 can recognize Nt-acetylated Gly and Pro, few 
proteins with N-terminal Gly or Pro are Nt-acetylated. 
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Fig. 1.4. Specificities and subunit compositions of N± -terminal acetylases (Nt-
acetylases). A. Substrate specificities of S. cerevisiae Nt-acetylases. •Ac• denotes the N± 
-terminal acetyl moiety. The bulk of Nt-acetylases are associated with ribosomes. The 
specificities of mammalian Nt-acetylases are similar to those of their yeast counterparts, 
but an individual mammalian genome encodes more than ten Nt-acetylases, in contrast to 
four in S. cerevisiae. Some mammalian Nt-acetylases, such as NatF (its catalytic subunit 
is called Naa60, can Nt-acetylate N-terminal motifs that include Met-Lys or Met-Arg, 
which are rarely if ever Nt-acetylated in S. cerevisiae. This compilation of Nt-acetylases 
and their specificities is derived from data in the literature. (B) Subunits of S. cerevisiae 
Nt-acetylases.  
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Fig. 1.5.  Functional complementarity between the Arg/N-end rule and Ac/N-end 
rule pathways. This complementarity stems from the recognition of unacetylated 
Met¦ /N-degrons in Met-¦  proteins vs. the recognition of the Nt-acetylated AcMet¦ /N-
degrons in AcMet-¦  proteins. AcMet¦ /N-degrons are a subset of Ac/N-degrons in Nt-
acetylated cellular proteins. Met-¦  proteins are defined, in this study, as those that bear 
N-terminal Met followed by a large hydrophobic (¦ ) non-Met residue. 
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INTRODUCTION 
Arylalkylamine N-acetyltransferase (AANAT) converts the neurotransmitter 
serotonin to N-acetylserotonin (NAS) (1-11). Regulatory functions of NAS include its 
activity as an agonist of TrkB, the receptor for the brain-derived neurotrophic factor 
(BDNF) (12-14). NAS is the immediate precursor of melatonin, a circulating hormone 
that regulates sleep and other circadian processes in vertebrates. Melatonin is also present 
in invertebrates, including insects, as well as in animals that lack recognizable neurons 
(1,15-21). The functions of melatonin in mammals include the modulation of circadian 
rhythms in response to light-dark cycles. Melatonin also contributes to the control of 
seasonal physiology (20). These mechanisms are a part of a broader range of processes 
that involve distinct biological oscillators in all organisms (22-24). In the course of daily 
light-dark cycles, the activity of AANAT and the level of the ~23-kDa AANAT protein 
in the brain’s pineal gland are high during nocturnal periods and rapidly decrease 
following exposure to light (1,20,25). 
In mammals, changes of AANAT levels in the brain’s pineal gland are controlled 
by the circadian oscillator in the suprachiasmatic nucleus (SCN) of the hypothalamus. At 
night, axons of rodent superior cervical ganglion neurons release norepinephrine (NE) in 
the pineal gland, in response to circadian signals from the SCN, thereby activating 
adrenergic receptors to increase intracellular Ca2+ and cAMP. The resulting 
phosphorylation of CREB, the cAMP response element (CRE)-binding protein, 
upregulates the Aanat transcriptional promoter, which contains CRE sequence elements 
(1,4,25-27). Increases in cAMP also stimulate site-specific phosphorylation of AANAT 
by the protein kinase A (PKA), thereby causing the binding of AANAT to 14-3-3 
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proteins. These transitions augment the enzymatic activity of AANAT and inhibit its 
degradation (1,6,7,28). While AANAT is predominantly expressed in the pineal gland 
and the retina, this enzyme (and, consequently, the AANAT-dependent synthesis of NAS 
and melatonin) is also present in cells of the gastrointestinal tract, and apparently at other 
sites as well, including the hippocampus, the olfactory bulb, the cerebellum, and the 
spinal cord (12,29,30). 
The activity of AANAT determines the rate of NAS synthesis. Melatonin is 
produced from NAS by hydroxyindole-O-methyltransferase (HIOMT). The levels of 
NAS, synthesized by AANAT, can constrain the rate of melatonin synthesis from NAS 
during light parts of daily cycles (when NAS levels are low) but appear to be not the rate-
limiting step during dark parts of these cycles, when both AANAT and NAS levels are 
high (21). In rodents such as rats the activity of AANAT starts to increase 3 to 4 h after 
the onset of darkness and begins to decrease before the onset of light in the morning 
(21,31). Therefore the importance of regulating the expression and enzymatic activity of 
AANAT, as these parameters determine the levels of both NAS and melatonin. 
Earlier studies have shown that the concentration of AANAT, a largely cytosolic 
enzyme (32), is controlled through both transcriptional and posttranslational mechanisms, 
and that vertebrate species can differ in their mode of AANAT regulation (1,11,31,33-
35). In rodents, the onset of darkness leads to an increase in melatonin (requiring a 
preceding increase of NAS) after a lag period, whereas in sheep and primates increases in 
melatonin occur rapidly upon the onset of darkness. The levels of Aanat mRNA in 
rodents can vary by >100-fold during light-dark cycles (10), whereas in non-rodent 
mammals, such as sheep for example, these differences can be as low as ~2-fold, 
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suggesting a major involvement of translational and/or posttranslational AANAT 
regulation in latter cases (11,36). In addition to variability in regulation at the level of 
AANAT-encoding mRNAs, AANAT is also unusual in the extent of variability of its N-
terminal amino acid sequences during vertebrate evolution (Fig. 1C). In 2010, one of our 
laboratories showed that N-terminal residues of rat AANAT play a role in the control of 
its degradation, suggesting that at least rodent AANATs may be targeted for degradation 
by the N-end rule pathway (37). 
The N-end rule pathway is a set of cytosolic/nuclear proteolytic systems whose 
unifying feature is the ability to recognize and polyubiquitylate proteins containing 
N-terminal degradation signals (degrons) called N-degrons, thereby causing degradation 
of these proteins by the proteasome (Fig. 1A, B) (38-46). Ubiquitin (Ub) ligases of the N-
end rule pathway, called N-recognins, can recognize (bind to) not only N-degrons but 
also specific internal (non-N-terminal) degradation signals (47-50). The main determinant 
of an N-degron is either an unmodified or chemically modified destabilizing N-terminal 
residue of a protein. The identity of the next residue, at position 2, is often important as 
well. Another determinant of an N-degron is a protein’s internal Lys residue(s). It 
functions as the site of a protein’s polyubiquitylation and tends to be located in a 
conformationally disordered region (41,51,52). Bacteria also contain the N-end rule 
pathway, but Ub-independent versions of it (53-58). 
Regulated degradation of proteins and their natural fragments by the N-end rule 
pathway has been shown to mediate a strikingly broad range of biological functions, 
including the sensing of heme, nitric oxide (NO), oxygen, and short peptides; the control, 
through subunit-selective degradation, of the input stoichiometries of subunits in 
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oligomeric protein complexes; the elimination of misfolded or otherwise abnormal 
proteins; the degradation of specific proteins after their retrotranslocation to the cytosol 
from mitochondria or other membrane-enclosed compartments; the regulation of 
apoptosis and repression of neurodegeneration; the regulation of DNA repair, 
transcription, replication, and chromosome cohesion/segregation; the regulation of 
G proteins, cytoskeletal proteins such as actin and myosin, autophagy, peptide import, 
meiosis, immunity, fat metabolism, cell migration, cardiovascular development, 
spermatogenesis, and neurogenesis; the functioning of adult organs, including the brain, 
muscle, testis, and pancreas; and the regulation of leaf and shoot development, leaf 
senescence, and many other processes in plants (Figs. 1A, B) ((41-46) and references 
therein). 
In eukaryotes, the N-end rule pathway consists of two branches. One branch, 
called the Ac/N-end rule pathway, targets proteins for degradation through their N±-
terminally acetylated (Nt-acetylated) residues (Fig. 1B) (39,40,46,59-62). Degradation 
signals and E3 Ub ligases of the Ac/N-end rule pathway are called Ac/N-degrons and 
Ac/N-recognins, respectively. Nt-acetylation of cellular proteins is apparently 
irreversible, in contrast to acetylation-deacetylation of proteins’ internal Lys residues. 
About 90% of human proteins are cotranslationally Nt-acetylated by ribosome-associated 
Nt-acetylases (63). Posttranslational Nt-acetylation is known to occur as well. Ac/N-
degrons are present in many, possibly most, Nt-acetylated proteins (Fig. 1B). Natural 
Ac/N-degrons are regulated through their reversible shielding in cognate protein 
complexes (59). 
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The pathway’s other branch, called the Arg/N-end rule pathway, targets specific 
unacetylated N-terminal residues (Fig. 1A) (40,64-68). The “primary” destabilizing 
N-terminal residues Arg, Lys, His, Leu, Phe, Tyr, Trp, and Ile are directly recognized by 
N-recognins. The unacetylated N-terminal Met, if it is followed by a bulky hydrophobic 
($ ) residue, also acts as a primary destabilizing residue (Fig. 1A) (40). In contrast, the 
unacetylated N-terminal Asn, Gln, Asp, and Glu (as well as Cys, under some metabolic 
conditions) are destabilizing owing to their preliminary enzymatic modifications, which 
include N-terminal deamidation (Nt-deamidation) of Asn and Gln and Nt-arginylation of 
Asp, Glu and oxidized Cys (Fig. 1A) (41-43,69). In the yeast Saccharomyces cerevisiae, 
the Arg/N-end rule pathway is mediated by the Ubr1 N-recognin, a 225 kDa RING-type 
E3 Ub ligase and a part of the targeting complex comprising the Ubr1-Rad6 and 
Ufd4-Ubc4/5 E2-E3 holoenzymes (41,70). In multicellular eukaryotes, several E3 Ub 
ligases, including Ubr1, function as N-recognins of the Arg/N-end rule pathway (Fig. 
1A). 
In S. cerevisiae, the Ac/N-end rule pathway is mediated by (at least) the 
cytosolic/nuclear E3 Ub ligase Not4 and by Doa10, an endoplasmic reticulum (ER) 
membrane-embedded E3 (59). In mammalian cells, this pathway is mediated by (at least) 
the Teb4 E3, which is sequelogous (similar in sequence (71)) to yeast Doa10 (60). 
Human RGS2, a regulator of specific G proteins, has been shown to be a short-lived 
substrate of the Ac/N-end rule pathway both in mammalian cells and in the heterologous 
setting of S. cerevisiae (60,72,73). In addition, the naturally occurring (blood pressure-
elevating) human RGS2Q2L mutant (in which Gln at position 2 is replaced by Leu) is 
targeted for degradation by both the Ac/N-end rule pathway and the Arg/N-end rule 
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pathway in either yeast or mammalian cells (60). The Ac/N-end rule pathway recognizes 
the Nt-acetylated Ac-RGS2Q2L (specifically, its N-terminal Ac-Met residue), whereas the 
non-Nt-acetylated RGS2Q2L is targeted (through its N-terminal Met-Leu sequence) by the 
Arg/N-end rule pathway (60).  
In the present work, we analyzed the proteasome-mediated degradation of rat 
AANAT (37), whose N-terminal sequence Met-Leu (Fig. 1C) is identical to that of the 
previously examined and otherwise unrelated human RGS2Q2L protein (60). We also 
characterized human AANAT, which is highly sequelogous (71) (84% identical) to rat 
AANAT but bears a different N-terminal sequence (Fig. 1C). Our analyses employed, 
among other things, the previously helpful approach of dissecting degradation of a 
mammalian protein of interest not only in a homologous (mammalian) setting but also in 
S. cerevisiae (60,66), thereby making possible the use of yeast genetics.  
We show here that two alternative versions of rat AANAT, its Nt-acetylated and 
non-Nt-acetylated forms, are targeted for degradation by the Ac/N-end rule pathway and 
the Arg/N-end rule pathway, respectively. In contrast, human AANAT, whose N-terminal 
sequence differs from that of rodent AANATs, is significantly longer-lived than its rat 
counterpart, and appears to be largely refractory to degradation by the N-end rule 
pathway. Together, these and related results indicate both a major involvement of the N-
end rule pathway in the control of rodent AANATs and substantial differences in the 
regulation of rodent and human AANATs that stem from differences in their N-terminal 
sequences.  
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EXPERIMENTAL PROCEDURES 
Yeast Strains, Media, and Genetic Techniques – Standard yeast genetic techniques 
were used (74-76). S. cerevisiae strain BWY29 was constructed by transforming the 
strain CHY345 (ubr1• ::LEU2 in the strain background of BY4742) with a PCR-
amplified DNA fragment that encoded the selection marker KanMX6 (making cells 
resistant to kanamycin) and was targeted to the 5’ and 3’ flanking regions of the NAA10 
gene, thereby replacing the open reading frame (ORF) of NAA10 with KanMX6 (Table 
S1). S. cerevisiae strain JOY487 was made by transforming BY4742 with a PCR-
amplified DNA fragment that encoded the natNT2 marker (making cells resistant to 
nourseothricin) and was targeted to the 5’ and 3’ flanking regions of the PDR5 gene, 
thereby replacing the ORF of PDR5 with natNT2 (Table S1). The resulting pdr5•  cells 
were used in experiments that involved the MG132 proteasome inhibitor (Fig. A1.S1A, 
B). Other S. cerevisiae strains used in this study were constructed previously and are 
cited in Table S1.  
S. cerevisiae were transformed using the LiAc/PEG method (77). S. cerevisiae 
media included YPD medium (1% yeast extract, 2% peptone, 2% glucose; only the most 
relevant components are cited); synthetic complete (SC) medium (0.17% yeast nitrogen 
base, 0.5% ammonium sulfate, 2% glucose); and synthetic drop-out (SD) medium (0.17% 
yeast nitrogen base, 0.5% ammonium sulfate, 2% glucose, plus a drop-out mixture of 
amino acids as required by a given auxotrophic strain) (75,76). 
Plasmids, cDNAs, and Primers – NEB Turbo Escherichia coli (New England 
Biolabs (NEB), Ipswich, MA) was used for cloning and maintaining plasmids. Phusion 
High-Fidelity DNA polymerase (NEB) was used for carrying out PCR. Nucleotide 
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sequences of all plasmids were verified by DNA sequencing. The plasmids and PCR 
primers used in this study are described in Tables S2 and S3, respectively. 
The low copy pBW105, pBW106, pBW107, and pBW209 plasmids expressed 
respectively, the wild-type rat MLSrAANAT3f (wild-type rat AANAT bearing the N-
terminal sequence Met-Leu-Ser and C-terminally tagged with a triple-FLAG epitope) and 
its N-terminal mutants (M)SIrAANAT3f, (M)SMLSrAANAT3f, and (M)PLSrAANAT3f from the 
PGAL1 promoter. To construct these plasmids, the rat Aanat ORF was amplified from 
pCISII-rAANAT (78), using primers BW2394, BW240, BW241, BW412, BW243, and 
BW244 (Table S3). The resulting PCR products were digested with EcoRI and HindIII, 
and cloned in EcoRI/HindIII-cut pRS416GAL1. See items i-iv at the beginning of Results 
for information about the above rat AANAT notations. 
The low copy pBW135 and pBW394 plasmids expressed, respectively, the 
wild-type rat MLSrAANAT C-terminally tagged with the triple-HA epitope 
(MLSrAANAT3ha) and its Lys-8-to-Arg-8 mutant MLSrAANAAT3haK8R from the PCUP1 
promoter. To construct these plasmids, the rat Aanat ORF was amplified from 
pCISII-rAANAT (78) using primers BW339, BW704, BW338, BW339, BW340 (Table 
S3). The resulting PCR-amplified DNA fragments were digested with EcoRI and XhoI, 
and cloned in EcoRI/XhoI-cut pRS313CUP1 (59,79). See items v and vi at the beginning of 
Results for information about the above rat AANAT notations. 
The low copy pBW395 and pBW419 plasmids expressed, respectively, the 
wild-type human (M)SThAANAT C-terminally tagged with a triple-FLAG epitope 
((M)SThAANAT3f) and its N-terminal mutant (M)PThAANAT3f from the PGAL1 promoter. To 
construct these plasmids, the human AANAT ORF from Genscript Clone #OHu55705 
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(Genscript, Piscataway, NJ) was amplified using primers BW705, BW711, BW712, and 
BW244, or primers BW771, BW711, BW712, and BW244, respectively (Table S3). The 
PCR-amplified DNA fragments were digested with EcoRI and HindIII, and were ligated 
into EcoRI/HindIII-cut pRS416GAL1 (79). See items vi and vii at the beginning of Results 
for information about the above human AANAT notations. 
For expression of the above AANAT-encoding ORFs in human HEK293T cells, a 
wild-type Aanat ORF and its derivatives were cloned into a modified expression vector 
derived from pcDNA3. That (modified) plasmid, termed pcDNA3CMVt1, contained a 
truncated (weakened) version of the PCMV promoter, termed PCMVt1. The pcDNA3CMVt1 
plasmid was constructed by amplifying, using PCR, the 276-base pairs (bp) fragment that 
encompassed 104 bp at the 3’ end of the PCMV promoter region in pcDNA3, its T7 
promoter site, and its multiple cloning site, using primers BW375 and BW376 (Table 
S3). The amplified DNA fragment was digested with NruI and XbaI and ligated into 
NruI/XbaI-cut pcDNA3, yielding the plasmid pBW173 (Tables S2). Its truncated PCMVt1 
promoter retained several proximal promoter elements, including a consensus NFkB site, 
a CREB-binding site, and two SP1/SP3-binding sites, but lacked more distal enhancer 
elements. This resulted in a ~70% lower activity of the PCMVt1 promoter in HEK293T 
cells, in comparison to PCMV (Fig. A1.S3A-C). 
The pcDNA3CMVt1-based plasmids pBW206, pBW211, pBW212, and pBW213 
expressed, in HEK293T cells, either the wild-type rat MLSrAANAT3f or its N-terminal 
mutants (M)SIrAANAT3f, (M)SMLSrAANAT3f, and (M)PLSrAANAT3f from the PCMVt1 
promoter. To construct these plasmids, the Aanat ORF was amplified from the plasmids 
pBW105, pBW106, pBW107, and pBW209 using primers BW352, BW353, BW354, 
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BW413, and BW355, respectively (Table S3). The amplified DNA fragments were 
digested with EcoRI and XhoI, and ligated in EcoRI/XhoI-cut pBW173 (Table S2). All 
pcDNA3-based constructs designed for expression in HEK293T cells contained the 
Kozak sequence 5’-ACC immediately upstream of the start codon. 
pBW477, which expressed the MLSrAANAT3ha from the PCMVt1 promoter, was 
constructed by using pBW135 as a PCR template and the primers BW352/BW340. The 
resulting PCR-amplified DNA fragment was digested with EcoRI and XhoI, and ligated 
into EcoRI/XhoI-cut pBW173 (Table S2). pBW478 expressed MLSrAANAAT3haKzero, i.e., 
the lysine-lacking derivative of MLSrAANAT3ha. It was constructed by using pBW135 as a 
PCR template to generate four separate DNA fragments containing lysine-to-arginine 
mutations. The primer pairs were 704/784, 785/786, 787/788, and 789/340 (Table S3). 
These fragments were then assembled into a contiguous ORF using PCR. The resulting 
DNA fragment, encoding lysine-to-arginine mutations at each of the 4 lysines contained 
in the wild-type rat MLSrAANAT3f, was digested with EcoRI and XhoI, and ligated into 
EcoRI/XhoI-cut pBW173. 
pBW466 and pBW467, the pcDNA3-based counterparts of pBW395 and 
pBW419 (Table S2) were generated by PCR using pBW395 and pBW419 as templates, 
and the primers BW866/BW355 and BW868/BW355, respectively (Table S3). PCR-
amplified DNA fragments were digested with EcoRI and XhoI and ligated into 
EcoRI/XhoI-cut pBW173 (Table S2). 
Cell Culture – The HEK293T cell line (derived from human embryonic kidney 
cells) was obtained from American Type Culture Collection (ATCC, Manassas, VA), and 
was grown at 37°C in 5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM) medium 
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supplemented with 10% fetal bovine serum (FBS) (Gemini Bio-Products, West 
Sacramento, CA) and penicillin/streptomycin (100 units/ml; Hyclone). Cells were 
transfected using Lipofectamine-2000 (Invitrogen) according to the manufacturer’s 
protocol.  
Cycloheximide Chase Assay in S. cerevisiae – Cycloheximide (CHX) chase 
assays in S. cerevisiae were performed largely as described (39,59). Briefly, S. cerevisiae 
cells were grown in overnight cultures, and expression of epitope-tagged test proteins 
was induced by the addition of 2% galactose (for plasmids containing the PGAL1 
promoter) or 0.1 mM CuSO4 (for plasmids containing the PCUP1 promoter (80)). 3 h post-
induction, CHX was added to the final concentration of 0.1 mg/ml. Samples were 
collected at the indicated time points, centrifuged at 11,200g for 2 min to pellet the cells, 
and snap-frozen in liquid nitrogen. Proteins were extracted by resuspending the pellets in 
1 ml of 0.2 M NaOH and incubating on ice for 20 min (81). Cells were then pelleted and 
resuspended in 50 µl of SUMEB loading buffer (1% SDS, 8 M urea, 10 mM EDTA, 
0.01% bromophenol blue, 10 mM MOPS, pH 6.8), followed by heating at 95°C for 10 
min. Samples were then centrifuged at 11,200g for 5 min, followed by the SDS-PAGE 
(with 10 µl loaded per well) using 4-12% NuPAGE gels (Invitrogen). Fractionated 
proteins were transferred onto nitrocellulose membranes for immunoblotting analyses 
(see below).  
Cycloheximide Chase Assay in Mammalian Cell Lines – HEK293T cells were 
transfected with 4 µg of plasmid DNA per well (10 cm2 surface area) in 6-well plates 
using Lipofectamine-2000 (Invitrogen) according to the manufacturer’s protocol. 24 h 
after transfection cells were treated with cycloheximide (CHX; 0.1 mg/ml) to initiate the 
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CHX chase. All cells from one well were collected at each of indicated time-points by 
washing cells quickly in ice-cold phosphate-buffered saline (PBS), then rapidly scraping 
cells into 1.5 ml tubes, pelleting them by centrifugation at 4°C (at 10,000g for 1 min), 
and snap-freezing the pellets in liquid nitrogen. Cells in these samples were later lysed by 
the addition of 0.2 ml of “mammalian lysis buffer” (1% NP40, 0.15 M NaCl, 50 mM 
Tris-HCl, pH 7.5) containing 1x Roche Complete Protease Inhibitor Cocktail, and brief 
sonication, followed by centrifugation at 11,200g for 10 min. Total protein concentration 
in the supernatants was measured by bicinchoninic acid (BCA) assay (Thermo Fisher 
Scientific, Waltham, MA). 30 µg of total protein in a thus prepared extract in lithium 
dodecyl sulfate (LDS)-sample buffer (in the volume of 45 µl) were heated at 70°C for 10 
min, followed by LDS-PAGE on a 4-12% Bis-Tris NuPAGE gel (Invitrogen), and 
subsequent transfer onto nitrocellulose membranes for immunoblotting.  
Immunoblotting – Following electrophoresis, proteins separated by LDS-PAGE or 
SDS-PAGE, as indicated above, were electroblotted on nitrocellulose membranes by 
iBlot (Invitrogen, Carlsbad, CA; Program 3; 7 min transfer). Membranes were blocked 
and incubated with the appropriate primary antibody, followed by LI-COR IRDye-
conjugated secondary antibodies. IRDye fluorescence was detected using LI-COR 
Odyssey 9120 (LI-COR, Lincoln, NE), facilitating quantification of immunoblots. All 
quantification was done on LI-COR Odyssey software. Antibodies used include anti-
FLAG mouse monoclonal antibody (clone M2; 1:2,000 dilution; Sigma-Aldrich, St. 
Louis, MO), anti-±-tubulin mouse monoclonal antibody (clone B-5-1-2; 1:10,000 
dilution; Sigma-Aldrich), anti-HA mouse monoclonal antibody (clone HA-7; 1:2000 
dilution; Sigma-Aldrich), anti-² -actin mouse monoclonal antibody Ab8224 (Abcam, 
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1:4,000 dilution; Cambridge, UK), and anti-14-3-3¶ rabbit monoclonal antibody 
EPR6379 (1:100,000 dilution; Abcam).  
Immunoprecipitation of Polyubiquitylated AANAT – HEK293T cells were 
transfected with 4 µg of plasmid DNA per well (10 cm2 surface area) in 6-well plates 
using Lipofectamine-2000 (Invitrogen) according to the manufacturer’s protocol. 24 h 
after transfection, cells were treated with the proteasome inhibitor MG132 (final 
concentration of 10 µM; AG Scientific, San Diego, CA), or with an equivalent volume of 
dimethylsulfoxide (DMSO) in which the 10 mM stock solution of MG132 was made, as 
indicated. 6 h post-treatment cells were collected by washing them quickly on a plate in 
ice-cold phosphate-buffered saline (PBS), then rapidly scraping cells into 1.5 ml tubes 
and pelleting them by centrifugation at 4°C at 10,000g for 1 min). Pellets were 
resuspended in 0.1 ml of buffer containing 1% SDS and 50 mM Tris (pH 7.5), and heated 
at 95°C for 10 min. After boiling, samples were diluted with 1 ml of buffer TNN (0.5% 
NP40, 0.25 M NaCl, 5 mM EDTA, 50 mM Tris, pH 7.5) containing 1x Roche Complete 
Protease Inhibitor Cocktail, 20 mM N-ethylmaleimide (NEM, Sigma-Aldrich) and 50 µM 
PR-619 (LifeSensors, Malvern, PA) as inhibitors of deubiquitylation. 25 µl of anti-HA 
magnetic beads were then added to each sample, which were incubated at 4°C overnight, 
followed by 3 washes in TNN, 1 wash in 10 mM Tris-HCl, pH 8.5, and elution with 50 µl 
0.1 M glycine, pH 2.0 by incubation at room temperature for 10 min. After elution, the 
samples were neutralized, then heated at 70°C in LDS-PAGE sample buffer, followed by 
LDS-PAGE on a 4-12% NuPAGE gel. Fractionated proteins were then electroblotted 
onto nitrocellulose membranes. The resulting membranes (containing transferred 
proteins) were autoclaved as previously described (82) prior to “downstream” 
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immunoblotting procedures with either anti-HA or anti-ubiquitin antibodies to increase 
the sensitivity of detection of polyubiquitin chains. 
 
RESULTS 
Wild-type Rat and Human AANATs and their Mutants – The start (AUG) 
codon-encoded N-terminal Met residue of nascent proteins is cotranslationally cleaved 
off by ribosome-associated Met-aminopeptidases (MetAPs) if and only if a residue at 
position 2 (it becomes N-terminal upon the removal of Met) is not larger than Val 
(41,83). Thus, for example, the Met residue of the N-terminal Met-Leu-Ser sequence of 
wild-type rat AANAT (denoted as MLSrAANAT) (Fig. 1C) is retained in mature 
MLSrAANAT, inasmuch as Leu is larger than Val. Given the previously demonstrated 
usefulness of employing genetic tractability of S. cerevisiae for understanding the 
targeting of mammalian N-end rule substrates (60,66), we carried out this study by 
expressing AANAT test proteins not only in human HEK293T cells but also in S. 
cerevisiae. Cited below are specific wild-type and mutant AANAT proteins that have 
been examined in this study. 
(i) MLSrAANAT3f, the wild-type rat MLSrAANAT C-terminally tagged with a 
triple-FLAG epitope (Figs. 1C and 2A). 
(ii) (M)SMLSrAANAT3f, in which the sequence (Met)-Ser was placed before the 
wild-type Met-Leu-Ser sequence of rat MLSrAANAT3f, yielding the N-terminal sequence 
(Met)-Ser-Met-Leu-Ser. Its N-terminal Met residue would be cotranslationally cleaved 
off by MetAPs (Fig. 2A). The (Met)-Ser sequence was added to wild-type MLSrAANAT3f 
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in order to mimic the (Met)-Ser N-terminal sequence of primate (including human) 
AANATs (Fig. 1C). 
(iii) (M)SIrAANAT3f, in which Leu at position 2 of the wild-type rat MLSrAANAT3f 
(Fig. 1C) was deleted, thereby making the N-terminal Met of the resulting (M)SIrAANAT3f 
removable by MetAPs (Figs. 1C and 2A). 
(iv) (M)PLSrAANAT3f, in which the Pro residue was inserted between N-terminal 
Met and second-position Leu of wild-type rat MLSrAANAT3f. This alteration aimed to 
address the relevance of Nt-acetylation to the degradation of wild-type rat MLSrAANAT3f. 
Specifically, the N-terminal sequence Met-Leu-Ser is a priori likely to be 
cotranslationally Nt-acetylated in vivo at its (retained) N-terminal Met (59,62,63). In 
contrast, the N-terminal Met residue of the mutant N-terminal sequence (Met)-Pro-Leu-
Ser of (M)PLSrAANAT3f would be cotranslationally cleaved off by MetAPs. The resulting 
N-terminal Pro is not Nt-acetylated at least in S. cerevisiae, and is usually not 
Nt-acetylated in mammalian cells as well (59,63). 
(v) MLSrAANAT3ha, the wild-type rat MLSrAANAT (Fig. 1C) C-terminally tagged 
with a triple-HA epitope. It was used as a control to the MLSrAANAAT3haK8R mutant 
described in item viii. 
(vi) (M)SThAANAT3f, the wild-type human (M)SThAANAT (Fig. 1C) C-terminally 
tagged with a triple-FLAG epitope. 
(vii) (M)PThAANAT3f, in which the second-position Ser of the wild-type human 
(M)SThAANAT3f (Fig. 1C) was replaced by the Pro residue, yielding (M)PThAANAT3f. The 
N-terminal Met residue of either the wild-type human (M)SThAANAT3f or the mutant 
(M)PThAANAT3f would be cotranslationally removed by MetAPs (41,83). However, in 
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contrast to the resulting N-terminal Ser of wild-type SThAANAT3f, which would be 
expected to be cotranslationally Nt-acetylated, the N-terminal Pro of the mutant 
PThAANAT3f is not Nt-acetylated at least in S. cerevisiae, and is usually not Nt-acetylated 
in mammalian cells as well (59,63). 
(viii) MLSrAANAAT3haK8R, the otherwise wild-type triple-HA-tagged rat 
MLSrAANAT in which the Lys-8 residue was replaced by Arg. 
(ix) MLSrAANAAT3haKzero, the otherwise wild-type triple-HA-tagged rat 
MLSrAANAT in which each of its four Lys residues were replaced by Arg (Fig. 5B, D). 
(x) (M)SThAANAAT3haKzero, the otherwise wild-type triple-HA-tagged human 
(M)SThAANAT in which both its Lys residues were replaced by Arg (Fig. 5B, D). 
Degradation of Rat AANAT by the S. cerevisiae N-end Rule Pathway – In 
cycloheximide (CHX) assays, a protein of interest is analyzed by immunoblotting as a 
function of time after the inhibition of translation by CHX (39,59,60). Both the wild-type 
rat MLSrAANAT3f (Fig. 1C) and its (M)SMLSrAANAT3f mutant (see item ii above) were 
rapidly degraded in wild-type S. cerevisiae, with half-lives (t1/2) < 5 min (Fig. 2B, lanes 
3-10, and Fig. 2D). In striking contrast, (M)SIrAANAT3f (see item iii above), produced 
from wild-type MLSrAANAT3f by deleting the Leu residue at position 2, was virtually 
completely stable under the same conditions, with a t1/2 > 1 h (Fig. 2B, lanes 11-14 and 
Fig. 2D). When present, parentheses around a superscript’s N-terminal Met residue in the 
notations of AANAT test proteins denote the fact that this Met is cotranslationally 
cleaved off by MetAPs. See items ii and iv above. 
Since the N-terminal Met residue in the Met-Leu-Ser sequence of the wild-type 
rat MLSrAANAT3f would be likely to be Nt-acetylated in vivo (59,62,63), the rapid 
46 
 
degradation of MLSrAANAT3f  (t1/2 < 5 min) (Fig. 2B, D) suggested the involvement of 
the Ac/N-end rule pathway (Fig. 1A). To address this possibility, we constructed the non-
Nt-acetylatable (M)PLSrAANAT3f mutant (see item iv above). (This mutant would also not 
be expected to be targetable by the Arg/N-end rule pathway, as the latter does not 
recognize N-terminal Pro (40,41)). Remarkably, (M)PLSrAANAT3f was long-lived in S. 
cerevisiae, in comparison to the short-lived wild-type MLSrAANAT3f (t1/2 H 1h versus t1/2 
< 5 min, respectively), suggesting (but not proving) a role for the Ac/N-end rule pathway 
in the degradation of the wild-type rat MLSrAANAT3f (Fig. 2B, lanes 15-18, and Fig. 2D; 
see also below). 
To further address the involvement of the Ac/N-end rule pathway and the 
Arg/N-end rule pathway (Fig. 1A, B) in the degradation of wild-type MLSrAANAT3f, we 
performed CHX-chases in S. cerevisiae mutants that lacked essential components of 
either one or both of these pathways. The normally short-lived rat MLSrAANAT3f (t1/2 < 5 
min; Fig 2C, lanes 2-5, and Fig. 2E) was partially stabilized in both naa30”  and ubr1”  
mutants (Fig. 2C, lanes 6-9, lanes 14-17, and Fig. 2E). S. cerevisiae naa30”  cells lack the 
cognate NatC Nt-acetylase whose substrates include proteins bearing the N-terminal Met-
Leu sequence (59,62,63,84,85). S. cerevisiae ubr1”  cells lack Ubr1, the E3 Ub ligase (N-
recognin) that is essential for the proteolytic activity of the Arg/N-end rule pathway (Fig. 
1A) (40,41,59). 
Crucially, the relative stabilization of MLSrAANAT3f was dramatically higher in 
the double mutant naa30”  ubr1”  than in either one of the single mutants (Fig 2C, lanes 
18-21, and Fig.2E). These findings should be considered together with the conceptually 
independent result that the non-Nt-acetylatable (and also not targetable by the Arg/N-end 
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rule pathway) (M)PLSrAANAT3f mutant (see the preceding paragraph) was strikingly 
longer-lived in wild-type S. cerevisiae than its wild-type MLSrAANAT3f counterpart (Fig. 
2B, lanes 15-18 vs. lanes 3-6, and Fig. 2D). Together, these sets of findings indicated that 
the wild-type rat MLSrAANAT3f (its two alternative forms) was targeted for degradation 
by both the Ac/N-end rule pathway and the Arg/N-end rule pathway. Specifically, the Nt-
acetylated Ac-MLSrAANAT3f is destroyed through the recognition of its Nt-acetylated 
N-terminal Met residue by the Ac/N-end rule pathway (Fig. 1B), whereas the 
non-Nt-acetylated MLSrAANAT3f is targeted by the “complementary” Arg/N-end rule 
pathway, which recognizes the unacetylated N-terminal Met-Leu sequence of 
MLSrAANAT3f as the Met-$  motif (N-terminal Met followed by a bulky hydrophobic 
residue) (Fig 1A). 
This conclusion was in agreement with the finding that the rapid degradation of 
MLSrAANAT3f in wild-type S. cerevisiae (t1/2 < 5 min) remained unchanged in naa10”  
cells, which lacked the non-cognate NatA Nt-acetylase (which does not Nt-acetylate N-
terminal Met) (59,85). Furthermore and also in agreement with the above conclusion, the 
degradation of MLSrAANAT3f in double-mutant naa10”  ubr1”  cells proceeded at a rate 
similar to that in the single ubr1”  mutant (Fig. 2C, lanes 22-25, and Fig. 2E). Thus, a 
double-mutant background that nearly completely stabilizes the wild-type rat 
MLSrAANAT3f must be naa30”  ubr1”  in that it must also lack the activity of the cognate 
NatC Nt-acetylase (Fig. 2C, lanes 18-21, and Fig. 2E). In agreement with this conclusion, 
the ablation of NAA10, encoding the non-cognate NatA Nt-acetylase, did not have a 
synergistic effect on the rate of MLSrAANAT3f degradation in double-mutant naa10”  
ubr1”  cells (Fig. 2C, lanes 22-25, and Fig. 2E). 
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Previous work has identified the ER membrane-embedded E3 Ub ligase Doa10 as 
one Ac/N-recognin of the S. cerevisiae Ac/N-end rule pathway (39,59). We found that 
the degradation of the wild-type rat MLSrAANAT3f (t1/2 < 5 min in wild-type S. cerevisiae) 
was not significantly impaired in doa10”  cells, in comparison to wild-type cells (Fig. 3D, 
F). We did not examine, so far, the other yeast Ac/N-recognin, Not4 (see the 
Introduction), for its possible role in targeting the Nt-acetylated rat Ac-MLSrAANAT3f in 
S. cerevisiae. We also don’t know, thus far, whether Teb4, the mammalian counterpart of 
the yeast Doa10 N-recognin (60), is involved in the degradation of rat MLSrAANAT3f in a 
homologous (mammalian) setting. 
Degradation of Rat AANAT Is Proteasome-Dependent and Does Not Require Lys-
8 – The demonstrated degradation of two forms of the wild-type rat MLSrAANAT3f (Ac-
MLSrAANAT3f and its non-Nt-acetylated counterpart) by the two branches of the N-end 
rule pathway (Fig. 2) already implied the proteasome dependency of this degradation, 
given the known organization of the N-end rule pathway (Fig. 1A, B). To verify this in S. 
cerevisiae by independent means, CHX-chases with rat MLSrAANAT3f were carried out in 
wild-type vs. pdr5”  cells in either the presence or absence of the MG132 proteasome 
inhibitor. (Cells lacking the transmembrane transporter PDR5 are more sensitive to 
MG132 (86,87).) 
As expected, given the proteasome dependence of the N-end rule pathway 
(Fig. 1A, B), the normally rapid degradation of the wild-type rat MLSrAANAT3f was 
substantially inhibited in wild-type S. cerevisiae in the presence of 50 µM MG132 (Fig. 
A1.S1A, B). This degradation was inhibited even more strongly in mutant pdr5”  cells 
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under the same conditions, confirming the proteasome dependence of at least the bulk of 
MLSrAANAT3f degradation (Fig. A1.S1A, B). 
N-terminal regions of mammalian AANATs contain a highly conserved Lys 
residue (e.g., Lys-8 in rat AANAT and Lys-10 in human AANAT) that has been 
suggested as a potential ubiquitylation site and thus a determinant of AANAT’s degron 
(33,88-90). To address this possibility, CHX-chases were performed in S. cerevisiae with 
wild-type MLSrAANAT3ha and a mutant containing a Lys-8-Arg mutation 
(MLSrAANAAT3haK8R). Wild-type MLSrAANAT3ha and the mutant MLSrAANAAT3haK8R were 
degraded at similar rates, indicating that the conserved lysine at this position (Lys-8 in rat 
MLSrAANAT) is not, by itself, a significant determinant of MLSrAANAT stability (Fig. 
A1.S1C). However, in contrast to the Lys-8-Arg mutation, the conversion of all four 
lysines of rat MLSrAANAT to Arg residues did confer metabolic stability on MLSrAANAT 
in HEK293T cells (see below and Fig. 4B). 
Degradation of human AANAT in S. cerevisiae – Fig. 3A, lanes 6-9, and Fig. 3B 
show the results of a CHX-chase, in wild-type yeast, with the 207-residue (not counting 
the tag) (M)SThAANAT3f , the wild-type human AANAT C-terminally tagged with a 
triple-FLAG epitope. Parentheses around the superscript’s N-terminal Met residue denote 
the fact that this Met is cotranslationally cleaved off by MetAPs. While human 
(M)SThAANAT3f  was relatively unstable in S. cerevisiae (t1/2 H 30 min), it was much 
longer-lived (including its higher zero-time, pre-chase level) than the wild-type rat 
MLSrAANAT3f under the same conditions (Fig. 3A, B). 
As was also done with the wild-type rat MLSrAANAT3f (Fig. 2C), we 
characterized the degradation of wild-type human (M)SThAANAT3f in S. cerevisiae strains 
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deficient in specific components of the N-end rule pathway. The N-terminal Ser-Thr 
sequence of wild-type human (M)SThAANAT3f (after the cotranslational removal of the 
initially present N-terminal Met) made it likely that (M)SThAANAT3f was cotranslationally 
Nt-acetylated in vivo (59,63). This modification of human (M)SThAANAT3f would make it 
a potential target for degradation by the Ac/N-end rule pathway (Fig. 1B). In contrast, the 
non-Nt-acetylated human (M)SThAANAT3f would not be expected to be recognized by 
either the Ac/N-end rule or the Arg/N-end rule pathway (Fig. 1A), in the latter case 
owing to the absence of both a destabilizing N-terminal residue and a bulky hydrophobic 
($ ) second residue. (A Met-$  N-terminal motif, containing a second-position $  residue, 
can act as an N-degron recognized by the Arg/N-end rule pathway (60,91).)  
Indeed, the rate of degradation of human (M)SThAANAT3f in ubr1”  S. cerevisiae, 
which lacked the Ubr1 N-recognin and therefore lacked the Arg/N-end rule pathway (Fig. 
1A), was similar to the rate of (M)SThAANAT3f degradation in wild-type cells (Fig. 3, 
lanes 1-4 vs. lanes 9-12). The rate of (M)SThAANAT3f degradation characteristic of wild-
type S. cerevisiae was also not significantly changed in doa10”  cells, which lacked one 
of two known Ac/N-recognins of the Ac/N-end rule pathway (Fig. 1B and Fig. 3D, lanes 
10-13 vs. lanes 2-5). Surprisingly, however, (M)SThAANAT3f was strongly destabilized in 
naa10”  cells, which lacked the cognate Nt-acetylase for the N-terminal Ser residue 
(59,62); similar results were obtained with double-mutant naa10”  ubr1”  cells (Fig. 3C-
F). 
Given the much faster degradation of (M)SThAANAT3f in the absence of Naa10 
(e.g., Fig. 3C, lanes 1-4 vs. lanes 5-8, and Fig. 3E), i.e., in cells that would be incapable 
of Nt-acetylating (M)SThAANAT3f, we also carried out CHX-chases, in wild-type 
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S. cerevisiae, with (M)PThAANAT3f. In the latter mutant, the N-terminal Ser was replaced 
by the non-Nt-acetylatable Pro residue. In contrast to wild-type (M)SThAANAT3f in 
naa10”  cells, in which the (non-Nt-acetylated) (M)SThAANAT became strikingly short-
lived, the (non-Nt-acetylatable) (M)PThAANAT mutant was found to be longer-lived, in 
wild-type cells, than the Nt-acetylatable wild-type (M)SThAANAT3f (Fig. A1.S2). These 
results indicated that the observed accelerated degradation of the wild-type human 
(M)SThAANAT in naa10”  S. cerevisiae was not caused by the failure to Nt-acetylate 
(M)SThAANAT in the absence of the NatA Nt-acetylase.  
We do not understand the mechanistic cause of the (reproducibly observed) much 
faster degradation of human (M)SThAANAT in naa10”  S. cerevisiae (Fig. 3C-F). One 
possibility, which remains to be examined, is the apparent inhibition of the yeast Hsp90 
chaperone system (centered on the S. cerevisiae Hsc82/Hsp82 proteins) in naa10”  cells 
(J.-H.O. and A.V., unpublished data). If human (M)SThAANAT expressed in wild-type S. 
cerevisiae is a protected (from degradation) client of the Hsc82/Hsp82 system, a failure 
of this protection in naa10”  mutant cells would make (M)SThAANAT vulnerable to a 
currently unknown pathway of the Ub system that is distinct from the Arg/N-end rule 
pathway. (A proteolytic pathway in question would be distinct from the Arg/N-end rule 
pathway because (M)SThAANAT was equally short-lived in single-mutant naa10”  and 
double-mutant naa10”  ubr1”  cells (Fig. 3C-F).) In sum, the above Hsp90-based 
mechanism (which remains to be addressed in the context of the (M)SThAANAT protein) 
might underlie the strongly accelerated degradation of (M)SThAANAT in naa10”  
S. cerevisiae. 
52 
 
Degradation of Rat AANAT in Human HEK293T Cells – To compare the relative 
rates of degradation of N-terminal mutants of rat AANAT in human HEK293T cells, the 
wild-type rat MLSrAANAT3f and its mutants (M)SMLSrAANAT3f, (M)SIrAANAT3f, and 
(M)PLSrAANAT3f (see items i-iv at the beginning of Results) were expressed in these cells 
using transient transfection. Preliminary experiments with wild-type MLSrAANAT3f 
encoded by a pcDNA3-based plasmid and expressed from the full-strength PCMV 
promoter indicated that the levels of expression of MLSrAANAT3f were high enough to 
saturate or near-saturate pathways that targeted MLSrAANAT3f for degradation in 
HEK293T cells. Specifically, at those (high) levels of expression, wild-type rat 
MLSrAANAT3f was either stable or was degraded slowly (data not shown). 
We addressed this problem by constructing a set of truncated derivatives of the 
original PCMV promoter, aiming to attenuate its activity. The resulting nested set of 
truncated promoters, denoted as PCMVt1, PCMVt2, and PCMVt3, comprised progressively 
shortened versions of the original PCMV. These truncations (Fig. A1.S2A) were similar 
(though not identical) to a series of PCMV truncations described earlier by Promega Inc. 
(92). Each of the PCMVt1, PCMVt2, and PCMVt3 promoter variants was cloned into pcDNA3, 
replacing full-length PCMV. 
The wild-type rat MLSrAANAT3f was cloned into each of the above pcDNA3-
based plasmids, and CHX chases were performed in HEK293T cells transiently-
transfected with these constructs. Expression of MLSrAANAT3f  from the PCMVt1 and 
PCMVt2 promoters reduced time-zero levels of MLSrAANAT3f  (measured by 
immunoblotting at the beginning of CHX-chase) by ~70% and by ~97%, respectively, in 
comparison to the unmodified PCMV promoter (Fig. A1.S3). As to the most truncated 
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promoter, PCMVt3, no MLSrAANAT3f could be detected at the same level of 
immunoblotting sensitivity (data not shown). The lower levels of MLSrAANAT3f 
expression that have been attained through the use of the PCMVt1 and PCMVt2 promoters 
resulted in a strongly increased rate of the posttranslational degradation of MLSrAANAT3f 
(t1/2 < 2 h vs. t1/2 > 8 h when expressed from the full-length PCMV promoter; Fig. A1.S3). 
Treatment of HEK293T cells with the proteasome inhibitor MG132 during the chase 
increased the levels of MLSrAANAT3f expressed from these promoters, thereby 
confirming that in each case the bulk of degradation was proteasome-dependent (Fig. 
A1.S3). The pcDNA3CMVt1 plasmid, which containing PCMVt1, a weakened version of the 
PCMV promoter, was chosen for experiments with HEK293T cells in this study. 
In agreement with the relative metabolic stabilities of AANAT proteins expressed 
in S. cerevisiae (Fig. 1A, B), the mutant rat  (M)SIrAANAT3f, bearing a deletion of the Leu 
residue at position 2 of wild-type MLSrAANAT3f (Fig. 2A), was the longest-lived protein 
in the set of rat AANAT mutants examined in HEK293T cells (t1/2 > 4 h; Fig. 4A, lanes 
12-16, and Fig. 4C). The wild-type rat MLSrAANAT3f and its (M)SMLSrAANAT3f mutant 
(see items i and ii at the beginning of Results) were significantly shorter-lived in 
HEK293T cells than  (M)SIrAANAT3f, with t1/2 H 1 h and t1/2 < 1 h, respectively, versus t1/2 
> 4 h (Fig. 4A, lanes 2-11, and Fig. 4C).  
Although the mutant (M)PLSrAANAT3f was partially stabilized relative to wild-type 
MLSrAANAT3f, the former protein was still significantly shorter-lived (t1/2 H 2 h) than the 
most stable (M)SIrAANAT3f mutant (Fig. 4A, lanes 17-21, and Fig. 4C). While N-terminal 
Pro is not Nt-acetylated (59,63) (this makes N-terminal Pro-bearing proteins invulnerable 
to the Ac/N-end rule pathway), the N-terminal Pro residue might still be (weakly) 
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recognized by the Arg/N-end rule pathway in some sequence contexts. Specifically, our 
SPOT-type, peptide-based binding assays (93) suggested that the Ubr1 N-recognin of the 
S. cerevisiae Arg/N-end rule pathway (and, by inference, mammalian Ubr1 and Ubr2 as 
well) may weakly bind to N-terminal Pro when this residue is followed by a hydrophobic 
residue (J.-H. O., B.W. and AV., unpublished data). Thus, one interpretation of the 
“residual” instability of the rat (M)PLSrAANAT3f mutant (in comparison to the longest-
lived (M)SIrAANAT3f mutant) is that the (non-Nt-acetylated) N-terminal sequence Pro-Leu 
of (M)PLSrAANAT3f is weakly targeted by the Arg/N-end rule pathway, in contrast to the 
absence of targeting of the N-terminal Ser-Ile sequence of the (M)SIrAANAT3f mutant 
(Fig. 4A, C; see also Fig. 2B, D). 
The Bulk of Degradation of Rat AANAT Is Mediated by Polyubiquitylation of Its 
Lys residue(s)  – An earlier study, in which the wild-type rat MLSrAANAT was apparently 
not stabilized by conversion of its Lys residues to Arg, was based on measurements of 
steady-state levels of MLSrAANAT in HEK293 cells that had been treated or left untreated 
with the proteasome inhibitor MG132 (37). To address this issue more directly, we 
generated a triple-HA-tagged mutant, denoted MLSrAANAAT3haKzero, of the wild-type rat 
MLSrAANAT in which all four of its Lys residues were converted to Arg. (A FLAG-based 
epitope tag could not be employed in these experiments, because FLAG contains a Lys 
residue that could potentially serve as a target for polyubiquitylation.)  
CHX chases in HEK293T cells (performed as described above) with the wild-type 
MLSrAANAT3ha versus its lysine-lacking MLSrAANAAT3haKzeromutant indicated that 
MLSrAANAAT3haKzerowas nearly completely stable during the chase (t1/2 >> 4 h), whereas 
the wild-type MLSrAANAT3ha was degraded, with t1/2 H 2 h (Fig. 4B and 4D). A treatment 
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with MG132 during CHX-chase strongly stabilized the wild-type MLSrAANAT3ha, 
confirming that its degradation is proteasome-dependent (Figure 4B, lanes 2 and 6, and 
Fig. 4D). In contrast, the MG132 treatment during CHX-chase of the lysine-lacking 
MLSrAANAAT3haKzero mutant produced at most a marginal stabilizing effect, suggesting 
that even if there is a small (residual) amount of lysine-independent degradation of 
MLSrAANAAT3haKzero, such a degradation would still require the proteasome (Figure 4B, 
lanes 7 and 11, and Fig. 4D). 
In a different approach to the same problem, HEK293T cells were transiently-
transfected with the pcDNA3 vector or with plasmids expressing either MLSrAANAT3ha or 
MLSrAANAAT3haKzero. Cells were then treated for 6 h with either MG132 or an equivalent 
volume of DMSO (in which the stock solution of MG132 was made). Thereafter cell 
extracts were immunoprecipitated with anti-HA magnetic beads, and the 
immunoprecipitates were fractionated by SDS-PAGE, followed by immunoblotting with 
anti-HA and anti-ubiquitin antibodies. Polyubiquitin chains (presumably linked to 
MLSrAANAT3ha) could be readily detected in fractionated immunoprecipitates of extracts 
from cells that expressed MLSrAANAT3ha (but, crucially, not from cells that expressed an 
empty vector), and the levels of polyubiquitin chains were significantly increased in the 
presence of MG132 (Fig. 4F, lanes 1-4). In contrast, significantly lower amounts of 
polyubiquitin chains were observed in fractionated immunoprecipitates of extracts from 
cells that expressed the lysine-lacking MLSrAANAAT3haKzero (Fig. 4F, lane 5). Moreover, 
the presence of MG132 did not increase the low levels of detected polyubiquitin chains 
(Fig. 4F, lane 5 vs. lane 6). The latter result suggested that (residual) polyubiquitin chains 
observed in cells that expressed MLSrAANAAT3haKzero may be of a kind (e.g., (94)) that do 
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not contribute to the proteasome-dependent degradation of MLSrAANAAT3haKzero. In 
agreement with this interpretation, the lysine-lacking MLSrAANAAT3haKzero mutant was 
expressed at significantly higher steady-state levels than the wild-type rat MLSrAANAT3ha 
in the absence of MG132 (in DMSO-treated cells) (Fig. 4E, lower panel), suggesting that 
the absence of Lys residues stabilized MLSrAANAAT3haKzero against degradation throughout 
life histories of MLSrAANAAT3haKzero molecules, including, possibly, their degradation 
during or immediately after their synthesis. 
Degradation of Human AANAT in Human HEK293T Cells – Degradation of the 
wild-type human (M)SThAANAT3f and its N-terminal Pro residue-bearing mutant 
(M)PThAANAT3f (see items vi and vii at the beginning of Results) were examined by 
CHX-chases in HEK293T cells. In agreement with the findings in S. cerevisiae (Figs. 2 
and 3), the wild-type human (M)SThAANAT was longer-lived than the wild-type rat 
MLSrAANAT3f in HEK293T cells (compare Fig. 5A with Fig. 4A). Interestingly, the 
mutant human (M)PThAANAT3f was less stable than the wild-type human MLSrAANAT3f  
during the course of a 2 h chase in HEK293T cells (Fig. 5A, C). 
We also asked whether the (relatively slow) degradation of the wild-type human 
(M)SThAANAT3f (Fig. 5A, C) required both its lysine-dependent ubiquitylation and the 
proteasome. CHX-chases were carried out with (M)SThAANAT3ha and its lysine-lacking 
mutant (M)SThAANAAT3haKzero. The latter protein was stable during the chase (t1/2 >> 4 h), 
whereas wild-type (M)SThAANAT3ha exhibited a weak but observable instability (Fig. 5B, 
D). Treatment with the MG132 proteasome inhibitor significantly increased the level of 
the wild-type human (M)SThAANAT3ha during CHX-chase, confirming proteasome 
dependence of its (slow) degradation (Fig. 5B, lanes 3 and 7, and Fig. 5D). 
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DISCUSSION 
The ~23-kDa arylalkylamine N-acetyltransferase (AANAT), an enzyme 
apparently universal among animals (it is present in plants as well), converts the 
neurotransmitter serotonin to N-acetylserotonin (NAS), a regulatory compound in its own 
right and the immediate precursor of melatonin, a circulating hormone that regulates 
sleep and other circadian processes in vertebrates. The levels of melatonin and NAS are 
modulated by oscillatory circadian circuits and at the same time impact those circuits, in 
addition to other effects of these compounds (see the Introduction), hence the importance 
of temporal control of the AANAT enzyme. The expression of AANAT is regulated 
through both transcriptional and posttranslational mechanisms. Specific details of these 
mechanisms differ among vertebrates. In addition, although AANAT enzymes from 
different species are highly sequelogous (similar in sequence (71)) throughout their 
ORFs, the sequences of the first ~10 amino acid residues of ANAATs tend to differ even 
among relatively closely related mammals, let alone other animals (Fig. 1C). This pattern 
of variation suggests a blend of adaptive (function-linked, natural selection-based) 
changes in N-terminal sequences of AANATs versus an unknown (extent-wise) but 
apparently strong flux of unselected, drift-mediated changes of these N-terminal 
sequences on evolutionary timescales. 
In the present study, we approached the proteolysis-based regulation of rat and 
human AANATs (Fig. 1C) by expressing them and their mutants not only in mammalian 
cells but also in the yeast S. cerevisiae. This strategy made possible the use of yeast 
genetics to illuminate specific proteolytic pathways involved, in parallel with 
experiments in mammalian cells. 
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We found that the wild-type rat AANAT (MLSrAANAT; the superscript indicates 
the N-terminal Met-Leu-Ser sequence of this AANAT) is targeted for degradation by two 
complementary branches of the N-end rule pathway. Specifically, we showed that the 
N±-terminally acetylated (Nt-acetylated) Ac-MLSrAANAT is destroyed through the 
recognition of its Nt-acetylated N-terminal Met residue by the Ac/N-end rule pathway, 
whereas the non-Nt-acetylated MLSrAANAT is targeted for degradation by the Arg/N-end 
rule pathway, which recognizes the unacetylated N-terminal Met-Leu sequence of 
MLSrAANAT. (See the Introduction and Fig. 1A, B for a description of mechanisms and 
functions of the N-end rule pathway.)  
The N-terminal (Met)-Ser-Thr sequence of the wild-type human (M)SThAANAT is 
different from the Met-Leu-Ser sequence of rat MLSrAANAT (Fig. 1C). (The Met residue 
of (M)SThAANAT is in parentheses to indicate its cotranslational removal by MetAPs; see 
the beginning of Results.) We found that the wild-type human (M)SThAANAT is 
considerably longer-lived than its rat MLSrAANAT counterpart, and does not appear to be 
an efficacious N-end rule substrate. Together, these and related results (Figs. 2-5) 
indicated both a major involvement of the N-end rule pathway in the control of rodent 
AANATs and substantial differences in the regulation of rodent and human AANATs 
that stem from differences in their N-terminal sequences. 
The observed co-targeting of the two “complementary” forms of the rat 
MLSrAANAT by the two “complementary” branches of the N-end rule pathway (Figs. 2 
and 3) is in agreement with the earlier finding that the N-terminal region of MLSrAANAT, 
and specifically its Leu-2 residue, are an important determinant of the observed metabolic 
instability of this AANAT (37). The cited study also suggested that either the Lys 
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residues of MLSrAANAT or its surface-exposed Cys residues were not essential for its 
proteasome-mediated degradation (37). In the present work, we compared the 
degradation of wild-type MLSrAANAT and its lysine-lacking MLSrAANAAT3haKzero mutant 
using cycloheximide (CHX) chases. Our results showed that the (C-terminally 
triple-HA-tagged) MLSrAANAAT3haKzero mutant was completely stabilized in human 
HEK293T cells, in contrast to instability of wild-type MLSrAANAT, indicating that at 
least some Lys residues of MLSrAANAT were required for its degradation (Fig. 4B). 
A possible explanation of the above discrepancy stems from different choices of 
C-terminal epitope tags in the earlier and the present study. Specifically, Huang et al. (37) 
employed MLSrAANAT C-terminally tagged with c-Myc epitope (EQKLISEEDL), which 
contains a Lys residue. In the present work, we used a triple-HA tag, which lacks Lys 
residues (the sequence of single HA is YPYDVPDYA). Previous analyses of N-degrons 
have shown that the targeting apparatus of the Arg/N-end rule pathway selects a 
substrate’s internal lysine as a polyubiquitylation site through a process in which different 
(spatially competing, conformationally mobile) Lys residues can be chosen 
stochastically, depending on their ability to become transiently close to the substrate-
bound E2-E3 complex (41,51,95). Thus, the presence of a Lys residue in the C-terminal 
c-Myc epitope of the earlier study (37) might have rendered the otherwise lysine-lacking 
MLSrAANAT mutant still targetable by the N-end rule pathway. Indeed and tellingly, our 
initial experiments with lysine-lacking mutants of MLSrAANAT have employed, 
inadvertently, a lysine-containing C-terminal FLAG tag, instead of the lysine-lacking HA 
tag. Remarkably, the otherwise lysine-lacking but FLAG-tagged MLSrAANAAT3fKzero 
mutant was found to be unstable and ubiquitylated (B.W. and A.V., unpublished data), in 
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contrast to the actually (completely) lysine-lacking, HA-tagged MLSrAANAAT3haKzero 
mutant (Fig. 4), in agreement with the above tag-based explanation. 
In addition to polyubiquitylation and degradation, AANAT is also regulated 
through a site-specific phosphorylation, a modification that stimulates the binding of 
AANAT to at least one of the 14-3-3 chaperone-like proteins (they are encoded by a 
family of several 14-3-3 genes in mammals). This interaction both protects 
(phosphorylated) AANAT from degradation and enhances its catalytic activity. Rat, 
human and other AANATs contain two previously mapped phosphorylation sites, Thr-29 
and Ser-203 (numbers refer to the sequence of rat MLSrAANAT). Phosphorylation at Thr-
29 is conserved in all examined mammalian AANATs (31). This phosphorylation, by 
protein kinase A (PKA) and/or by protein kinase C (PKC), augments the interaction 
between AANAT and 14-3-3 both in vitro and in vivo (1,5,37). By expressing AANATs 
not only in mammalian cells but also in the heterologous setting of S. cerevisiae, we 
could analyze the degradation of AANATs in the possible absence of phosphorylation at 
Thr-29 (or its equivalent) and also in the possible absence of AANAT interactions with 
14-3-3 proteins. (While S. cerevisiae has two 14-3-3 proteins (96), there is no evidence, 
so far, that bears on their binding, in vivo, to a mammalian AANAT.) 
Our attempts to observe a phosphorylation-induced in vivo binding of the wild-
type rat MLSrAANAT either to an endogenous yeast 14-3-3 protein or to the 
(overexpressed) human 14-3-3¶ protein were unsuccessful so far, despite a variety of 
tried approaches (B.W. and A.V., unpublished data). Nevertheless, the likely conceptual 
benefit of achieving a phosphorylation-inducible interaction between a mammalian 
AANAT and a specific 14-3-3 protein, in a setting of greatly reduced complexity of 14-3-
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3s (in comparison to the large set of their mammalian counterparts), justifies further work 
in this direction. 14-3-3 proteins are abundant, broadly expressed, multifunctional 
chaperone-like proteins that modulate catalytic activities of enzymes to which 14-3-3s 
bind, and also regulate protein-protein interactions and subcellular targeting of specific 
proteins (97-99). It is possible, indeed likely, that 14-3-3 proteins may bind, in a 
regulated manner, not only to, for example, rat MLSrAANAT but to other N-end rule 
substrates as well, thereby controlling the rates of degradation of such substrates in ways 
that remain to be explored. 
Recently, the naturally occurring mutant human protein RGS2Q2L was shown to 
be a conditionally short-lived substrate of both the Ac/N-end rule pathway and the 
Arg/N-end rule pathway (60). This clinically-relevant mutant of RGS2 (a negative 
regulator of specific G proteins) was identified in a cohort of hypertensive Japanese 
patients (100) (see also the Introduction). In the present study, we demonstrated that the 
otherwise unrelated rat MLSrAANAT protein, whose N-terminal Met-Leu sequence is 
identical to that of RGS2Q2L, is also targeted for degradation by both branches of the N-
end rule pathway (Figs. 1 and 2). These results further expanded the set of identified 
mammalian N-end rule substrates of the Met-¦  type (N-terminal Met followed by a 
bulky hydrophobic residue; Fig. 1A). 
Interestingly, RGS2, an N-end rule substrate (60), has been identified as a 
physiologically relevant inhibitor of the AANAT-dependent melatonin production (101). 
Light-stimulated, norepinephrine-induced increases in the levels and activity of AANAT 
are mediated by G-protein-coupled adrenergic receptors, whose activation increases 
intracellular cAMP, and subsequently the levels of AANAT as well, at least in part 
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through an increased phosphorylation of AANAT and the resulting induction of its 
binding to protective 14-3-3 proteins (5,28). While acting to increase the levels and 
activity of AANAT (which is required for the synthesis of NAS and melatonin), cAMP 
also acts as a negative-feedback inhibitor of melatonin production through up-regulation 
of Rgs2 transcription. The resulting increase in RGS2 inhibits the activity of G proteins 
that are coupled to the norepinephrine-responsive receptor, a negative-feedback circuit 
that acts to decrease cAMP levels (101). AANAT results of the present study, together 
with the earlier evidence that RGS2 is both a conditionally short-lived N-end rule 
substrate and an (indirect) down-regulator of AANAT (60,101), indicate that the N-end 
rule pathway is a pleiotropic controller of circuits that either directly or indirectly 
modulate AANAT.  
Previous studies of AANAT demonstrated that its transcriptional regulation can 
be different in different species, but it has been conjectured that mechanisms and 
regulation of AANAT degradation would be more conserved in evolution (11,34-36). As 
shown in the present study, the rates of degradation of the human and rat AANAT 
proteins are quite different. Moreover, whereas rat MLSrAANAT is destroyed by the N-
end rule pathway (Figs. 2 and 4), human (M)SThAANAT is substantially resistant to this 
pathway (Figs. 3 and 5). Nevertheless, if the identification of RGS2 as a feedback 
inhibitor of AANAT expression in the rat pineal gland (101) could also be shown to 
extend to human RGS2, the N-end rule pathway would be a regulator of AANAT in 
humans as well, albeit an indirect one. 
An earlier study of human (M)SThAANAT described its apparent degradation by 
the proteasome, but did not detect its ubiquitylation (33). In that study, the instability of 
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human (M)SThAANAT was inferred from increases in its steady-state levels in the 
presence of a proteasome inhibitor. In the present work, we employed, in particular, 
CHX-chases to show that while human (M)SThAANAT is degraded by the proteasome, it 
is substantially longer-lived than rat MLSrAANAT under the same conditions, either in 
mammalian cells or in S. cerevisiae (Figs. 2-5).  
In sum, our results indicate both a major involvement of the N-end rule pathway 
in the control of rodent AANATs and substantial differences in the regulation of rodent 
and human AANATs that stem from differences in their N-terminal regions (Fig. 1C). 
What is the cause of the remarkable variability of N-terminal sequences of AANATs 
during mammalian (and, more generally, animal) evolution? Given the level of extant 
variability (Fig. 1C), it is nearly certain that a substantial fraction of these changes 
resulted from a quasi-neutral genetic drift (102). At the same time, the wide and 
biologically relevant variation in detailed circadian rhythms among different animal 
species (owing to specific ecological and physiological adaptations) and the role of 
AANAT in these rhythms suggest that the seeming randomness of AANATs’ N-terminal 
sequences (Fig. 1C) may be obscuring, thus far, a set of adaptive (selected) changes in 
these sequences over evolutionary timescales.  
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Fig. 2.1. The mammalian N-end rule pathway and N-terminal regions of AANAT 
enzymes. See the Introduction for references and descriptions of the N-end rule 
pathway’s mechanistic aspects and biological functions. Amino acid residues are denoted 
by single-letter abbreviations. A, the mammalian Arg/N-end rule pathway. It targets 
proteins for degradation through their specific unacetylated N-terminal residues. A 
yellow oval denotes the rest of a protein substrate. “Primary”, “secondary”, and “tertiary” 
refer to mechanistically distinct classes of destabilizing N-terminal residues. Ntan1 and 
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Ntaq1 are N-terminal amidases (Nt-amidases) that convert, respectively, the tertiary 
destabilizing N-terminal residues Asn and Gln to Asp and Glu. The Ate1 
arginyltransferase (R-transferase) conjugates Arg, a primary destabilizing residue, to 
N-terminal Asp, Glu and (oxidized) Cys. “Type 1” and “type 2” refer to two sets of 
primary destabilizing N-terminal residues, basic (Arg, Lys, His) and bulky hydrophobic 
(Leu, Phe, Trp, Tyr, Ile, and Met, if the latter is followed by a bulky hydrophobic residue 
($ )), respectively. These sets of N-terminal residues are recognized by two distinct 
substrate-binding sites of N-recognins, the pathway’s E3 ubiquitin ligases, whose 
(possibly incomplete) list includes Ubr1, Ubr2, Ubr4, and Ubr5. B, the mammalian Ac/N-
end rule pathway. It targets proteins through their N±-terminally acetylated 
(Nt-acetylated) residues. Red arrow on the left indicates the cotranslational removal of 
the N-terminal Met residue by Met-aminopeptidases (MetAPs). N-terminal Met is 
retained if a residue at position 2 is larger than Val. C, the first 10 amino acid residues of 
animal AANAT enzymes, in vertebrates and an invertebrate such as Drosophila 
melanogaster. See the Introduction for descriptions of AANATs. 
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Fig 2.2. The wild-type rat MLSrAANAT as a substrate of both branches of the N-end 
rule pathway. A, the wild-type rat MLSrAANAT and its mutants that were constructed 
and analyzed in the present study. Amino acid residues are denoted by single-letter 
abbreviations. The Leu (L) residue, at position 2 in wild-type MLSrAANAT, is highlighted 
in red to make it easier to follow sequence alterations in specific mutants. B, 
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immunoblotting with antibody to actin was used as a loading control. Lane 1, 
fluorescently labeled molecular mass markers (Li-Cor), with their masses, in kDa, 
indicated on the left. Lane 2, wild-type S. cerevisiae were transformed with vector (V) 
alone (control). Cycloheximide (CHX)-chases were performed at 30°C for the indicated 
times in wild-type S. cerevisiae with the wild-type rat MLSrAANAT3f (lanes 3-6), and 
with its mutants (M)SMLSrAANAT3f (lanes 7-10), (M)SIrAANAT3f (lanes 11-14), and 
(M)PLSrAANAT3f (lanes 15-18). The bands of AANAT3f and actin are indicated on the 
right. C, immunoblotting with antibody to tubulin was used as a loading control. Lane 1, 
37 kDa and 50 kDa molecular mass markers (see lane 1 in B). CHX-chases with the 
wild-type rat MLSrAANAT3f in wild-type S. cerevisiae (lanes 2-5) and its mutants naa30”  
(lanes 6-9), naa10”  (lanes 10-13), ubr1”  (lanes 14-17), naa30”  ubr1”  (lanes 18-21), 
and naa10”  ubr1”  (lanes 22-25). The bands of MLSrAANAT3f and tubulin are indicated 
on the right. D, quantification of data in B. E, quantification of data in C. 
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Fig. 2.3. Degradation assays with the wild-type human (M)SThAANAT in 
S. cerevisiae. A, Comparison of degradation rates of the wild-type rat MLSrAANAT3f and 
the wild-type human (M)SThAANAT3f in S. cerevisiae. Immunoblotting with antibody to 
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actin was used as a loading control. Lane 1, wild-type S. cerevisiae were transformed 
with vector (V) alone (control). CHX-chases were performed at 30°C for the indicated 
times in wild-type S. cerevisiae with the wild-type rat MLSrAANAT3f (lanes 2-5) and with 
the wild-type human (M)SThAANAT3f (lanes 6-9). The bands of AANAT and actin are 
indicated on the left. B, quantification of data in A. C, CHX-chases with the wild-type 
human (M)SThAANAT3f in wild-type S. cerevisiae (lanes 1-4) and its mutants naa10”  
(lanes 5-8), ubr1”  (lanes 9-12), and naa10”  ubr1”  (lanes 13-16). The bands of human 
(M)SThAANAT3f and actin are indicated on the left. D, Lane 1, wild-type S. cerevisiae 
were transformed with vector (V) alone (control). CHX-chases with the wild-type human 
(M)SThAANAT3f in wild-type S. cerevisiae (lanes 2-5) and its mutants naa10”  (lanes 6-9), 
doa10”  (lanes 10-13), and ubr1”  (lanes 14-17). The bands of human (M)SThAANAT3f and 
actin are indicated on the left. E, quantification of data in C. F, quantification of data in 
D. 
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Fig. 2.4. Degradation and ubiquitylation assays with rat and human AANATs in 
human HEK293T cells. A, Lane 1, HEK293T cells were transformed with vector (V) 
alone (control) bearing the (weakened) PCMVt1 promoter (see Results and Fig. A1.S3). 
Immunoblotting with antibody to tubulin was used as a loading control. CHX-chases 
were performed at 37°C for the indicated times in HEK293T cells with the wild-type rat 
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MLSrAANAT3f (lanes 2-5), and with its mutants (M)SMLSrAANAT3f (lanes 7-10), 
(M)SIrAANAT3f (lanes 12-15), and (M)PLSrAANAT3f (lanes 17-20). Lanes 6, 11, 16, and 21 
are the same as lanes 5, 10, 15, and 20 except that the MG132 proteasome inhibitor was 
present during a 4-h CHX-chase, in each case (see Experimental Procedures). The bands 
of AANAT3f and tubulin are indicated on the right. An asterisk on the left denotes a band 
of protein that crossreacted with anti-flag antibody (the band is also present in lane 1, the 
vector-only control). B, Lane 1, the same as the control in lane 1 of A. CHX-chases were 
performed at 37°C for the indicated times in HEK293T cells with the wild-type rat 
MLSrAANAT3ha (lanes 2-5) and with its lysine-lacking mutant MLSrAANAAT3haKzero(lanes 
7-10). Lanes 6 and 11, same as lanes 5 and 10 except that MG132 was present during a 4-
h CHX-chase, in each case. C, quantification of data in A. D, quantification of data in B. 
Symbols shown separately and framed in black squares or rectangles correspond to 
altered levels of test proteins in the presence of MG132. E, immunoblot analyses, using 
anti-Ub antibody, of total, input (before immunoprecipitation) extracts from HEK293T 
cells that had been transfected either with vector alone (lanes 1 and 2), or with plasmid 
expressing the wild-type rat MLSrAANAT3ha (lanes 3 and 4), or with plasmid expressing 
its lysine-lacking counterpart MLSrAANAAT3haKzero(lanes 5 and 6). The MG132 
proteasome inhibitor was either omitted (lanes 1, 3, and 5) or added to HEK293T cells (to 
the final concentration of 10 µM) 6 h before preparation of extracts (lanes 2, 4, and 6). 
The lower panel shows the results of detecting non-ubiquitylated MLSrAANAT3ha (absent 
in the control lanes 1 and 2) with anti-ha antibody. F, same as in E, but immunoblot 
analyses (using anti-Ub antibody) of the input samples after their immunoprecipitation 
with anti-ha antibody (followed by SDS-PAGE), to isolate and detect ubiquitylated 
AANAT3ha species. 
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Fig. 2.5. Degradation of the wild-type human (M)SThAANAT and its mutants in 
human HEK293T cells. The test proteins were expressed in HEK293T cells using a 
plasmid bearing the (weakened) PCMVt1 promoter (see Results and Fig. A1.S3). A, Lane 1, 
fluorescently labeled molecular mass markers (Li-Cor), with their masses, in kDa, 
indicated on the left. CHX-chases were performed at 37°C for the indicated times in 
HEK293T cells with the wild-type human (M)SThAANAT3f (lanes 2-5) and with its mutant 
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(M)PThAANAT3f (lanes 6-9). B, Lane 1, fluorescently labeled molecular mass markers, 
with their masses, in kDa, indicated on the left. Lane 2, HEK293T cells were transformed 
with vector (V) alone (control). CHX-chases were performed at 37°C for the indicated 
times in HEK293T cells with the wild-type human (M)SThAANAT3ha (lanes 3-6) and with 
its lysine-lacking mutant (M)SThAANAAT3haKzero (lanes 8-11). Lanes 7 and 12, same as 
lanes 6 and 11, except that the MG132 proteasome inhibitor was present during a 4-h 
CHX-chase, in each case (see Experimental Procedures). The bands of actin and AANAT 
are indicated on the right. Asterisks on the right in A and B denote a protein band 
(possibly the same protein and possibly a derivative of AANAT) that reacted with both 
anti-flag antibody in A and anti-ha antibody in B. C, quantification of data in A. D, 
quantification of data in B. 
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ABSTRACT 
Rgs2, a regulator of G proteins, lowers blood pressure by decreasing signaling 
through G±q. Human patients expressing Met-Leu-Rgs2 (ML-Rgs2) or Met-Arg-Rgs2 
(MR-Rgs2) are hypertensive compared to people expressing wild-type Met-Gln-Rgs2 
(MQ-Rgs2). Here we found that wild-type MQ-Rgs2 and its mutant MR-Rgs2 were 
destroyed by the Ac/N-end rule pathway, which recognizes N±-terminally acetylated (Nt-
acetylated) proteins. The shortest-lived mutant ML-Rgs2 was targeted by both the Ac/N-
end rule and Arg/N-end rule pathways. The latter pathway recognizes unacetylated N-
terminal residues. Thus, the Nt-acetylated Ac-MX-Rgs2 (X=Q, L, R) proteins are 
specific substrates of the mammalian Ac/N-end rule pathway. Furthermore, the Ac/N-
degron of Ac-MQ-Rgs2 was conditional, and Teb4, an endoplasmic reticulum 
membrane-embedded ubiquitin ligase, was able to regulate G protein signaling by 
targeting Ac-MX-Rgs2 proteins for degradation through their N±-terminal acetyl group.  
 
RESULTS AND DISCUSSION 
Regulators of G protein signaling (RGSs) bind to specific G± subunits of 
heterotrimeric G proteins (G±² ³ ) and accelerate the hydrolysis of G±-bound GTP, 
thereby abrogating the signaling by G proteins (1-4). The mammalian Rgs2 protein 
regulates stress responses, translation, circadian rhythms, Ca2+ channels, specific 
hormones, and cardiovascular homeostasis (3-10). Blood pressure-increasing 
vasoconstrictors such as norepinephrine and angiotensin II are upregulated by activated 
G±q proteins. The latter are deactivated by Rgs2 (7). Both Rgs2-/- and heterozygous 
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Rgs2+/- mice are strongly hypertensive (8, 9). Human patients with decreased Rgs2 
signaling are hypertensive as well (10). 
In some hypertensive patients, one of two Rgs2 genes encoded Met-Leu-Rgs2 
(ML-Rgs2), in which Gln at position 2 of wild-type Met-Gln-Rgs2 (MQ-Rgs2) had been 
replaced by Leu. Another hypertension-associated Rgs2 mutant is Met-Arg-Rgs2 (MR-
Rgs2) (10). The Q2L and Q2R mutations are not detected in the general population (10). 
All three Rgs2 proteins are upregulated by a proteasome inhibitor, suggesting that they 
may be targeted by a proteasome-dependent proteolytic system (11). 
The N-end rule pathway recognizes proteins containing N-terminal (Nt) 
degradation signals called N-degrons, polyubiquitylates these proteins and thereby causes 
their degradation by the proteasome (fig. A2.S1) (12-20). The main determinant of an N-
degron is a destabilizing Nt-residue of a protein. Recognition components of the N-end 
rule pathway, called N-recognins, are E3 ubiquitin ligases that can target N-degrons. 
Regulated degradation of proteins by the N-end rule pathway mediates a broad range of 
biological functions (fig. A2.S1) (12-20). 
The N-end rule pathway consists of two branches. One branch, the Arg/N-end 
rule pathway, targets unacetylated destabilizing Nt-residues (12, 14, 16). The Nt-residues 
Arg, Lys, His, Leu, Phe, Tyr, Trp, and Ile, as well as Nt-Met (if it is followed by a bulky 
hydrophobic ($ ) residue) are directly recognized by N-recognins (16). In contrast, the 
unacetylated Asn, Gln, Asp, and Glu (as well as Cys, under some conditions) Nt-residues 
are destabilizing owing to their preliminary enzymatic modifications (fig. A2.S1D). 
The pathway’s other branch, called the Ac/N-end rule pathway, targets proteins 
through their N±-terminally acetylated (Nt-acetylated) residues (fig. A2.S1A, C) (13, 15, 
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16). Degrons and E3 ubiquitin ligases of the Ac/N-end rule pathway are called Ac/N-
degrons and Ac/N-recognins, respectively. Approximately 90% of human proteins are 
cotranslationally and irreversibly Nt-acetylated by ribosome-associated Nt-acetylases (21, 
22). (In contrast, acetylation of internal Lys residues is reversible and largely 
posttranslational.) Doa10, an endoplasmic reticulum (ER) membrane-embedded E3 
ubiquitin ligase of the yeast Saccharomyces cerevisiae (23, 24), functions as an Ac/N-
recognin (13). Not4, a cytosolic and nuclear E3, is another yeast Ac/N-recognin (15). 
The Arg/N-end rule pathway is present in all examined eukaryotes, from fungi to 
mammals and plants (fig. A2.S1D) (12, 18, 19). In contrast, the Ac/N-end rule pathway 
(fig. A2.S1C) has been identified in S. cerevisiae (13, 15, 16), but its presence in 
mammals and other multicellular eukaryotes has been conjectural so far. 
Owing to genetic tractability of S. cerevisiae, we began by examining wild-type 
human MQ-Rgs2 and its ML-Rgs2 mutant using cycloheximide (CHX) chases in yeast 
(13, 15, 16). The C-terminally HA-tagged MQ-Rgs2ha was short-lived (t1/2 H 30 min) in 
wild-type yeast, and was stabilized in both naa20” and doa10” cells, which lacked, 
respectively, the cognate NatB Nt-acetylase and the Doa10 Ac/N-recognin (13) (Figs. 
1A, C, S1C and S2). Thus wild-type MQ-Rgs2ha was degraded, in yeast, largely by the 
Ac/N-end rule pathway (13, 15, 16). 
The mutant human ML-Rgs2ha was also short-lived in wild-type S. cerevisiae 
(t1/2 < 15 min), and was partially stabilized in both naa30” and ubr1” cells, which 
lacked, respectively, the cognate NatC Nt-acetylase and the Ubr1 N-recognin of the 
Arg/N-end rule pathway (Figs. 1B, D, S1C, S2, and S3A, D). Tellingly, ML-Rgs2ha was 
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nearly completely stabilized in double-mutant naa30” ubr1” cells, including strongly 
elevated time-zero (pre-chase) levels of ML-Rgs2ha (Figs. 1B, D and S3A, D). 
Many cellular proteins are partially Nt-acetylated (21). Non-Nt-acetylated yeast 
M$ -type proteins are eliminated by the Arg/N-end rule pathway, while the Nt-acetylated 
counterparts of these proteins are destroyed by the Ac/N-end rule pathway (15, 16). This 
dual-targeting pattern was also observed with human ML-Rgs2ha (Figs. 1B, D and S3A, 
D). The contribution of the Ubr1 N-recognin to the degradation of ML-Rgs2ha (Figs. 1B 
and S3A) indicated its incomplete Nt-acetylation in S. cerevisiae, similarly to results with 
natural M$ -type yeast proteins (15, 16). Both wild-type MQ-Rgs2 and the second 
hypertension-associated mutant MR-Rgs2 were targeted (after their Nt-acetylation) 
solely by the Ac/N-end rule pathway, because the unacetylated Nt-Met followed by a 
non-$  residue such as Gln or Arg is not recognized by the Arg/N-end rule pathway (in 
contrast to an M$ -type protein such as ML-Rgs2ha) (fig. A2.S1D) (16). 
Wild-type MQ-Rgs2 is a predicted substrate of the NatB Nt-acetylase (fig. 
A2.S2), in agreement with stabilization of MQ-Rgs2ha in naa20” S. cerevisiae, which 
lack NatB (Fig.1A, C). We analyzed, using mass spectrometry (13), the MQ-Rgs2 
protein from human HEK293 cells, confirming its Nt-acetylation (fig. A2.S5A). 
Considerably unequal levels of transiently expressed MQ-Rgs2ha, MR-Rgs2ha, 
and ML-Rgs2ha in human HeLa cells suggested their different stabilities (MQ > MR > 
ML) in these cells, an interpretation consistent with near-equal levels of the 
corresponding MX-Rgs2 mRNAs (fig. A2.S4C, F, G). Indeed, CHX-chases in HeLa cells 
showed that MR-Rgs2ha (t1/2 < 8 min) and ML-Rgs2ha (t1/2 < 5 min) were shorter-lived 
than the also unstable wild-type MQ-Rgs2ha (t1/2 H 15 min) (Figs. 1E, F and S3B, E). The 
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same (MQ > MR > ML) order of degradation rates was observed in 35S-pulse-chases of 
MQ-Rgs2ha, MR-Rgs2ha, and ML-Rgs2ha (Figs. 1J and S4J). 
In contrast to Nt-acetylatable and (therefore) short-lived wild-type MQ-Rgs2ha, 
the otherwise identical PQ-Rgs2ha (Pro-Gln-Rgs2ha) (generated cotranslationally from 
MPQ-Rgs2ha) was neither Nt-acetylated nor recognized by the Arg/N-end rule pathway 
(figs. S1 and S2). PQ-Rgs2ha was long-lived in HeLa cells (Fig. 1G, H). This result was 
an additional, conceptually independent evidence for the targeting of Ac-MQ-Rgs2ha by 
the Ac/N-end rule pathway (fig. A2.S1C). 
Remarkably, the exogenous (overexpressed) wild-type MQ-Rgs2ha was much 
shorter-lived (t1/2 H 15 min) than the endogenous MQ-Rgs2 (t1/2 H 3 hr) in HeLa cells that 
did not overexpress MQ-Rgs2ha (Figs. 1E, F, 2B, S3B, E and S4A, B). These results, 
with human cells, agreed with the recent demonstration of the biologically relevant 
conditionality of Ac/N-degrons in S. cerevisiae, owing to steric shielding of these 
degrons in cognate protein complexes (15). Given this understanding with natural Ac/N-
end rule substrates in yeast (15, 16, 25), the present results (Figs. 1E, F, 2B, S3B, E and 
S4A, B) are what one would expect if Ac-MQ-Rgs2, in human cells that do not 
overexpress it, can be (reversibly) shielded from the Ac/N-end rule pathway soon after 
Nt-acetylation of MQ-Rgs2. This shielding would occur through formation of a 
physiologically relevant protective complex(es) between Ac-MQ-Rgs2 and its protein 
ligand(s). In contrast to the long half-life of the endogenous, “stoichiometrically” 
expressed MQ-Rgs2, its overexpression in HeLa cells would make the resulting 
“unprotectable” excess of Ac-MQ-Rgs2ha molecules vulnerable to destruction by the 
Ac/N-end rule pathway, thereby accounting for the large difference between the slowly 
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degraded endogenous MQ-Rgs2 (in cells that do not overexpress MQ-Rgs2) and the 
short half-life of overexpressed MQ-Rgs2ha (Figs. 1E, F, 2B, S3B, E and S4A, B). 
Indeed, the short-lived MQ-Rgs2 was strongly stabilized by co-overexpression of one of 
its binding partners, the G±q protein (Fig. 3A, B). 
A candidate Ac/N-recognin of the mammalian Ac/N-end rule pathway was Teb4, 
an ER membrane-embedded E3 ubiquitin ligase that polyubiquitylates proteins 
retrotranslocated from the ER. Teb4 is similar to the S. cerevisiae Doa10 Ac/N-recognin 
(13, 23, 24). We found that human Teb4 was indeed an Ac/N-recognin: 
(i) Transiently expressed MQ-Rgs2ha was upregulated by a proteasome inhibitor, 
while coexpression of human Teb4 (Teb43f) and MQ-Rgs2ha in HeLa cells down-
regulated MQ-Rgs2ha (Fig. 2A, F). In addition, incrementally higher levels of Teb43f 
resulted in incrementally lower levels of endogenous MQ-Rgs2 (Fig. 2G). 
(ii) The level of MQ-Rgs2ha in HeLa cells was not decreased if MQ-Rgs2ha was 
coexpressed with Teb43fC9A, a missense mutant that is inactive as a ubiquitin ligase (24) 
(Fig. 2F). Analogous assays with MR-Rgs2ha and ML-Rgs2ha gave similar results (fig. 
A2.S4D, E).  
(iii) The in vivo polyubiquitylation of MQ-Rgs2ha in HeLa cells was increased by 
coexpression of Teb43f, but not by coexpression of the mutant Teb43fC9A (Fig. A2.S3F). 
(iv) In CHX-chases, endogenous MQ-Rgs2 was stabilized by RNAi-mediated 
knockdowns of either endogenous Teb4 E3 or endogenous cognate NatB Nt-acetylase 
(Figs. 2B and S4A). Similar results were obtained with exogenous (overexpressed) MQ-
Rgs2ha, confirming the targeting of MQ-Rgs2 by Teb4 and indicating that this targeting 
required Nt-acetylation of MQ-Rgs2 by the NatB Nt-acetylase (Figs. 2B and S4A, B). In 
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addition, overexpressed MR-Rgs2ha as well as the also tested MK-Rgs2ha (containing a 
different basic residue at position 2) were stabilized by RNAi-based knockdown of 
Naa60, the catalytic subunit of cognate NatF Nt-acetylase (21, 22), but these MX-Rgs2ha 
proteins were not stabilized by knockdown of the non-cognate NatB (Naa20) Nt-
acetylase (Figs. 1I and S4H, I). 
(v) Crosslinking-coimmunoprecipitation experiments indicated that Teb4 
interacted with MQ-Rgs2 (more accurately, with Nt-acetylated Ac-MQ-Rgs2ha, as shown 
below) (Fig. 2H, I). 
(vi) PQ-Rgs2ha was neither Nt-acetylated nor recognized by the Arg/N-end rule 
pathway, and was a long-lived protein, in contrast to short-lived MQ-Rgs2ha (Figs. 1G, H 
and S1C). In agreement with these in vivo results, Teb43f was coimmunoprecipitated with 
MQ-Rgs2ha (Ac-MQ-Rgs2ha) but not with PQ-Rgs2ha (Figs. 2H, I and S3C). 
(vii) GST-pulldown assays showed that Teb4f interacted with Ac-MQ-Rgs21-10-
[GST] but not with MQ-Rgs21-10-[GST] or GST alone, indicating that the binding of 
Teb4 to Ac-MQ-Rgs21-10-[GST] required its Nt-acetyl group (Figs. 2C-E and S5B). 
By increasing the rate of deactivation of G±q, Rgs2 can down-regulate G±q-
activated protein kinases, including the growth-promoting kinase Erk1/2 (3, 4). We asked 
whether the Teb4 Ac/N-recognin could regulate the activation of Erk1/2 through the 
degradation of Nt-acetylated Ac-MQ-Rgs2. The G±q-coupled M3 acetylcholine receptor 
was expressed in HeLa cells either alone or together with MQ-Rgs2ha. By activating the 
M3 receptor-coupled G±q, the agonist carbachol strongly increased the level of activated 
Erk1/2 (measured by detecting its phosphorylation by the “upstream” Mek1/Mek2 
kinases (3, 4)). As predicted by the model in which the Teb4-Rgs2 circuit regulates the 
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activation of Erk1/2, this effect of carbachol on Erk1/2 was decreased in cells that also 
expressed MQ-Rgs2ha, and was further diminished upon the RNAi-mediated knockdown 
of Teb4, a change that stabilized MQ-Rgs2ha and thereby further elevated its level (Fig. 
3C). 
Thus, wild-type human Ac-MQ-Rgs2, its hypertension-associated natural mutants 
Ac-ML-Rgs2 and Ac-MR-Rgs2, and its engineered mutant Ac-MK-Rgs2 are 
conditionally short-lived physiological substrates of the mammalian Ac/N-end rule 
pathway, and the Teb4 ubiquitin ligase acts as an Ac/N-recognin by targeting these 
proteins for degradation. Teb4 promotes G protein signaling by destroying the Ac-
MX-Rgs2 proteins (X=Q, L, R), which are targeted for degradation through their 
N±-terminal acetyl group. The faster degradation of ML-Rgs2 and MR-Rgs2 (in 
comparison to wild-type MQ-Rgs2), and their consequently lower levels can account, at 
least in part, for hypertensive phenotypes of these mutants. The resulting understanding 
of Rgs2 vis-á-vis the N-end rule pathway is summarized in fig. A2.S6. 
Identification of Teb4 as an Ac/N-recognin of the mammalian Ac/N-end rule 
pathway suggests that some previously characterized substrates of Teb4, including 
specific transmembrane proteins ((23, 24, 26) and references therein), may be recognized 
by Teb4 at least in part though their Nt-acetylated Nt-residues (Ac/N-degrons), a testable 
proposition. 
More than 30 human proteins contain an RGS-type domain (fig. A2.S7) (3, 4). 
The N-terminal Cys residue, a common feature of Rgs4, Rgs5, and Rgs16, can be 
oxidized in vivo by nitric oxide (NO) and oxygen. The resulting Nt-arginylation of 
oxidized Cys and the ensuing degradation of these RGSs by the Arg/N-end rule pathway 
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mediate its previously described function as a sensor of NO and oxygen (fig. A2.S1D) 
(reviewed in (12, 18, 19)). The present study identified Rgs2 (MQ-Rgs2) as a different 
kind of N-end rule substrate, an Nt-acetylated one. Given their inferred N-terminal 
sequences, it is possible, indeed likely, that a number of other mammalian RGS proteins 
(in addition to Rgs2, Rgs4, Rgs5 and Rgs16) may also prove to be substrates of either the 
Ac/N-end rule pathway, or the Arg/N-end rule pathway, or both of these proteolytic 
systems (fig. A2.S7). 
Many cellular proteins contain Ac/N-degrons, having acquired them at birth (13). 
These degradation signals, recognized by the Ac/N-end rule pathway, tend to be 
conditional, owing to their shielding in cognate protein complexes (15). In addition, the 
Ac/N-end rule pathway and the Arg/N-end rule pathway are functionally complementary 
(16). These insights suggest the medically relevant possibility of controlling the levels 
(and thus the activities) of many different proteins, including Rgs2 and other RGSs, by 
modulating their Ac/N-degrons or specific components of the Ac/N-end rule pathway. 
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Fig. 3.1. Rgs2 as an N-end rule substrate. (A) CHX chases with wild-type human 
MQ-Rgs2ha in wild-type, naa20”, and doa10” S. cerevisiae. (B) As in A but with ML-
Rgs2ha in wild-type, naa30”, ubr1”, and naa30” ubr1” strains. (C, D, E) Quantification 
of data in A, B and F, respectively. See the legend to fig. A2.S3 for definitions of 
“100%” levels at zero time. (F) CHX-chases with exogenously expressed MX-Rgs2ha 
(X=Q, R, L) in HeLa cells. (G) As in F but with MQ-Rgs2ha vs. PQ-Rgs2ha. (H) 
Quantification of data in G. (I) CHX-chases with exogenously expressed MR-Rgs2 in 
HeLa cells subjected to RNAi for a either a “scrambled” target or Naa60. (J) 35S-pulse-
chases with MX-Rgs2ha (X=R, Q, L) in HeLa cells.  
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Fig. 3.2. Teb4 as an Ac/N-recognin. (A) MQ-Rgs2ha in HeLa cells with or without 
Teb43f or the MG132 proteasome inhibitor. (B) CHX-chases with endogenous MQ-Rgs2, 
Teb4, and Naa20 subjected to RNAi for a “scrambled” target, or Teb4, or Naa20. The 
asterisk indicates a protein crossreacting with anti-Teb4. (C) Mr standards, purified MQ-
Rgs21-10-[GST] and purified Ac-MQ-Rgs21-10-[GST], respectively. (D) Lane 1, Teb43f 
input. Lanes 2-4, GST-pulldowns with GST alone, MQ-Rgs21-10-[GST], and Ac-MQ-
Rgs21-10-[GST], respectively. (E) As in D but Coomassie-stained GST fusions released 
from beads. (F) MQ-Rgs2ha in HeLa cells overexpressing wild-type Teb43f or Teb43fC9A. 
(G) Increases in Teb43f led to decreases in MQ-Rgs2ha. (H) HeLa cells expressing MQ-
Rgs2ha alone (lane 1) or together with Teb43f (lane 2) were treated with a cell-penetrating 
crosslinker, followed by immunoprecipitations with anti-FLAG, reversal of crosslinks, 
SDS-PAGE, and immunoblotting with anti-HA and anti-FLAG. (I) As in H but Teb43f 
alone in lane 1, and immunoprecipitations with anti-HA. 
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Fig. 3.3. G±q stabilizes Rgs2 while the Teb4-mediated degradation of Rgs2 increases 
signaling by G±q. (A) CHX-chase of MQ-Rgs2ha in HeLa cells that did not express or 
overexpressed the HA-tagged G±q. (B) Quantification of data in A. See the legend to fig. 
A2.S3 for definitions of “100%” levels at zero time. (C) HeLa cells were subjected to 
RNAi either for a “scrambled“ target or for Teb4. The M3 receptor was transiently 
expressed either alone or together with MQ-Rgs2ha. The levels of indicated proteins, 
including the levels of either total Erk1/2 or the activated (specifically phosphorylated) 
Erk1/2p, were determined by SDS-PAGE and immunoblotting of cell extracts that had 
been prepared 10 min after treatment of cells with carbachol.
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CHAPTER 4: 
ANALYZING N-TERMINAL ARGINYLATION THROUGH THE USE OF 
PEPTIDE ARRAYS AND PROTEIN DEGRADATION ASSAYS 
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INTRODUCTION 
N-terminal arginylation (Nt-arginylation) of proteins is catalyzed by the Ate1 
arginyltransferase (Arg-tRNA-protein transferase; R-transferase). This enzyme, present 
in all eukaryotes, from fungi to mammals and plants, is a component of the Arg/N-end 
rule pathway of protein degradation. R-transferase can Nt-arginylate “secondary” 
destabilizing N-terminal residues. The latter are a part of N-degrons that can be 
recognized by the Arg/N-end rule pathway. The “canonical” (definitively identified and 
characterized) secondary destabilizing  residues are N-terminal Asp and Glu, and Cys, the 
latter after its oxidation to Cys-sulfinate or Cys-sulfonate through reactions involving 
nitric oxide (NO), oxygen, and N-terminal Cys oxidases [1, 2]. Therefore N-terminal Cys 
is, formally, a “tertiary” destabilizing residue, as it has to undergo two chemical 
modification steps (oxidation and Nt-arginylation) before the recognition of a 
corresponding N-degron by N-recognins (Ub ligases) of the Arg/N-end rule pathway. 
(For a complete introduction to the N-end rule pathway see Introduction to the thesis, 
beginning on page 6, and Figs. 1.3 and 4.1). In mammals such as the mouse, there are at 
least six isoforms of R-transferase, produced through alternative splicing of the Ate1 pre-
mRNA (Fig. 4.1B and C). Differences in substrate specificity have been reported 
between R-transferase isoforms, with disagreements, on this score, among different 
laboratories [3-5]. While there are more than 10 mammalian proteins (or natural protein 
fragments) that have already been directly identified as physiological substrates of the 
Ate1 R-transferase and the rest of the Arg/N-end rule pathway, the number of 
mammalian proteins (or protein fragments) that can be predicted to be Nt-arginylated by 
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R-transferase measures in the hundreds, if predictions are based on the presence, in a 
protein or its natural fragment, of the N-terminal Glu, Asp, or Cys residues [6-10].  
The first natural proteins that were shown to contain N-terminal Cys (Nt-Cys)-
based N-degrons were the regulators of G proteins Rgs4, Rgs5, and Rgs16. They were 
initially identified as N-end rule substrates through the use of an expression-cloning 
screen in reticulocyte extract [11]. Subsequent analyses of these natural substrates 
revealed that prior to their recognition and Nt-arginylation by R-transferase, the N-
terminal Cys residue had to be oxidized to Cys-sulfonate (CysO3) [12]. This finding, as 
well as the observation that Rgs4, Rgs5, and Rgs16 each contain a basic residue 
immediately following their N-terminal Cys, led, initially, to the suggestion that a basic 
residue at position 2 (not counting the initially present and cotranslationally removed N-
terminal Met) would be required for efficient in vivo Cys-oxidation and subsequent 
Nt-arginylation. More recently, several other Ate1-dependent Arg/N-end rule substrates 
bearing N-terminal Cys but lacking a position-2 basic residue, have been identified, 
indicating that N-terminus-proximal amino acid sequence motifs that facilitate the 
oxidation and subsequent Nt-arginylation of N-terminal Cys are more complex than the 
presence of a basic residue at position 2 [6].  
Several studies, largely by the Kashina laboratory, over the last decade have 
claimed that R-transferase can also arginylate, in vivo, several “non-canonical” (non-Asp, 
non-Glu, non-Cys) Nt-residues [13-17]. Whether these claims are correct remained 
unclear, in part because the cited data were non-definitive, and also because other 
laboratories have, so far, failed to find evidence for a broader specificity of Ate1 R-
transferase [18-20]. Furthermore, another laboratory described a novel form of the 13-
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residue neurotensin hormone that apparently contained the arginylated internal Glu-4 
residue. In this posttranslational modification, the Arg residue was apparently conjugated, 
via an isopeptide bond, to the ³ -carboxyl of the Glu-4 residue [21]. While the study’s 
authors did not identify the enzyme catalyzing this reaction, a later work by Kashina and 
colleagues produced evidence consistent with the possibility that the Ate1 R-transferase 
is capable of arginylating not only alpha-amino groups of specific N-terminal residues 
but also side-chain carboxylate groups of internal (non-N-terminal) Asp and Glu residues 
[22]. These still extant, but neither definitively confirmed nor refuted lines of evidence 
[13-17, 22-25], illustrate the current uncertainty about “non-canonical” substrates of R-
transferase, outside of its unambiguously defined specificities for N-terminal Asp, Glu or 
(oxidized) Cys.  
In the present study, we employed arrays of immobilized short peptides to address 
the substrate specificity of the mouse Ate1 R-transferase. We also used reticulocyte-
based pulse-chase degradation assays to identify novel Nt-Cys substrates of the Arg/N-
end rule pathway. We report here that the four major splicing-derived isoforms of the 
mouse Ate1 R-transferase have similar Nt-arginylation specificities in vitro. We also 
demonstrate that the sequence context of a substrate’s N-terminus, particularly the 
identity of a residue at position 2, can significantly influence the rate of arginylation 
activity by R-transferase. That rate, in turn, would influence the overall kinetics of 
degradation of a corresponding protein by the Ate1-dependent arginylation branch of the 
Arg/N-end rule pathway. Furthermore, as described below, we found no evidence for any 
significant activity of the Ate1 R-transferase toward previously claimed non-canonical N-
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terminal amino acid sequences, suggesting that the earlier evidence about non-canonical 
arginylation specificities of R-transferase [14, 23] is incorrect.  
 
EXPERIMENTAL PROCEDURES 
Plasmids, cDNAs, and Primers  
 A cDNA library was generated from wild-type C57BL/6J embryonic day 12 
mouse embryos (The Jackson Laboratory, Bar Harbor, ME). Briefly, a single embryo was 
homogenized by bead-beating in Buffer RLT (Qiagen, Hilden, Germany) for 5 cycles (30 
s each, speed 6.5, resting 2 min on ice between cycles) using a FastPrep-24 (MP 
Biomedicals, Santa Ana, CA). RNA was purified from embryo homogenates using an 
RNeasy Mini kit, following manufacturer’s instructions (Qiagen). Total embryonic 
cDNA was synthesized using a Transcriptor First Strand cDNA Synthesis kit (Roche Life 
Sciences). cDNA was synthesized following manufacturer’s instructions, with 1 µg total 
RNA used as substrate with a mixture of random hexamer and oligo(dT) primers.  NEB 
Turbo Escherichia coli (New England Biolabs (NEB), Ipswich, MA) was used for 
cloning and maintaining plasmids. Phusion High-Fidelity DNA polymerase (NEB) was 
used for PCR. All constructed plasmids were verified by DNA sequencing. pKP496, the 
parental plasmid used for constructing Ub-fusion-technique (URT) plasmids, has been 
described previously [8]. 
Mdm2 – The mouse Mdm2 open reading frame (ORF) was amplified using total 
mouse embryo cDNA and primers 316 and 319 for Cys-Mdm2, primers 317 and 319 for 
Val-Mdm2, or primers 318 and 319 (Table 4.4) for ArgCys-Mdm2. The resulting 
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fragments were cut with SacII and ClaI and cloned into SacII/ClaI-cut pKP496, yielding 
the plasmids pBW117, pBW130, and pBW131, respectively. 
JunB – The mouse JunB ORF was amplified using total mouse embryo cDNA 
and primers 312 and 315 for Cys-JunB, primers 313 and 315 for Val-JunB, or primers 
314 and 315 (Table 4.4) for ArgCys-JunB. The resulting fragments were cut with SacII 
and ClaI and cloned into SacII/ClaI-cut pKP496, yielding the plasmids pBW116, 
pBW128, and pBW129, respectively. 
Cdk14 – The mouse Cdk14 ORF was amplified using total mouse embryo cDNA 
and primers 304 and 307 for Cys-Cdk14, primers 305 and 307 for Val-Cdk14, or primers 
306 and 307 (Table 4.4) for ArgCys-Cdk14. The resulting fragments were cut with SacII 
and ClaI and cloned into SacII/ClaI-cut pKP496, yielding the plasmids pBW115, 
pBW167, and pBW168, respectively. 
B2L14– The mouse B2L14 ORF was amplified using total mouse embryo cDNA 
and primers 300 and 303 for Cys-B2L14, primers 301 and 303 for Val-B2L14, or primers 
302 and 303 (Table 4.4) for ArgCys-B2L14. The resulting fragments were cut with SacII 
and ClaI and cloned into SacII/ClaI-cut pKP496, yielding the plasmids pBW114, 
pBW165, and pBW166, respectively. 
Usp27x– The mouse Usp27x ORF was amplified using total mouse embryo 
cDNA and primers 320 and 323 for Cys-Usp27x, primers 321 and 323 for Val-Usp27x, 
or primers 322 and 323 (Table 4.4) for ArgCys-Usp27x. The resulting fragments were cut 
with SacII and ClaI and cloned into SacII/ClaI-cut pKP496, yielding the plasmids 
pBW118, pBW169, and pBW170, respectively. 
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hMDM4 – The human MDM4 ORF was amplified from Dharmacon cDNA 
(Clone ID: 8144109) and primers 841 and 844 for Cys362-MDM4, primers 842 and 844 
for Val362-MDM4, or primers 843 and 844 (Table 4.4) for ArgCys362-MDM4. The 
resulting fragments were cut with SacII and ClaI and cloned into SacII/ClaI-cut pKP496, 
generating the plasmids pBW448, pBW449, and pBW450, respectively.  
hMDM2 – The human MDM2 ORF was amplified from Dharmacon cDNA 
(Clone ID:3049213) and primers 860 and 863 for Cys362-MDM2, primers 861 and 863 
for Val362-MDM2, or primers 862 and 863 (Table 4.4) for ArgCys362-MDM2. The 
resulting fragments were cut with SacII and ClaI and cloned into SacII/ClaI-cut pKP496, 
yielding the plasmids pBW448, pBW449, and pBW450, respectively.  
 
Purification of Mouse Ate1 R-Transferase from E. coli 
 E. coli plasmids expressing the untagged mouse Ate1 cDNAs, encoding Ate1 
isoforms, have been described previously [26] (Table 4.3). These plasmids pCB407 
(Ate11B7A), pCB408 (Ate11B7B), pCB409 (Ate11A7A), and pCB410 (Ate11A7B) expressed 
His10-Ub Ate1 fusions that could be purified and deubiquitylated in vitro using a  
previously described technique [27].  
 1-liter cultures of BL21(DE2) E. coli transformed with one of the above plasmids 
were grown to an A600 of ~0.6 at 37°C in Luria Broth (LB) containing 50 µg/ml 
ampicillin. Cultures were cooled on ice for 45 min, then induced by the addition of 
isopropyl-² -D-thiogalactoside (IPTG) to the final concentration of 0.25 mM for 6 h at 
room temperature. Cells were harvested by centrifugation at 2,000g for 10 min at 4°C. 
Pelleted cells were resuspended in 15 ml PBS containing 30% (vol/vol) glycerol, 0.3 M 
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NaCl, 12 mM imidazole, 20 mM ² -mercaptoethanol, and 1 mg/mL lysozyme, followed 
by freezing in liquid nitrogen. Samples were then thawed slowly on ice and centrifuged at 
27,000g for 30 min at 4°C. The N-terminal His10-Ub fusions of Ate1 isoforms were then 
purified by Ni-NTA chromatography, with elution by 0.3 M imidazole. Eluted proteins 
were dialyzed overnight against 5% (vol/vol) glycerol, 0.3 M NaCl, 2 mM ² -
mercaptoethanol, and 50 mM Na2HPO4-NaH2PO4 (pH 8.0), containing 1X Complete 
EDTA-free protease inhibitor cocktail (Roche). The N-terminal His10-Ub moiety was 
cleaved off by incubating dialyzed samples for 1 h at 37°C with purified Usp2cc 
deubiquitylase [27]. The latter was added at a 1:10 molar ratio. The resulting samples 
were dialyzed against 5% (vol/vol) glycerol, 0.15 M NaCl, 10 mM ² -mercaptoethanol, 
and 50 mM Tris (pH 7.4), followed by further purification of (deubiquitylated) Ate1 
using Mono-S chromatography (Pharmacia Biotech: Id #9723125), with an elution 
gradient between 0.15 M and 1 M NaCl in the above dialysis buffer. Peak Ate1 fractions 
were pooled and dialyzed overnight at 4°C against 30% (vol/vol) glycerol, 0.15 M NaCl, 
10 mM ² -mercaptoethanol, and 50 mM Tris-HCl (pH 7.4). 
 
CelluSpots-Based Arginylation Assay 
CelluSpots™ peptide arrays spotted on glass slides were synthesized by Intavis 
(Köln, Germany). Each slide contained two side-by-side identical copies of the array 
(Fig. 4.2A). Ate1-dependent arginylation assays were performed as described previously 
[4], with slight modifications. The peptide arrays were “outlined” with ImmEdge 
hydrophobic barrier pen (Vector Labs, Burlingame, CA) to minimize the required 
reaction volume. 90-µl reactions containing 5.8 µM 14C-Arg (Perkin Elmer 
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NEC267E050UC; 346 mCi/mmol), purified Escherichia coli tRNA (0.6 mg/mL), and E. 
coli aminoacyl-tRNA synthestases (800 U/mL; Sigma-Aldrich) in 5 mM ATP, 0.15 M 
KCl, 10 mM MgCl2, 1 mM dithiothreitol (DTT), 50 mM Tris-HCl (pH 8.0) were 
preincubated at 37°C for 15 min to allow the formation of Arg-tRNA. Thereafter a 
specific purified Ate1 isoform (2 µg) was added and the resulting mixtures (100 µl final 
volumes) were added to each array. Arginylation reactions were allowed to proceed for 1 
h at 37°C in a humidified chamber with gentle rocking. Reactions were quenched by 
rinsing the arrays twice with a large volume excess (10 ml) of Tris-Buffered Saline (TBS) 
containing also 1% Tween-20 and RNase A (10 µg/µl). Arrays were then washed 3 times 
for 20 min each in the same buffer (including RNase A) at 37°C, followed by an 
overnight (~16 h) wash in TBS containing 1% Tween-20 (without RNase A) at room 
temperature. The resulting slides were washed once with 10 mM Tris, pH 7.5, and were 
allowed to air-dry, followed by a 2-week autoradiograhy, using a Phosphorimager-type 
screen. The exposed screens were scanned using a Storm-860 Scanner (Molecular 
Dynamics, Caesarea, Israel). Quantification of 14C spot intensities was performed using 
the array analysis module of ImageQuant TL software (GE Healthcare, Little Chalfont, 
UK).  
 
In Vitro Transcription–Translation–Degradation Assay 
The TNT T7 Coupled Transcription/Translation System (Promega, Madison, WI) 
was used to carry out transcription–translation–degradation assays, largely as described 
previously [8, 9, 28]. Nascent proteins in reticulocyte extract were pulse-labeled with L-
[35S]methionine (0.55 mCi/ml, 1,000 Ci/ mmol; MP Biomedicals, Santa Ana, CA) for 10 
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min at 30°C in the total volume of 30 µl. The labeling was quenched by the addition of 
cycloheximide and unlabeled methionine to the final concentrations of 0.1 mg/ml and 5 
mM, respectively, bringing the total volume to 40 µl. Samples of 10 µl were removed at 
the indicated time points, and the reaction was terminated by the addition of 80 µl of TSD 
buffer (1% SDS, 5 mM DTT, 50 mM Tris-HCl, pH 7.4), snap-frozen in liquid nitrogen, 
and stored at -80°C until use. Samples were then heated at 95°C for 10 min and then 
diluted with 1 ml of TNN buffer (0.5% NP40, 0.25 M NaCl, 5 mM Na-EDTA, 50 mM 
Tris-HCl, pH 7.4) containing 1x Complete Protease Inhibitor Cocktail (Roche 
Diagnostics, Indianapolis, IN). Samples were immunoprecipitated using 10 µl of 
anti-FLAG M2 magnetic beads (Sigma-Aldrich) with rocking at 4°C for 4 h, followed by 
four washes in TNN buffer, resuspension in 20 µl SDS sample buffer, and heating at 
95°C for 10 min followed by SDS 4–15% PAGE and autoradiography. Quantification of 
autoradiograms was carried out using Storm 860 Scanner (Molecular Dynamics).  
 
RESULTS and DISCUSSION 
Use of CelluSpots Peptide Arrays to Analyze the Specificity of R-Transferase 
 CelluSpots arrays are produced by the synthesis of peptides on a modified 
cellulose support that is dissolvable in trifluoroacetic acid (TFA) solution, thereby 
allowing the synthesized peptides to be (repeatedly) spotted onto coated microscope 
slides. This technology makes possible the synthesis of many replicate copies of a peptide 
array from a single set of peptide-synthesizing reactions. CelluSpots arrays have been 
successfully used to examine the specificity of histone-modifying enzymes for amino 
acid sequences in histones, to analyze the binding specificity of antibodies, to 
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characterize the binding specificity of SH2 (Src homology 2 domain) protein regions for 
phosphotyrosine-containing peptides, and to survey the specificities  of kinases and 
kinase inhibitors [29-32].   
 To analyze the in vitro substrate specificity of the mouse Ate1 R-transferase, we 
performed 14C-arginylation assays using a set of identical CelluSpots peptide arrays, each 
of which comprised 96 11-residue peptides. The readily attainable amino acid sequence 
diversity of these peptide-based assays, the availability of nearly unlimited identical 
copies of a given peptide array, and technically straightforward biochemical conditions of 
in vitro arginylation made CelluSpots a particularly promising approach to defining the in 
vitro specificity of mouse Ate1 R-transferase isoforms [4, 12, 33]. Amino acid sequences 
of peptides in our CelluSpots arrays were designed to examine several substrate-
recognition aspects of R-transferase, including effects of a second-position residue, 
effects of charge clusters immediately downstream of the (arginylatable) N-terminal 
residue, effects of the Pro residue (an imino acid) close to N-terminal residue, and the 
influence of oxidation of N-terminal Cys on its ability to act as an acceptor of Arg in 
Ate1-catalyzed reactions. We also wished to address, using the technically direct and 
conceptually independent peptide-array technology, the earlier claims about arginylation, 
by the Ate1 R-transferase, of non-canonical amino acid sequences [14, 21-23] (Fig 4.2 
and Table 4.1).  
As a part of initial quality controls, and also to verify that peptides on CelluSpots 
arrays could actually serve as efficacious substrates of R-transferase, the arginylation 
reaction was optimized on slides containing duplicate copies of the 96-peptide array, in 
either the presence or absence of the purified mouse Ate1 R-transferase (Fig. 4.2). In 
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addition, the expected “positive” (a priori arginylatable) peptides and “negative” (a priori 
non-arginylatable, control) peptides were interspersed with other peptides throughout a 
CelluSpots array. Several peptides were included in duplicate, making it possible to 
assess the extent of variability of these arginylation assays within each experiment (see 
Methods). Preliminary experiments confirmed that CelluSpots peptides could serve as 
efficacious Ate1-dependent arginylation substrates, as illustrated by the incorporation of 
14C-Arg vis-à-vis each peptide spot and by the strict dependence of this incorporation on 
the presence of added Ate1 (Fig. 4.2B and Methods).  
 
Different Ate1 Isoforms Exhibit Similar Substrate Preferences 
The first subset of peptides on the array was designed to examine the effects of a 
second-position amino acid residue on Ate1-dependent arginylation. The 11-mer peptides 
for this experimental set, termed GSG, contained the Gly-Ser-Gly sequence at positions 
3-5, followed by a quasi-randomly chosen sequence, Phe-Gly-Pro-Ala-Ser-Gly, at 
positions 6-11 (Fig. 4.3). The resulting sequence (positions 3-11) is not significantly 
similar to sequences in natural mouse proteins. Twenty 11-residue peptides containing 
the above “downstream” 9-residue sequence were designed to bear N-terminal Asp, a 
residue that is apparently the most efficacious acceptor of Arg (among N-terminal Asp, 
Glu or oxidized Cys), followed by a variable residue at position 2. In the resulting 
notation, specific 11-residue peptides of this set are denoted as D(X)GSG, with “D” 
signifying N-terminal Asp. A second set of twenty otherwise identical peptides, termed 
R(X)GSG, contained, each, the N-terminal Arg residue, which is not expected to be 
arginylated by Ate1. Peptides of this (R(X)GSG) set were used as negative controls. 
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Preliminary experiments indicated that each of the twenty a priori arginylatable D(X)GSG 
peptides, with varied residues at position 2, could indeed be arginylated by the added R-
transferase, whereas none of the otherwise identical twenty R(X)GSG peptides (negative 
controls) were arginylated above background levels (Fig. 4.2B).  
Four major splicing-derived isoforms of the mouse Ate1 R-transferase have been 
described. They differ by the presence or absence of exon 1a versus 1b and exon 7a 
versus exon 7b. (Fig. 4.1B, 4.1C, and Introduction). To determine whether these Ate1 
isoforms are comparably sensitive to the identity of the second residue in a substrate 
peptide, we examined each purified Ate1 isoform using CelluSpots arrays. The relative 
activities of all four mouse Ate1 R-transferase isoforms toward the same test peptides in 
four identical peptide arrays were found to be approximately the same (Fig. 4.3). Among 
the four isoforms, Ate11A7B exhibited a significantly lower overall enzymatic activity (per 
µg of added enzyme) than the other three isoforms, but the substrate preferences of 
Ate11A7B, vis-à-vis the examined set of peptides, were still similar to those of the other 
three isoforms (Fig. 4.3). All four Ate1 isoforms exhibited a significant preference for 
either a hydrophobic or a basic residue at position 2, in comparison to acidic residues or 
the Pro residue at this position (Fig. 4.3).  
 
The Rate of Arginylation Is Influenced by the Overall Charge of a Region Adjacent 
to N-Terminal Residue  
 To examine whether the overall charge of a substrate’s N-terminal region 
significantly affects arginylation of, for example, N-terminal Asp by Ate1, we assayed 
specific isoforms of purified mouse R-transferase using a D(X)GSG peptide array in which 
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“X” was either a single residue or a stretch of four consecutive Asp, Arg, or Ala residues, 
starting at position 2. In the peptides where only a single Asp, Arg, or Ala residue was 
present (at position 2), the adjacent 3-residue sequence Gly-Ser-Gly remained at positions 
3-5. In the peptides bearing a stretch of four consecutive Asp, Arg, or Ala residues, both 
position 2 and the Gly-Ser-Gly motif in positions 3-5 were replaced by these runs of 
identical residues (Fig. 4.5C). 
All four Ate1 R-transferase isoforms exhibited significantly decreased efficacies 
of arginylation with peptides in which N-terminal Asp was followed by four basic (Arg) 
residues, in comparison to a single Arg at position 2 (Fig. 4.5A, columns 1 and 2; 
DR1GSG versus DR4GSG). All four Ate1 isoforms were also significantly less efficacious 
when N-terminal Asp was followed by four acidic (Asp) residues, in comparison to a 
single Asp at position 2 (Fig. 4.5A, columns 5 and 6; DD1GSG versus DD4GSG). In 
contrast, a difference in the efficacy of arginylation was much smaller when the N-
terminal Asp residue was followed by four small uncharged (Ala) residues, in 
comparison to a single Ala at position 2 (Fig. 4.5A, columns 9 and 10; DA1GSG versus 
DA4GSG). Notably, even a single downstream (second-position) Asp made the resulting 
peptide a significantly less efficacious arginylation substrate than the otherwise identical 
peptide in which N-terminal Asp was followed by either a single positive (Arg) residue or 
a single small uncharged (Ala) residue (Fig 4.5A, compare column 1 with columns 5 and 
9).  
 We next asked whether specific single-residue changes at position 2 altered the 
efficacy of Nt-arginylation of peptides containing the “canonical” arginylatable N-
terminal residues, specifically Asp, Glu, or (oxidized) Cys. With peptides bearing N-
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terminal Asp or Glu, their Ate1-mediated arginylation was found to be decreased (other 
parameters being equal) when either an acidic residue (Asp), or the Pro residue was 
present at position 2, in comparison to otherwise identical peptides bearing either Ser or 
Lys at position 2 (Fig. 4.6, columns 2, 4, 10, and 12). The isoform Ate11B7B was more 
sensitive to the presence of Asp at position 2 than the other three Ate1 isoforms, a rare 
example of detectable specificity differences among Ate1 isoforms (Fig. 4.6A and B). In 
this set of experiments, peptides bearing N-terminal Cys were not significantly Nt-
arginylated nearly irrespective of the identity of a residue at position 2, in agreement with 
the previously identified requirement for a preliminary oxidation of N-terminal Cys [1, 
12]. A small increase over background 14C-Arg incorporation could be consistently 
observed with peptides bearing unmodified Cys when the second residue was basic (Arg) 
(Fig. 4.6A, columns 5-8). This effect could be caused either by a weak increase in the 
otherwise negligible activity of R-transferase toward unoxidized N-terminal Cys when 
the second residue was basic (Arg) or, non-alternatively, by a (possibly) increased 
propensity of N-terminal Cys to be partially (and nonenzymatically) oxidized to Cys-
sulfinate or Cys-sulfonate by oxygen in the air if the second residue was basic.  
 
The Rate of Ate1-Dependent Protein Degradation is Sensitive to the Overall Charge 
of a Region Adjacent to N-terminal Residue  
To determine whether the observed influence of second-position residues and 
charge clusters on the efficacy of Nt-arginylation in CelluSpots assays were relevant to 
the rate of Ate1-dependent protein degradation, we carried out degradation assays using 
the previously described transcription-translation-degradation reticulocyte extract that 
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contains the Arg/N-end rule pathway [7-9]. Our Arg/N-end rule substrates were based on 
Rgs4, a regulator of specific G proteins that has been identified as an Ate1-dependent 
physiological substrate of the Arg/N-end rule pathway [1, 11, 34]. Mammalian Rgs4 
proteins bear N-terminal Cys, after the cotranslational removal of their N-terminal Met 
by MetAPs. N-terminal Cys of Rgs4 has been shown to be efficaciously oxidized, by NO 
and oxygen, either in vivo or in reticulocyte extract to (ultimately) Cys-sulfonate, which 
can be Nt-arginylated by the Ate1 R-transferase. The resulting Nt-arginylated Rgs4 is 
processively destroyed to short peptides by the post-arginylation part of the Arg/N-end 
rule pathway (Fig. 4.4) [1, 12].  
Our degradation assays in reticulocyte extract employed the Ub reference 
technique (URT), derived from the Ub fusion technique [35]. In this method, the 
cotranslational cleavage of a URT-based protein fusion by deubiquitylases in reticulocyte 
extract produces, at the initially equimolar ratio, a test protein with a desired N-terminal 
residue and a “reference” protein, in the present case fDHFR-UbK48R, a flag-tagged 
derivative of the mouse dihydrofolate reductase (Fig. 4.4A). In URT-based pulse-chase 
assays, a pulse-labeled test protein is quantified, during chase, by measuring its level 
relative to that of a stable reference protein at each time point, thereby increasing the 
accuracy of pulse-chase assays [35-37] 
To simplify the mechanics of initial targeting, i.e., to bypass the N-terminal Cys-
oxidation step required for the degradation of wild-type Rgs4 [1, 12, 34], its natural N-
terminal Cys was mutated to Asp, in the context of a URT fusion (Fig 4.4A). The 
resulting Rgs4C2Dwas a direct substrate of the Ate1 R-transferase. In rabbit reticulocyte 
extract, DARgsS4f (bearing the N-terminal sequence Asp-Ala, i.e., bearing two N-terminal 
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mutations vis-à-vis the wild-type CKRgs4 protein)) was degraded with a t1/2 < 10 min 
(Fig. 4.4B, lanes 5-8), whereas the otherwise identical RARgs4f (bearing the N-terminal 
sequence Arg-Ala) was degraded even more rapidly (t1/2 < 1 min; Fig 4.4B, lanes 1-4), 
because in the latter case the preliminary step of Nt-arginylation was neither possible nor 
necessary (Fig. 4.1A). In contrast, the otherwise identical VARGS4f protein (bearing the 
N-terminal sequence Val-Ala, which is not recognized by the Arg/N-end rule pathway) 
was stable during the chase (t1/2 >> 45 min; Fig. 4.4B, lanes 9-12). In sum, this set of 
otherwise identical test proteins, which differ solely at their positions 1 and 2, is a 
particularly suitable setting for examining effects of N-terminus-proximal changes on the 
rate of protein degradation by the Arg/N-end rule pathway (Fig 4.4B and C).  
We also constructed derivatives of RGS4C2D that contained either one or four Asp 
residues at positions 2-5 or, alternatively, either one or four Arg residues at the same 
positions, to determine whether the overall charge in the immediate vicinity of protein’s 
N-terminus can affect the degradation of a protein by the Arg/N-end rule pathway. 
Remarkably, a stretch of four acidic (Asp) residues after N-terminal Asp (DD4RGS4f) 
rendered the test substrate long-lived, despite the fact that the N-terminal Asp residue, 
when it is present in favorable downstream sequence contexts (see above), is apparently 
the best substrate for Ate1-mediated arginylation (Fig. 4.5D, lanes 13-16, and Fig. 4.5E). 
In contrast, when four basic (Arg) residues followed Asp, the rate of degradation of the 
resulting DR4RGS4f was nearly identical to that of DR1RGS4f, which contained a single 
Arg residue after N-terminal Asp (Fig. 4.5D, lanes 5-8 versus lanes 1-4, and Fig. 4.5E). 
These protein degradation-based findings were in agreement with the results of peptide-
based Nt-arginylation assays with peptides whose N-terminal sequences were identical to 
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those of XZ-Rgs4f test proteins. Together, the results with CelluSpots peptide arrays and 
protein degradation assays in reticulocyte extract (Fig. 4.5A and B) indicated that acidic 
residues immediately downstream of an otherwise Nt-arginylatable N-terminal residue 
(e.g., Asp) of a protein can strongly attenuate its R-transferase-mediated Nt-arginylation 
and, consequently, the rate of its degradation by the Arg/N-end rule pathway.  
We also compared degradation-rate effects of a second-position basic residue 
(Arg) versus acidic residue (Asp) and versus the imino residue Pro in the corresponding 
Asp-Z-Rgs4 proteins (Z=Asp, Pro, Lys). In agreement with a partial inhibition of 
arginylation of the analogous CelluSpot peptides (Fig. 4.6A), either an acidic residue 
(Asp) or the Pro residue at position 2 of the above Asp-Z-Rgs4f reporters significantly 
decreased the rate of their degradation , in comparison to otherwise identical Asp-Z-
Rgs4f proteins that contained a basic (Lys) residue at position 2 (Fig. 4.6C and D). These 
results indicated that the identity of a residue at position 2 of an arginylation-dependent 
N-degron in a protein can strongly influence its degradation rate, at least in part by 
altering the rate of its (pre-degradation) Nt-arginylation.   
 
Oxidation of N-terminal Cys in CelluSpots Peptides Allows Their Arginylation  
Earlier studies of N-degrons containing N-terminal Cys have shown that the Ate1-
mediated Nt-arginylation of Cys required its preliminary oxidation to Cys-sulfinate or 
Cys-sulfonate [1, 12]. In contrast, other earlier studies suggested that the Ate1 isoforms 
Ate11A7A and Ate11A7B might be R-transferases that are relatively specific for N-terminal 
Cys [3]. Our results with CelluSpots arrays indicated that the unmodified N-terminal Cys 
is either a poor arginylation substrate of the Ate1 R-transferase or not a substrate at all. 
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The latter possibility would obtain if the observed weak (barely above background) Nt-
arginylation of N-terminal Cys-bearing CelluSpots peptides resulted from their partial 
nonenzymatic oxidation during preparation and handling of peptide arrays (Fig. 4.6A, 
columns 5-8). 
To compare specific Ate1 R-transferase isoforms by their ability to arginylate the 
unmodified versus oxidized N-terminal Cys residue, we used Rgs4-derived (“wild-type” 
or modified) N-terminal peptides that contained either an unmodified (i.e., not 
deliberately oxidized) N-terminal Cys or oxidized N-terminal Cys (Cys-sulfonate) that 
was substituted for unmodified Cys during the synthesis of these peptides. As expected 
(given the previous evidence about oxidized N-terminal Cys being a prerequisite for its 
Nt-arginylation [1, 12]), we found that peptides bearing the N-terminal Cys-sulfonate 
residue (incorporated during peptide synthesis) were much better arginylation substrates 
than the otherwise identical peptides bearing the unoxidized (more accurately, not 
deliberately oxidized) N-terminal Cys residue (Fig. 4.7A, column 4 versus column 3).  
Significantly, peptides bearing the oxidized (at the stage of peptide synthesis) N-
terminal Cys-sulfonate were still not as efficacious acceptors of Arg in the Ate1-
catalyzed conjugation reaction as were the otherwise identical peptides bearing N-
terminal Asp (Fig. 4.7A, column 4 versus column 2). As one would expect, the negative-
control peptides, bearing the N-terminal Arg-Cys sequence (a mimic of Nt-arginylated 
oxidized Cys) were not arginylated at all (Fig. 4.7A, column 1). All four examined 
isoforms of the mouse Ate1 R-transferase exhibited indistinguishable relative efficacies 
of arginylation in this N-terminal Cys-based setting. This result overtly disagreed with 
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the earlier assertion that some among these isoforms of Ate1 are relatively specific for N-
terminal Cys [3]. 
 
Results with CelluSpots Assays Contradict the Earlier Claim About Arginylation of 
Proteins with N-terminal Residues That Are Distinct From Asp, Glu and Cys  
 Papers by Kashina and colleagues [14, 15, 21] have claimed, largely on the basis 
of mass spectrometric (MS) data, that several proteins (or protein fragments) were 
arginylated in vivo despite the absence of the canonical arginylatable N-terminal residues 
(Asp, Glu, Cys) at the N-termini of those proteins. Inasmuch as these claims were not 
based on a technically definitive evidence, and given the utility of CelluSpots arrays in 
addressing the substrate specificity of  arginylation, we carried out arginylation assays 
with 11-residue peptides whose sequences were identical to N-terminal sequences of 
several mammalian proteins (or protein fragments) that Kashina and colleagues described 
as in vivo arginylation substrates [14].  
Of the ten examined CelluSpots peptides, corresponding to N-terminal sequences 
of the ten previously described putative in vivo arginylation substrates [14], only one of 
them exhibited a (possible) weak above-background arginylation in CelluSpots 
arginylation assays (Fig. 4.7C, lanes 2-11, and Table 4.1). The sequence of the (weakly) 
positive 11-residue peptide (Fig. 4.7A, column 6) was identical to the first 11 residues of 
the Lys448-Lys464 fragment of the mouse MPAST2 protein (MPAST2K448-K464 that was 
detected by the earlier MS analyses and classified as an arginylated fragment [14]. The 
observed weakly-above-background arginylation of the MPAST2-derived peptide, in 
CelluSpots assays, was weaker than the extent of arginylation of unmodified Cys test 
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peptides (Fig. 4.6A) and considerably weaker than the arginylation of “positive” control 
peptides in the same row of peptides (Fig. 4.7C, columns 1 and 12). The nine other 
peptides, whose amino acid sequences were identical to the N-terminal sequences of 
peptides from the nine other proteins that have been claimed, by Kashina and colleagues, 
to be arginylated [14], did not exhibit any arginylation above background levels of 
CelluSpots arginylation assays (Fig. 4.7C, lanes 2-11, and Table 4.1). 
 In one of the above-cited earlier  works, a peptide corresponding to the Met589-
Lys606 fragment of the mouse Myh9 protein (termed Myh9M589-K606), was detected by 
MS and was classified as a peptide bearing the arginylated “non-canonical” Met-589 
residue, with the underlying assumption that the Met-589 residue was the N-terminal 
residue of a corresponding (in vivo-formed) fragment of the Myh9 protein [14]. We 
carried out additional CelluSpots assays to determine whether, for example, an altered 
chemical state of N-terminal Met of the Met589-Lys606 fragment might have been 
responsible for the earlier data indicating that fragment’s arginylation [14]. Specifically, 
we asked whether the Ate1 R-transferase could arginylate any of the 11-residue peptides 
whose sequences were either identical to the N-terminal sequence of the Myh9M589-K606 
peptide [14] (bearing unmodified N-terminal Met), or contained the same sequence save 
for an N-terminal Met-sulfoxide (instead of unmodified Met), or Met-sulfone, or Arg-
Met. The latter would be an a priori non-arginylatable N-terminal sequence, used as a 
negative control. We found that none of these peptides, including the “wild-type” 
sequence of Myh9M589-K606, generated a 14C-Arg arginylation signal above background of 
CelluSpots arginylation assays, indicating the inability of these peptides to serve as Ate1 
substrates at least in vitro (Fig. 4.7B, columns 1-4).  
124 
 
In another earlier study, a short peptide called neurotensin (it is produced through 
the processing of a larger precursor protein in the endoplasmic reticulum (ER) and Golgi, 
i.e., outside the currently known locations of the cytosolic/nuclear Ate1 R-transferase), 
was observed to be arginylated at its internal Glu-4 residue, presumably through the 
conjugation of Arg to the ³ -carboxyl group of Glu-4 [21]. We examined, using 
CelluSpots arginylation assays, a set of 11-residue peptides designed to mimic the N-
terminal sequence of neurotensin that encompasses its Glu-4 residue. These peptides 
were synthesized to contain either the above Glu-4 of wild-type neurotensin or one of 
several other residues (Asp, Glu, Asn, or Gln) at the same position 4. Because the natural 
N-terminal sequence of neurotensin starts with the Gln residue, a nonenzymatic 
deamidation of that Gln would result in N-terminal Glu, a canonical arginylatable N-
terminal residue (Fig. 4.1A) [38, 39]. To preclude the possibility of Nt-arginylation of 
neurotensin-like CelluSpots peptides, their N-termini were designed to bear Ala instead 
of wild-type Gln. We found that none of these neurotensin peptide mimics generated a 
14C-Arg arginylation signal above background of CelluSpots assays, indicating their 
inability to serve as Ate1 substrates at least in vitro (Fig. 4.7B, columns 5-8). 
To the best of our knowledge, the most plausible alternative explanation of the 
overt discrepancy between our results and the earlier reports by Kashina and colleagues 
(cited above) that might “rescue” the arginylation-based interpretation of the earlier 
evidence is that our arginylation assays, which employed purified mouse Ate1 R-
transferase isoforms, might have been missing a relevant (protein-based?) modifier of R-
transferase activity that would have endowed Ate1 with the claimed (expanded) substrate 
specificity. 
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To address this possibility, we carried out otherwise identical CelluSpots 
arginylation assays in which gently prepared extracts from mouse Neuro2A cells were 
added to reaction mixes either in the absence or the presence of additionally added 
purified Ate11B7A. This modification of CelluSpots assays did not alter any of the findings 
described above, making the above (potential) explanation much less likely but not 
definitively refuted, given the in vitro nature of CelluSpots assays. 
 
Analyzing Natural N-terminal Cys-Bearing Proteins for Their Degradation by the 
Arg/N-end rule pathway 
 At present, Rgs4, Rgs5 and Rgs16 proteins are the only known physiological 
substrates of the mammalian Arg/N-end rule pathway that bear N-terminal Cys as a result 
of the cotranslational removal of N-terminal Met, by MetAPs, from nascent counterparts 
of these proteins [1, 11, 34]. In an attempt to identify other physiological Arg/N-end rule 
substrates whose N-terminal Cys is, initially, a position-2 residue, we employed the Ub-
reference technique (URT) (Fig. 4.4A) to express specific natural proteins whose N-
termini begin with a Met-Cys sequence. A search, in the UniprotKB/Swiss-Prot 
databases, for human proteins whose ORFs encode the N-terminal Met-Cys sequence 
brought up ~180 such proteins (excluding splice variants; ScanProsite). As described 
below, we examined five proteins from this set (Fig. 4.8). These proteins were chosen for 
pulse-chase assays in reticulocyte extract in part because their (encoded) Met-Cys N-
termini were highly (essentially completely) conserved among at least mammals (data not 
shown). Despite this conservation, and in contrast to results with Rgs4, Rgs5, and Rgs16, 
the URT-based pulse-chase assays with the above five N-terminal Cys-bearing proteins 
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showed that none them were significantly more unstable when expressed with N-terminal 
Cys versus N-terminal Val (the latter residue is not recognized by the Arg/N-end rule 
pathway at least in reticulocyte extract [6, 7, 9]). 
An N-degron recognized by the Arg/N-end rule pathway comprises at least two 
determinants: a destabilizing N-terminal residue and a targetable (usually 
conformationally mobile) internal Lys residue(s) [40]. We asked whether the lack of 
degradation of the above  proteins (Fig. 4.8) by the Arg/N-end rule pathway (which can 
confer a short half-life on, for example, Cys-Rgs4, a previously identified N-terminal 
Cys-bearing Arg/N-end rule substrate) was caused by the failure to arginylate their N-
terminal Cys residues in reticulocyte extract, or was, instead, the result of a block at a 
post-arginylation step, owing, for example, to the absence of an efficaciously 
ubiquitylatable internal Lys and/or to inefficient degradation of a targeted and 
polyubiquitylated protein by the proteasome. To distinguish between some of these 
possibilities, each of the proteins in Fig. 4.8 was also expressed as its “pre-arginylated” 
Arg-Cys counterpart. 
Tellingly, in each of these cases the Arg-Cys-bearing versions of the original N-
terminal Cys-bearing proteins were short-lived in reticulocyte extract, in contrast to 
otherwise identical proteins bearing N-terminal Cys (Figs. 4.8B-J). We conclude that the 
lack of rapid degradation of the examined N-terminal Cys-bearing proteins that are cited 
in Fig. 4.8 was caused by their slow (possibly negligible) Nt-arginylation, implying that 
their N-terminal Cys residues could not be efficaciously oxidized under conditions in 
which the N-terminal Cys of, for example, Rgs4 could be rapidly oxidized and 
arginylated [11, 34] (Fig. 4.8).  
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With some of the tested N-terminal Arg-Cys-bearing proteins, a decrease in the 
level of an Arg-Cys-protein band during the chase was accompanied by the accumulation 
of high molecular mass derivatives of that proteins, suggesting that even when “pre-
arginylated” Arg-Cys proteins were polyubiquitylated, some of them encountered 
additional kinetic inefficiencies at a stage that followed their polyubiquitylation, e.g., the 
stage of their actual degradation by the proteasome (data not shown).  
 
Identification of a Natural Fragment of hMDM4 as an N-terminal Cys-
Bearing Substrate of the Arg/N-end rule pathway  
A Cys residue that resides at position 2 of a nascent protein is made N-terminal 
cotranslationally, through the (usually) complete removal of the initially present Met 
residue by ribosome-associated MetAPs [41]. In contrast, an internal Cys residue can be 
made N-terminal through a sequence-specific cleavage of a protein by a nonprocessive 
protease, such as a caspase, a calpain, or a separase. These and analogous intracellular 
proteases would cleave, posttranslationally, a subset of a given protein’s molecules at a 
cleavage site in which the above Cys would be a P1’ residue. Both N-terminal and 
internal Cys residues are susceptible not only to oxidation (described above) but also, for 
example, to palmitoylation (a reversible modification) or, alternatively, to Nt-acetylation, 
an apparently irreversible modification that can make a protein a target for degradation 
by the Ac/N-end rule pathway (Fig. 4.1) [42-47]. In sum, the actual metabolic fate of a 
newly exposed (cotranslationally or posttranslationally) N-terminal Cys is a function 
ofseveral kinetically competing, mutually exclusive chemical modifications. This 
complexity accounts, in part, for the current difficulty of predicting whether a specific N-
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terminal Cys-bearing protein would be an efficacious substrate of the arginylation branch 
of the Arg/N-end rule pathway (positive examples: the Rgs4, Rgs5, Rgs16), or whether 
such a protein would remain long-lived, despite the presence of N-terminal Cys (negative 
examples: the proteins cited in Fig. 4.8).  
Our laboratory has previously described two (out of two actually tested) natural 
C-terminal protein fragments that are produced through posttranslational cleavages of 
full-length proteins by caspases, bear (as a result) N-terminal Cys, and could be shown to 
be short-lived substrates of the Arg/N-end rule pathway [6].  It is possible that 
posttranslationally (as distinguished from cotranslationally) generated protein fragments 
bearing N-terminal Cys would be, in general, more likely to be efficacious (short-lived) 
substrates of the Arg/N-end rule pathway, owing, for example, to their relatively slow 
posttranslational Nt-acetylation (since the bulk of Nt-acetylases are associated with the 
ribosomes, resulting in their relative low levels in the bulk solvent). To address this 
possibility, we searched CutDB [48], a database of proteolytic cleavages, for 
posttranslationally generated C-terminal protein fragments bearing N-terminal Cys, 
identifying 39 C-terminal fragments of natural proteins that are produced by single 
posttranslational proteolytic cleavages and bear N-terminal Cys (Table 4.2). Two of these 
N-terminal Cys-bearing proteins, Traf1 and Ripk1, were previously identified by our 
laboratory as short-lived Arg/N-end rule substrates [8].  
Four of the newly identified (through the above CutDB search), 
posttranslationally generated C-terminal protein fragments bearing N-terminal Cys also 
contained a second-position basic residue. The resulting Cys-basic residue motif is 
identical to the one in, e.g., Rgs4, a known arginylated and short-lived substrate of the 
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Arg/N-end rule pathway [1, 11, 34]. We used pulse-chase assays in reticulocyte extract to 
examine two of the above four N-terminal Cys-bearing, caspase-generated protein 
fragments specifically the Mdm4 protein (mouse double minute 4 homolog) and the 
Mdm2 protein, an E3 Ub ligase that targets, in particular, the p53 protein (Fig. 4.9).  
URT-based pulse-chases indicated that the N-terminal Cys-bearing fragment of 
human Mdm4 was, in fact, short-lived in reticulocyte extract, in contrast to its otherwise 
identical N-terminal Val-bearing counterpart (Fig. 4.9B). In vivo pulse-chases, in human 
HEK293T cells, of the same set of Mmd4 fragments, bearing N-terminal Cys, Val, or 
ArgCys, confirmed the instability of the fragments bearing N-terminal Cys and N-
terminal ArgCys, in comparison to their N-terminal Val-bearing counterpart (a control) 
(Fig. 4.9C). We conclude that this N-terminal Cys-bearing fragment of human Mdm4 is 
indeed, most likely, a physiological substrate of the Arg/N-end rule pathway. 
In contrast to instability of the human Mdm4 C-terminal fragment, the caspase-
generated, N-terminal Cys-bearing fragment of human Mdm2, which also contained the 
N-terminal Cys-basic residue motif, was found to be long-lived in reticulocyte extract 
(Fig. 9A). Together, these findings indicated, yet again, that the metabolic instability of 
an N-terminal Cys-bearing protein (or a protein fragment) is a function of multiple 
kinetic variables, including the timing of fragment’s formation (e.g., cotranslational 
versus posttranslational), the nature of a sequence immediately downstream of N-
terminal Cys, and other parameters as well including specific aspects of a (potential) N-
degron outside the immediate vicinity of the fragment’s N-terminus. Further studies, 
including those that use wild-type versus Ate1-lacking mice, will be required to verify, 
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definitively, whether the caspase-generated, N-terminal Cys-bearing C-terminal fragment 
of Mdm4 is a bona fide Arg/N-end rule substrate in specific mouse tissues.  
Experimental approaches described above employed CelluSpots peptide arrays as 
a useful tool for analyzing Ate1-mediated arginylation and its specificity. By examining a 
broad range of N-terminal sequences and by taking advantage of the “repeatability” 
(multiple copies) of CelluSpots assays, we were able to demonstrate that there is little if 
any qualitative difference, at least in vitro, between the four mouse Ate1 R-transferase 
isoforms in their specificities of arginylation. We also verified and confirmed, using the 
CelluSpots strategy, the canonical arginylatable N-terminal residues Asp, Glu, and 
(oxidized) Cys are, in fact, the most preferred (and possibly virtually exclusive) 
substrates of Ate1-encoded R-transferases. We also analyzed specific sequence 
requirements immediately downstream of an (arginylatable) N-terminal residue, and 
showed, among other things, that the identity of a residue at position 2 can significantly 
influence the efficacy of arginylation by R-transferase and ultimately, therefore, the 
degradation rate of a corresponding protein (or a protein fragment) by the Arg/N-end rule 
pathway. 
Tellingly, we found no evidence that the mouse Ate1 R-transferase can arginylate 
non-canonical N-terminal residues (as described above, such an ability was claimed in 
earlier studies by another laboratory [14]). We also found no supporting evidence for 
another earlier claim, by the same laboratory [22], of the possibility of Ate1-mediated 
arginylation of gamma-carboxyl side chains of either N-terminal or internal Asp or Glu 
residues. These negative results are in agreement with other recent reports that failed to 
confirm the above earlier claims [18-20]. Although our attempts to determine whether the 
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specificity of purified R-transferase can be altered (expanded?) by a factor present in 
mouse cell extracts have also yielded negative conclusions (see above), a caveat to these 
otherwise detailed and rigorous arginylation data (Figs. 4.5-4.7) is that they are largely 
based on in vitro assays, and therefore may still overlook a setting in which the 
specificity of R-transferase may be altered relative to the one observed in vitro. While 
unlikely, this possibility cannot be precluded, at present. 
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Fig. 4.1. The mammalian Arg/N-end rule pathway and Ate1 arginyltransferase isoforms. 
A. The Arg/N-end rule pathway. The prefix “Arg” in the pathway’s name refers to N-terminal 
arginylation (Nt-arginylation) of N-end rule substrates by the Ate1 arginyltransferase 
(R-transferase), a significant feature of this proteolytic system. The Arg/N-end rule pathway 
targets specific unacetylated N-terminal residues. In the yeast S. cerevisiae, the Arg/N-end rule 
pathway is mediated by the Ubr1 N-recognin, a 225 kDa RING-type E3 ubiquitin ligase and a 
part of the targeting apparatus comprising a complex of the Ubr1-Rad6 and Ufd4-Ubc4/5 
holoenzymes. In multicellular eukaryotes several functionally overlapping E3 ubiquitin ligases 
(Ubr1, Ubr2, Ubr4, Ubr5) function as N-recognins of this pathway. An N-recognin binds to the 
“primary” destabilizing N-terminal residues Arg, Lys, His, Leu, Phe, 9 Tyr, Trp, and Ile. In 
contrast, the N-terminal Asn, Gln, Asp, and Glu residues (as well as Cys, under some metabolic 
conditions) are destabilizing owing to their preliminary enzymatic modifications. These 
modifications include the Nt-deamidation of N-terminal Asn and Gln by the Ntan1 and Ntaq1 
Nt-amidases, respectively, and the Nt-arginylation of N-terminal Asp and Glu by the Ate1 R-
transferase, which can also Nt-arginylate oxidized Cys, either Cys-sulfinate or Cys-sulfonate. 
The latter derivatives of Cys can form in animal and plant cells through oxidation of Cys by 
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nitric oxide (NO) and oxygen, and also the catalysis by by N-terminal Cys-oxidases. In addition 
to its type-1 and type-2 binding sites that recognize, respectively, the basic and bulky 
hydrophobic unacetylated N-terminal residues, an N-recognin such as Ubr1 contains other 
substrate-binding sites as well, the ones that recognize internal (non-N-terminal) degrons. As 
shown in the diagram, the unacetylated Met of the N-terminal M$  motif can be recognized by 
both yeast and mammalian Ubr1; this capability greatly expands the substrate range of the 
Arg/N-end rule pathway. 
B. The exons, including alternative exons, of the mouse Ate1 gene, with deduced lengths of the 
corresponding peptide segments indicated on top. C. Mouse R-transferase isoforms encoded by 
the Ate1 mRNAs and the terminology of these isoforms (see the main text). 
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Fig. 4.2. Design of and validation of CelluSpots™-based arginylation assays.  A. Layout of 
the CelluSpots array and assay described in panel B. Each glass slide contains a pair of identical 
CelluSpots peptide arrays. An individual array was “bounded” through the use of a hydrophobic 
pen, making it possible for each slide to be used for two separate enzymatic reactions (see 
Methods). For the identity of each of the 96 peptides, see Table 4.1 and Supplemental File 1. B. 
Arginylation assays performed on CelluSpots array either in the absence of purified mouse 
Ate11B7A R-transferase (left) or in the presence of Ate11B7A (right). See Methods for additional 
details.  
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Fig. 4.3. Effect of a residue at position 2 on the arginylation activity of R-transferase. A. 
Effect of a residue at position 2 on the arginylation of D(X)GSG and R(X)GSG peptides in 
CelluSpots assays by each of the four major mouse Ate1 isoforms (see Methods and Results for 
specific notations and other details). Each Ate1 isoform was able to arginylate the full 
complement of D(X)GSG peptides, whereas none of the isoforms were able to arginylate any of 
the N-terminal Arg-bearing R(X)GSG control peptides. B. Quantification of data in (A) plotted as 
a function of Ate1 isoform and second-position residues of only the D(X)GSG peptides. 
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Fig. 4.4 Pulse-chase analyses of modified Rgs4, a physiological substrate of the arginylation 
branch of the Arg/N-end rule pathway, in rabbit reticulocyte extract. A. The Ub Reference 
Technique (URT) (see Results for its description) [35]. B. Pulse-chase analyses of XA-Rgs4 
proteins (X=Arg, Asp, Val).The varied N-terminal residues are indicated in red. The Ala residue, 
in blue, replace, in these derivatives of wild-type Rgs4, its natural Lys residue at position 2. 
RARGS4, DARGS4, and VARGS4 were expressed in rabbit reticulocyte extract and pulse-labeled 
with 35S-Met/Cys for 10 min at 30°C, followed by a chase, immunoprecipitation with anti-FLAG 
antibody, SDS-PAGE, and autoradiography. C. Quantification of data in B using the reference 
protein fDHFR-UbK48R. 
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Fig. 4.5 Influence of charge clusters immediately downstream of N-terminal residue 
on the relative efficacy of N-terminal arginylation (Nt-arginylation) and protein 
degradation. A. CelluSpots arginylation assays with of GSG peptides (see Results for 
specific terms and notations) containing mutations within 4 residues from their N-
terminal residues. B. Quantification of data in A. C. Sequences of 11-residue peptides 
used in A. D. Pulse-chase analyses, in reticulocyte extract, of Rgs4-based model 
substrates. Varied residues are indicated in red and blue (see also Results). DR1Rgs4, 
DR4Rgs4, DD1Rgs4, and DD4Rgs4 were expressed in rabbit reticulocyte extract and pulse-
labeled with 35S-Met/Cys for 10 min at 30°C, followed by a chase, immunoprecipitation 
with anti-FLAG antibody, SDS-PAGE, and autoradiography. E. Quantification of data in 
D.
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Fig. 4.6 Effect of a residue at position 2 on the relative efficacy of N-terminal arginylation. 
A. CelluSpots arginylation assays with GSG peptides (see Results for the terminology of 11-
residue peptides) containing specific mutations at positions 1 and 2. B. Quantification of data in 
A. C. Degradation of Rgs4-based model substrates. Varied residues are indicated in red. DDRgs4, 
DKRgs4, and DPRgs4 were expressed in rabbit reticulocyte extract and pulse-labeled with 35S-
Met/Cys for 10 min at 30°C, followed by a chase, immunoprecipitation with anti-FLAG 
antibody, SDS-PAGE, and autoradiography. D. Quantification of data in C. 
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Fig. 4.7. CelluSpots arginylation assays that addressed earlier claims of protein 
arginylation at non-canonical residues (see Results for references and additional details). 
A. Arginylation assays with CelluSpots peptides derived from the first 11 residues of mouse 
Rgs4. These peptides bear either ArgCys, or Asp, or unmodified (unoxidized) Cys, or Cys-
sulfonate at their N-termini. B. CelluSpots arginylation assays with 11-residue peptides whose 
amino acid sequences were derived from the Met589-Leu599 fragment of the mouse Myh9 protein 
previously reported to be arginylated at Myh9Met589 [14]. These peptides contained either N-
terminal ArgMet, or unmodified N-terminal Met, or N-terminal Met sulfoxide, or N-terminal 
Met sulfone (peptide spots 1-4). The tested peptides included a set of otherwise identical 11-
residue peptides whose sequences were identical to the N-terminal sequence neurotensin, with 
the indicated substitutions at the N-terminus (Ala instead of Gln) and at position 4 (see Results 
for additional details). C. CelluSpots arginylation assays with 11-residue peptides derived from 
sequences that have been previously reported to be arginylated on non-canonical residues in vivo 
[14]. Spots 1 and 12 are positive-control peptides derived from the N-terminus of mouse Rgs4, 
but containing the arginylatable N-terminal Asp.  
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Fig. 4.8. Degradation assays with proteins whose ORFs encode N-terminal Met-Cys. A. The 
Ub Reference Technique (URT) (see Results for its description) [35]. B. Degradation of mouse 
Mdm2 and its derivativesCysMdm2, ValMdm2, and ArgCysMdm2. They were expressed in rabbit 
reticulocyte extract and labeled with 35S-Met/Cys for 10 min at 30°C, followed by a chase, 
immunoprecipitation with anti-FLAG antibody, SDS-PAGE, and autoradiography. C. 
Quantification of data B using the reference protein fDHFR-UbK48R. D. Same as B but with 
mouse X-JunB (X= Cys, Val, ArgCys). E. Quantification of D. F. Same as B but with mouse X-
Cdk14 (X=Cys, Val, ArgCys). G. Quantification of F. H. Same as B but with mouse X-B2L14 
(X=Cys, Val, ArgCys). I. Quantification of H. J. Same as B but with mouse X-Usp27x (X=Cys, 
Val, ArgCys). K. Quantification of J. 
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Fig. 4.9. Degradation of C-terminal fragments of human Mdm2 and Mdm4. A. Degradation 
assays with human Mdm2362 C-terminal fragment and its derivatives using the URT technique 
(see Fig. 4.4A and its legend) in reticulocyte extract. Cys-Mdm2362, Val-Mdm2362, and ArgCys-
Mdm2362 were expressed in rabbit reticulocyte extract and labeled with 35S-Met/Cys for 10 min 
at 30°C, followed by a chase, immunoprecipitation with anti-FLAG antibody, SDS-PAGE, and 
autoradiography. B. Same as in A, but with human Mdm4362 C-terminal fragment (X= Cys, Val, 
ArgCys). C. In vivo degradation assays, in HEK293T human cells, and the human Mdm4362 C-
terminal fragment and its indicated derivatives.Cys-Mdm4362, Val-MDM2362, and ArgCys-
Mdm4362 were expressed in HEK293 cells by transient transfection and labeled with 35S-Met/Cys 
for 20 min at 37°C, followed by a chase, preparation of lysates, immunoprecipitation with anti-
FLAG antibody, SDS-PAGE, and autoradiography. 
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Table 4.1. Location and sequences of CelluSpots array peptides. 
 Spot Sequence Name N-term. 
1 A 1 DGGSGFGPASG DG-GSG amine 
2 A 2 DAGSGFGPASG DA-GSG amine 
3 A 3 DSGSGFGPASG DS-GSG amine 
4 A 4 DTGSGFGPASG DT-GSG amine 
5 A 5 DCGSGFGPASG DC-GSG amine 
6 A 6 DVGSGFGPASG DV-GSG amine 
7 A 7 DLGSGFGPASG DL-GSG amine 
8 A 8 DIGSGFGPASG DI-GSGS amine 
9 A 9 DMGSGFGPASG DM-GSG amine 
10 A10 DPGSGFGPASG DP-GSG amine 
11 A11 DFGSGFGPASG DF-GSG amine 
12 A12 DYGSGFGPASG DY-GSG amine 
13 A13 RGGSGFGPASG RG-GSG amine 
14 A14 RAGSGFGPASG RA-GSG amine 
15 A15 RSGSGFGPASG RS-GSG amine 
16 A16 RTGSGFGPASG RT-GSG amine 
17 A17 RCGSGFGPASG RC-GSG amine 
18 A18 RVGSGFGPASG RV-GSG amine 
19 A19 RLGSGFGPASG RL-GSG amine 
20 A20 RIGSGFGPASG RI-GSG amine 
21 A21 RMGSGFGPASG RM-GSG amine 
22 A22 RPGSGFGPASG RP-GSG amine 
23 A23 RFGSGFGPASG RF-GSG amine 
24 A24 RYGSGFGPASG RY-GSG amine 
25 B 1 DWGSGFGPASG DW-GSG amine 
26 B 2 DDGSGFGPASG DD-GSG amine 
27 B 3 DEGSGFGPASG DE-GSG 
 
amine 
28 B 4 DNGSGFGPASG DN-GSG amine 
29 B 5 DQGSGFGPASG DQ-GSG amine 
30 B 6 DHGSGFGPASG DH-GSG amine 
31 B 7 DKGSGFGPASG DK-GSG amine 
32 B 8 DRGSGFGPASG DR-GSG amine 
33 B 9 DGPSGFGPASG DGP3-GSG amine 
34 B10 DGGPGFGPASG DGP4-GSG amine 
35 B11 DGGSPFGPASG DGP5-GSG amine 
36 B12 DGGSGPGPASG DGP6-GSG amine 
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37 B13 RWGSGFGPASG RW-GSGS amine 
38 B14 RDGSGFGPASG RD-GSGS amine 
39 B15 REGSGFGPASG RE-GSGS amine 
40 B16 RNGSGFGPASG RN-GSGS amine 
41 B17 RQGSGFGPASG RQ-GSGS amine 
42 B18 RHGSGFGPASG RH-GSGS amine 
43 B19 RKGSGFGPASG RK-GSGS amine 
44 B20 RRGSGFGPASG RR-GSGS amine 
45 B21 RGPSGFGPASG RGP3-GSG amine 
46 B22 RGGPGFGPASG RGP4-GSG amine 
47 B23 RGGSPFGPASG RGP5-GSG amine 
48 B24 RGGSGPGPASG RGP6-GSG amine 
49 C 1 RCKGLAGLPASC Rgs4 Arg amine 
50 C 2 DKGLAGLPASC Rgs4 C2D amine 
51 C 3 CKGLAGLPASC Rgs4  amine 
52 C 4 C(sulfonic 
acid)KGLAGLPASC 
Rgs4, Cys(sulfonic acid) amine 
53 C 5 RMDPLNDNIATL Myh9, Arg amine 
54 C 6 MDPLNDNIATL Myh9  amine 
55 C 7 M(sulfoxide)DPLNDNIATL Myh9, Met(sulfoxide) amine 
56 C 8 M(sulfone)DPLNDNIATL Myh9, Met(sulfone) amine 
57 C 9 ALYENKPRRPY NT1-11, Q1A acetyl 
58 C10 ALYDNKPRRPY NT1-11, Q1A, E4D acetyl 
59 C11 ALYNNKPRRPY NT1-11, Q1A, E4N acetyl 
60 C12 ALYQNKPRRPY NT1-11, Q1A, E4Q acetyl 
61 C13 DSGSGFGPASG GSG, G1D amine 
62 C14 DDGSGFGPASG GSG, G1D,A2D amine 
63 C15 DKGSGFGPASG GSG, G1D,A2K amine 
64 C16 DPGSGFGPASG GSG, G1D,A2P amine 
65 C17 CSGSGFGPASG GSG, G1C amine 
66 C18 CDGSGFGPASG GSG, G1C,A2D amine 
67 C19 CKGSGFGPASG GSG, G1C,A2K amine 
68 C20 CPGSGFGPASG GSG, G1C,A2P amine 
69 C21 ESGSGFGPASG GSG, G1C amine 
70 C22 EDGSGFGPASG GSG, G1E,A2D amine 
71 C23 EKGSGFGPASG GSG, G1E,A2K amine 
72 C24 EPGSGFGPASG GSG, G1E,A2P amine 
73 D 1 DKGLAGLPASC Rgs4, C2D amine 
74 D 2 MCDRKAVIKNA dynein, cytoplasmic, light peptide amine 
75 D 3 LEVLNFFNNQI Ras suppressor protein 1  amine 
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76 D 4 PVLCFTQYEES Properdin factor, complement amine 
77 D 5 AWGKIGGHGAE hemoglobin alpha 1 chain amine 
78 D 6 KPVYDELFYTL EH domain containing protein 
MPAST2 
amine 
79 D 7 GDDGAEYVVES similar to GAPDH amine 
80 D 8 NSALQCLSNTA ubiquitin specific protease 4 amine 
81 D 9 FYNELRVAPEE actin, beta, cytoplasmic amine 
82 D10 HSQAVEELADQ myosin, heavy polypeptide 9, non-
muscle iso. 
amine 
83 D11 VLVGDVKDRVA phosphoribosyl pyrophosphate 
synthetase 
amine 
84 D12 DKGLAGLPASC Rgs4, C2D amine 
85 D13 DRGSGFGPASG DR1-GSG amine 
86 D14 DRRRRFGPASG DR4-GSG amine 
87 D15 RRGSGFGPASG RR1-GSG amine 
88 D16 RRRRRFGPASG RR4-GSG amine 
89 D17 DDGSGFGPASG DD1-GSG amine 
90 D18 DDDDDFGPASG DD4-GSG amine 
91 D19 RDGSGFGPASG RD1-GSG amine 
92 D20 RDDDDFGPASG RD4-GSG amine 
93 D21 DAGSGFGPASG DA1-GSG amine 
94 D22 DAAAAFGPASG DA4-GSG amine 
95 D23 RAGSGFGPASG RA1-GSG amine 
96 D24 RAAAAFGPASG RA4-GSG amine 
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Table 4.2. Proteolytic cleavage sites, identified in the CutDB database, in specific 
proteins in which the Cys residue is present at the P1’ position of a cleavage site.  
 
 
Protease Substrate Substrate Species Cleavage Sequence Cleavage Site
caspase-3 MDM4 Mouse double minute 4 homolog Homo sapiens DVPD-CRRT 361-362
caspase-3 PKN2 Protein kinase n2 Homo sapiens DITD-CPRT 117-118
caspase-3 VAV1 vav1 oncogene Homo sapiens DLYD-CVEN 161-162
caspase-3 CCNE1 cyclin E1 isoform 2 Homo sapiens LDVD-CLEF 290-291
caspase-3 CCNE1 cyclin E1 isoform 2 Homo sapiens LDVD-CLEF 275-276
caspase-3 MDM2 E3 ubiquitin-protein ligase Mdm2 Homo sapiens DVPD-CKKT 361-362
caspase-3 GRIPAP1 GRIP1 associate protein 1 isoform 1 Homo sapiens EERD-CHLK 580-581
caspase-3 GRIPAP1 GRIP1 associate protein 1 isoform 2 Homo sapiens EERD-CHLK 501-502
caspase-3 SALL1 sal-like 1 isoform a Homo sapiens DQVD-CSDL 109-110
caspase-3 SALL1 sal-like 1 isoform b Homo sapiens DQVD-CSDL 109-110
caspase-3 SLC4A1AP solute carrier family 4, member 1, adaptor protein Homo sapiens DYQD-CSKT 722-723
caspase-3 SSFA2 sperm specific antigen 2 isoform 1 Homo sapiens DSTD-CLSL 517-518
caspase-3 SSFA2 sperm specific antigen 2 isoform 2 Homo sapiens DSTD-CLSL 517-518
caspase-3 HNRNPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1 isoform A2 Homo sapiens KLTD-CVVM 37-38
caspase-3 HNRNPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1 isoform B1 Homo sapiens KLTD-CVVM 49-50
caspase-3 ATXN3 ataxin 3 isoform 1 Homo sapiens DLPD-CEAD 171-172
caspase-3 TRAF1 Tnf receptor-associated factor 1 Homo sapiens LEVD-CYRA 163-164
caspase-6 TRAF1 Tnf receptor-associated factor 1 Homo sapiens LEVD-CYRA 163-164
caspase-8 TRAF1 Tnf receptor-associated factor 1 Homo sapiens LEVD-CYRA 163-164
caspase-8 RIPK1 Receptor-interacting serine-threonine kinase-1 Homo sapiens LQLD-CVAV 324-325
ADAMTS4 peptidase BGN biglycan preproprotein Homo sapiens RNMN-CIEM 186-197
cathepsin SERPINB1 serine (or cystein) proteinase inhibitor, clase B member 1 Homo sapiens IATF-CMLM 343-344
cathepsin B SLPI Secretory leukocyte peptidase inhibitor precursor Homo sapiens CPDT-CGIK 67-68
cathepsin S SLPI Secretory leukocyte peptidase inhibitor precursor Homo sapiens CPDT-CGIK 67-68
chymase SERPINB1 serine (or cystein) proteinase inhibitor, clase B member 1 Homo sapiens IATF-CMLM 343-344
chymotrypsin SERPINB1 serine (or cystein) proteinase inhibitor, clase B member 1 Homo sapiens IATF-CMLM 343-344
endothelin-converting enzyme 1 EDN1 endothelin-1 Homo sapiens CVYF-CHLD 66-67
endothelin-converting enzyme 1 EDN1 endothelin-1 Homo sapiens RSKR-CSCS 52-53
furin EDN1 endothelin-1 Homo sapiens RSKR-CSCS 52-53
furin EDN1 endothelin-1 Homo sapiens RENR-CQCA 108-109
furin MMP2 matrix metalloproteinase 2 preproprotein Homo sapiens RKPR-CGNP 101-102
furin MMP3 matrix metalloproteinase 3 preproprotein Homo sapiens RKPR-CGVP 91-92
granzyme M SERPINB9 serine (or cystein) proteinase inhibitor, clase B member 9 Homo sapiens VVAE-CCME 340-341
kallikrein h SEMG2 Semenogelin ii precursor Homo sapiens RHLN-CGEK 359-360
matrix metallopeptidase-2 LGALS1 beta-galactoside-binding lectin precursor Homo sapiens KPGE-CLRV 16-17
neutrophil elastase TIMP-1 metalloprotease inhibitor Homo sapiens MESV-CGYF 92-93
plasmin MMP13 matrix metalloproteinase 13 preproprotein Homo sapiens KKPR-CGVP 95-96
procollagen C-peptidase COL1A1 alpha 1 type 1 collagen preproprotein Homo sapiens EGEC-CPVC 91-92
proprotein convertase 7 EDN1 preproendothelin-1 Homo sapiens RSKR-CSCS 52-53
S2P peptidase ATF-6A Cyclic-AMP-dependent transcription factor ATF-6 alpha Homo sapiens RRVV-CVMI 379-380
S2P peptidase ATF-6B Cyclic-AMP-dependent transcription factor ATF-6 beta Homo sapiens RKVV-CIMV 379-380
S2P peptidase SREBF2 sterol regulatory element binding transcription factor 2 Homo sapiens RILL-CVLT 484-485
S2P peptidase SREBF1 sterol regulatory element binding transcription factor 1 Homo sapiens RLAL-CTLV 490-491
thrombin AANAT Arylalkamine n-acetyltransferase Homo sapiens SEFR-CLTP 38-39
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Table 4.3.  Plasmids used in this study. 
Plasmid  Description Reference 
pKP496 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
MCS-flag under the control of CMV promoter 
Piatkov et 
al., 2012 
pBW114 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
Cys2-mB2L14-flag under the control of CMV promoter 
This study 
pBW115 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
Cys2-mCdk14-flag under the control of CMV promoter 
This study 
pBW116 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
Cys2-mJunB-flag under the control of CMV promoter 
This study 
pBW117 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
Cys2-mMdm2-flag under the control of CMV promoter 
This study 
pBW118 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
Cys2-Usp27x-flag under the control of CMV promoter 
This study 
pBW128 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
Val2-mJunB-flag under the control of CMV promoter 
This study 
pBW129 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
ArgCys2-mJunB-flag under the control of CMV promoter 
This study 
pBW130 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
Val2-mMdm2-flag under the control of CMV promoter 
This study 
pBW131 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
ArgCys2-mMdm2-flag under the control of CMV promoter 
This study 
pBW165 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
Val2-mB2L14-flag under the control of CMV promoter 
This study 
pBW166 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
ArgCys2-mB2L14-flag under the control of CMV promoter 
This study 
pBW167 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
Val2-mCdk14-flag under the control of CMV promoter 
This study 
pBW168 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
ArgCys2-mCdk14-flag under the control of CMV promoter 
This study 
pBW169 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
Val2-Usp27x-flag under the control of CMV promoter 
This study 
pBW170 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
ArgCys2-Usp27x-flag under the control of CMV promoter 
This study 
pBW448 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
Cys362-hMDM4-flag under the control of CMV promoter 
This study 
pBW449 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
Val362-hMDM4-flag under the control of CMV promoter 
This study 
pBW450 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
ArgCys362-hMDM4-flag under the control of CMV promoter 
This study 
pBW463 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
Cys2-hMDM362-flag under the control of CMV promoter 
This study 
pBW464 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
Val2-hMDM362-flag under the control of CMV promoter 
This study 
pBW465 AmpR; NeoR; pcDNA3-based plasmid encoding flag-DHFR-ha-Ub-
ArgCys2-hMDM362-flag under the control of CMV promoter 
This study 
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Table 4.4.  PCR primers used in this study. 
Primer Sequence 
BW300 5'-TCCGCGGAGGATGCAGCACCAGTGTGTATGA-3' 
BW301 5'-TCCGCGGAGGAGTGAGCACCAGTGTGTATGA-3' 
BW302 5'-TCCGCGGAGGAAGATGCAGCACCAGTGTGTATG-3' 
BW303 5'-ATTATCGATGTCTACTTCTTCATGTGAGATCCCA-3' 
BW304 5'-TCCGCGGAGGATGCGACCTCATTGAACCG-3' 
BW305 5'-TCCGCGGAGGAGTGGACCTCATTGAACCG-3' 
BW306 5'-TCCGCGGAGGAAGATGCGACCTCATTGAAC-3' 
BW307 5'-ATTATCGATGTGTTTGCTGTTCGATAGGCT-3' 
BW312 5'-TCCGCGGAGGATGCACGAAAATGGAACAGC-3' 
BW313 5'-TCCGCGGAGGAGTGACGAAAATGGAACAGC-3' 
BW314 5'-TCCGCGGAGGAAGATGCACGAAAATGGAAC-3' 
BW315 5'-ATTATCGATGAAGGCGTGTCCCTTGAC-3' 
BW316 5'-TCCGCGGAGGATGCAATACCAACATGTCTGTGTC-3' 
BW317 5'-TCCGCGGAGGAGTGAATACCAACATGTCTGTGTC-3' 
BW318 5'-TCCGCGGAGGAAGATGCAATACCAACATGTCTG-3' 
BW319 5'-ATTATCGATGTTGAAGTAAGTTAGCACAATCATTTG-3' 
BW320 5'-TCCGCGGAGGATGTAAAGACTATGTGTATGAC-3' 
BW321 5'-TCCGCGGAGGAGTGAAAGACTATGTGTATGAC-3' 
BW322 5'-TCCGCGGAGGAAGATGTAAAGACTATGTGTATG-3' 
BW323 5'-ATTATCGATGTAGGCTTGTGGAGTCATTTC-3' 
BW841 5'-TTTACCGCGGAGGATGTCGAAGAACCATTTCGG-3' 
BW842 5'-TTTACCGCGGAGGAGTGCGAAGAACCATTTCGG-3' 
BW843 5'-TTTACCGCGGAGGAAGATGTCGAAGAACCATTTCGG-3' 
BW844 5'-TTTAATCGATTGCTATAAAAACCTTAATAACCAGCTG-3' 
BW860 5'-TTTACCGCGGAGGATGTAAAAAAACTATAGTGAATGATTCCAG-3' 
BW861 5'-TTTACCGCGGAGGAGTGAAAAAAACTATAGTGAATGATTCCAG-3' 
BW862 5'-TTTACCGCGGAGGAAGATGTAAAAAAACTATAGTGAATGATTCCAG-3' 
BW863 5'-ATTATCGATGGGGAAATAAGTTAGCACAATCA-3' 
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ABSTRACT 
The Ate1 arginyltransferase (R-transferase) is a component of the N-end rule 
pathway, which recognizes proteins containing N-terminal degradation signals called N-
degrons, polyubiquitylates these proteins and thereby causes their degradation by the 
proteasome. Ate1 arginylates N-terminal Asp, Glu or (oxidized) Cys. The resulting N-
terminal Arg is recognized by ubiquitin ligases of the N-end rule pathway. In the yeast 
Saccharomyces cerevisiae, the separase-mediated cleavage of the Scc1/Rad21/Mcd1 
cohesin subunit generates a C-terminal fragment that bears N-terminal Arg and is 
destroyed by the N-end end rule pathway without requirement for arginylation. In 
contrast, the separase-mediated cleavage of Rec8, the mammalian meiotic cohesin 
subunit, yields a fragment bearing N-terminal Glu, a substrate of the Ate1 R-transferase. 
Here we constructed and used a germ cells-confined Ate1-/- mouse strain to analyze the 
separase-generated C-terminal fragment of Rec8. We show that this fragment is a short-
lived N-end rule substrate, that its degradation requires N-terminal arginylation, and that 
male Ate1-/- mice are nearly infertile, owing to massive apoptotic death of 
Ate1-/- spermatocytes during the metaphase of meiosis I. These effects of Ate1 ablation 
are inferred to be caused, at least in part, by the failure to destroy the C-terminal fragment 
of Rec8 in the absence of N-terminal arginylation. 
 
INTRODUCTION 
The N-end rule pathway is a set of proteolytic systems whose unifying feature is 
the ability to recognize and polyubiquitylate proteins containing degradation signals 
called N-degrons, thereby causing degradation of these proteins by the proteasome (Fig. 
150 
 
1A, B) (1-8). The main determinant of an N-degron is either an unmodified or chemically 
modified destabilizing N-terminal residue of a protein. The identity of the next residue, at 
position 2, is often important as well. A second determinant of an N-degron is a protein’s 
internal Lys residue. It functions as the site of a protein’s polyubiquitylation and tends to 
be located in a conformationally disordered region (4,9,10). Recognition components of 
the N-end rule pathway are called N-recognins. In eukaryotes, N-recognins are E3 
ubiquitin (Ub) ligases that can target N-degrons (Fig. 1A, B). Bacteria also contain the N-
end rule pathway, but Ub-independent versions of it (11-16). 
Regulated degradation of proteins and their natural fragments by the N-end rule 
pathway has been shown to mediate a strikingly broad range of biological functions, 
including the sensing of heme, nitric oxide (NO), oxygen, and short peptides; the control, 
through subunit-selective degradation, of the input stoichiometries of subunits in 
oligomeric protein complexes; the elimination of misfolded or otherwise abnormal 
proteins; the degradation of specific proteins after their retrotranslocation to the cytosol 
from mitochondria or other membrane-enclosed compartments; the regulation of 
apoptosis and repression of neurodegeneration; the regulation of DNA repair, 
transcription, replication, and chromosome cohesion/segregation; the regulation of 
G proteins, autophagy, peptide import, meiosis, immunity, fat metabolism, cell migration, 
actin filaments, cardiovascular development, spermatogenesis, and neurogenesis; the 
functioning of adult organs, including the brain, muscle, testis, and pancreas; and the 
regulation of leaf and shoot development, leaf senescence, and many other processes in 
plants (Figs. 1A, B) ((4-7) and references therein). 
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In eukaryotes, the N-end rule pathway consists of two branches. One branch, 
called the Ac/N-end rule pathway, targets proteins for degradation through their N±-
terminally acetylated (Nt-acetylated) residues (Fig. 1B) (2,3,17-19). Degradation signals 
and E3 Ub ligases of the Ac/N-end rule pathway are called Ac/N-degrons and Ac/N-
recognins, respectively. Nt-acetylation of cellular proteins is apparently irreversible, in 
contrast to acetylation-deacetylation of proteins’ internal Lys residues. About 90% of 
human proteins are cotranslationally Nt-acetylated by ribosome-associated Nt-acetylases 
(20). Posttranslational Nt-acetylation is known to occur as well. Many, possibly most, Nt-
acetylated proteins contain Ac/N-degrons (Fig. 1B). 
The pathway’s other branch, called the Arg/N-end rule pathway, targets specific 
unacetylated N-terminal residues (Fig. 1A) (3,21-25). The “primary” destabilizing 
N-terminal residues Arg, Lys, His, Leu, Phe, Tyr, Trp, and Ile are directly recognized by 
N-recognins. The unacetylated N-terminal Met, if it is followed by a bulky hydrophobic 
($ ) residue, also acts as a primary destabilizing residue (Fig. 1A) (3). In contrast, the 
unacetylated N-terminal Asn, Gln, Asp, and Glu (as well as Cys, under some metabolic 
conditions) are destabilizing owing to their preliminary enzymatic modifications, which 
include N-terminal deamidation (Nt-deamidation) of Asn and Gln and Nt-arginylation of 
Asp, Glu and oxidized Cys (Fig. 1A) (4-6,26). In the yeast S. cerevisiae, the Arg/N-end 
rule pathway is mediated by the Ubr1 N-recognin, a 225 kDa RING-type E3 Ub ligase 
and a part of the targeting complex comprising the Ubr1-Rad6 and Ufd4-Ubc4/5 E2-E3 
holoenzymes (4,27). In multicellular eukaryotes, several E3 Ub ligases, including Ubr1, 
function as N-recognins of the Arg/N-end rule pathway (Fig. 1A). 
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Nt-arginylation is mediated by the Ate1-encoded arginyltransferase (Arg-tRNA-
protein transferase; R-transferase), a component of the Arg/N-end rule pathway and one 
subject of the present study (Fig. 1A) (28-36). Alternative splicing of mouse Ate1 pre-
mRNAs yields at least six R-transferase isoforms, which differ in their Nt-arginylation 
activity (28,31). R-transferases are sequelogous (similar in sequence (37)) throughout 
most of their ~60 kDa spans from fungi to mammals (4). R-transferase can arginylate not 
only N-terminal Asp and Glu but also N-terminal Cys, if it has been oxidized to Cys-
sulfinate or Cys-sulfonate, through reactions mediated by NO, oxygen, and N-terminal 
Cys-oxidases (5,6,30). Consequently, the Arg/N-end rule pathway functions as a sensor 
of NO and oxygen, through the conditional oxidation of N-terminal Cys in proteins such 
as the Rgs4, Rgs5, and Rgs16 regulators of G proteins in mammals (30,38) and specific 
transcriptional regulators in plants (reviewed in (5,6)). By now, more than 200 distinct 
proteins (including natural protein fragments) have been either shown or predicted to be 
Nt-arginylated (21,22,39-41). Many, possibly most, Nt-arginylated proteins are 
conditionally or constitutively short-lived substrates of the Arg/N-end rule pathway (Fig. 
1A). 
Identified and predicted substrates of the Arg/N-end rule pathway include cohesin 
subunits of the kleisin family. Rings of oligomeric cohesin keep sister chromatids 
together through a topological confinement (42-53). Physiological roles of cohesins 
include DNA replication, cohesion/segregation, repair, transcription; and control of 
apoptosis (54-61). In S. cerevisiae, the Scc1/Rad21/Mcd1 cohesin subunit is cleaved at a 
specific site, late in mitosis, by the nonprocessive Esp1 protease called separase, allowing 
the release of sister chromatids and the transition from metaphase to anaphase (48,62-64).  
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In mammals and other multicellular eukaryotes, the bulk of cohesin-mediated 
confinement of sister chromatids is removed during prophase through openings of 
cohesin rings that do not involve proteolytic cuts. Sister chromatids continue to be held 
together until the end of metaphase, to a large extent through still intact cohesin rings at 
the centromeres. Once the bipolar spindle attachment of chromosomes is achieved at the 
end of metaphase, the activated separase cleaves the mammalian Rad21 subunit (a 
sequelog of yeast Scc1) in the closed cohesin complexes, resulting in their opening and 
allowing the separation of sister chromatids (45,48,58,65). At least in mammals, the 
Rad21 cohesin subunit can be cleaved in vivo not only by separase but also by calpain-1 
(a Ca2+-activated protease) (58), and by caspases as well (56,57). 
During meiosis, in which cohesins also play essential roles, the mitosis-specific 
cohesin subunit Rad21 is replaced by the sequelogous (similar in sequence (37)), 
meiosis-specific Rec8 subunit (43,59,66-70). (A second meiosis-specific kleisin-type 
subunit, called Rad21L, is expressed during early meiosis and disappears afterward (71).) 
Meiotic DNA replication is followed by two rounds of cell division to produce four 
haploid daughter cells. During the first meiotic cell division cycle (meiosis I), replicated 
homologous chromosomes pair and recombine with each other. The pairs of modified 
(recombined) homologous chromosomes are separated at the end of meiosis I, yielding 
two diploid daughter cells (72,73). During meiosis II, the replicated sister chromatids of 
each chromosome are pulled apart to produce haploid daughter cells. In the testis of male 
mice, meiosis I and II take place in meiotic spermatocytes, leading to the formation of 
haploid spermatids and later mature sperm cells (43,59,66,74). 
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In S. cerevisiae, the separase-generated C-terminal fragment of the Scc1 cohesin 
subunit bears N-terminal Arg. This fragment of Scc1 forms late in mitosis upon the 
activation of separase, and is rapidly destroyed by the Arg/N-end end rule pathway (62). 
A failure to eliminate this (normally short-lived) Scc1 fragment, for example, in a ubr1” 
mutant that lacks the Arg/N-end rule pathway, results in chromosome instability (62). 
The C-terminal fragment of Scc1 retains a physical affinity for the rest of cohesin 
complex (62). Therefore the plausible (but not proven) cause of chromosome instability 
in ubr1” cells is an interference with cohesin mechanics by the metabolically stabilized, 
cohesin-bound C-terminal fragment of Scc1. Since the yeast Scc1 fragment bears N-
terminal Arg, the fragment’s degradation by the Arg/N-end rule pathway does not require 
Nt-arginylation (62). In mammals, however, the separase-generated C-terminal fragments 
of the Rad21 subunit of mitotic cohesin and the Rec8 subunit of meiotic cohesin bear 
N-terminal Glu, a substrate of the Ate1 R-transferase (Fig. 1A, C) (47,75,76). 
In the present work, we constructed an Ate1-/- mouse strain in which the ablation 
of Ate1 was confined to germ cells. We show that the separase-generated C-terminal 
fragment of Rec8, a subunit of meiotic cohesin, is a short-lived physiological substrate of 
the Arg/N-end rule pathway, and that the degradation of this Rec8 fragment requires its 
Nt-arginylation. These and related results suggest that a failure to destroy this fragment in 
arginylation-lacking spermatocytes of Ate1-/- mice contributes to a greatly reduced male 
fertility of these mice, owing to the observed arrest and apoptotic death of 
Ate1-/- spermatocytes at the end of meiosis I. These results expand the already large set of 
functions of the Arg/N-end rule pathway. Together with earlier data about Ate1-/- and 
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Ubr2-/- mice (33,77), the present findings also indicate that perturbations of the 
Arg/N-end rule pathway may be among the causes of infertility in humans. 
EXPERIMENTAL PROCEDURES 
Mutant Mouse Strains – Conditional (cre-lox-based) Ate1flox/flox mice were 
described (33). Tnap-Cre mice, in which the Cre recombinase is selectively expressed in 
primordial germ cells (78), were purchased from Jackson Laboratory (Bar Harbor, ME). 
Germ-cell specific Ate1-/- mouse strains were constructed in the present study through 
matings of Ate1flox/flox mice (33) and Tnap-Cre mice (78). All animal experiments were 
approved by the Animal Research Panel of the Committee on Research Practice of the 
University of the Chinese Academy of Science. 
Antibodies – Mouse anti-Sycp3 monoclonal antibody (SC-74569) and mouse anti-
PLZF monoclonal antibody (SC-28319) were from Santa Cruz Biotechnology (Dallas, 
TX). Rabbit anti-Sycp3 polyclonal antibody (ab150292) and Rabbit anti-Rec8 polyclonal 
antibody were from Abcam (Cambridge, MA). Mouse anti-MLH1 monoclonal antibody 
(51-1327GR) was from BD Pharmingen (San Jose, CA). Rabbit anti-Sycp1 polyclonal 
antibody-Cy5 (NB300-228c) was from Novus Biologicals (Littleton, CO). Mouse anti-
Cyclin B1 monoclonal antibody (MA5-14319) was from Thermo Scientific (Waltham, 
MA). FITC-conjugated mouse monoclonal anti-±-tubulin antibody (F2168) was from 
Sigma-Aldrich (St. Louis, MO). FITC-conjugated goat anti-rabbit antibody, and TRITC-
conjugated goat anti-mouse antibody, as well as horseradish peroxidase (HRP)-
conjugated secondary antibody were from Zhong Shan Jin Qiao (Beijing, China). Alexa 
Fluor 680-conjugated goat anti-mouse antibody and Alexa Fluor 680-conjugated goat 
anti-rabbit antibody were from Invitrogen (Carlsbad, CA).  
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Male Fertility Assays – Breeding assays with wild-type and Ate1-/- male mice 
were carried out previously described (79). Briefly, each examined male mouse (8-9 
weeks old) was caged with two wild-type (CDI strain) female mice (6-8 weeks old), and 
their vaginal plugs were checked every morning. The number of pups produced by each 
pregnant female was counted within a week after birth. Each male was tested through six 
cycles of this breeding assay. 
Epididymal Sperm Count – The cauda epididymis was dissected from adult mice. 
Sperm was released by cutting the cauda epididymis into pieces, placing them in 1 ml of 
phosphate-buffered saline (PBS), and incubating for 10 min at 37°C. Thereafter, 10-µl 
samples were transferred to a hemocytometer for counting sperm cells. 
Immunoblotting and Related Procedures – Extracts from testes were prepared 
using a Dounce homogenizer in a cold high-salt RIPA-like buffer (0.5 M NaCl, 1% 
Nonidet-P40, 1% Na-deoxycholate, 0.1% SDS, 2 mM Na-EDTA, 25 mM Tris-HCl, pH 
7.6) supplemented with 1mM phenylmethylsulfonyl fluoride (PMSF) and a protein 
inhibitor cocktail (Roche, Basel, Switzerland, 04693132001). Extracts were centrifuged 
at 13,000g for 15 min. Samples of supernatants were fractionated by SDS-PAGE 
(NuPAGE 4-12% Bis-Tris Gel; Invitrogen) and electro-transferred to a nitrocellulose 
membrane, followed by incubation for 2-4 hrs at room temperature (RT) with a primary 
antibody, a further incubation with the (HRP)-conjugated secondary antibody, washes, 
and the detection of immunoblotting patterns using chemilumenescence, largely as 
described (18,80).  
The Ubiquitin Reference Technique (URT) and Analyses of Rec8 in Reticulocyte 
Extract – The mouse Rec8 open reading frame (ORF) was amplified by PCR, using 
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cDNA from GE Healthcare Dharmacon (Clone ID: 6335959) (Pittsburgh PA). The 
resulting DNA fragments were cut with SacII and ClaI and cloned into SacII/ClaI-cut 
pKP496, yielding the plasmids pBW442, pBW443, and pBW444, respectively. pKP496 
was an AmpR, NeoR, pcDNA3-based plasmid encoding flag-DHFR-ha-UbK48R-MCS 
(multiple cloning site)-flag under the control of the PCMV promoter (21). pBW442, 
pBW443, and pBW444 expressed, respectively, fDHFR-ha-UbK48R-Glu455-Rec8f, fDHFR-
ha-UbK48R-Val455-Rec8f, and fDHFR-ha-UbK48R-Arg-Glu455-Rec8f from the PCMV 
promoter. The plasmid pcDNA3MR8, expressing fDHFR-ha-UbK48R-Met206-Rec8f, was 
constructed similarly. 
Rabbit reticulocyte-based degradation assays were carried out using the TNT T7 
Coupled Transcription/Translation System (Promega, Madison, WI), largely as 
previously described (21-23). Nascent proteins translated in the extract were pulse-
labeled with 35S-L-methionine (0.55 mCi/mL, 1,000 Ci/mmol, MP Biomedicals, Santa 
Ana, CA) for 10 min at 30°C in the total volume of 30 µl. Labeling was quenched by the 
addition of 0.1 mg/ml cycloheximide, and 5 mM unlabeled methionine, bringing the final 
reaction volume to 40 µl. Samples of 10 µl were removed at the indicated time points and 
the reaction was terminated by the addition of 80 µl of TSD buffer (1% SDS, 5 mM 
dithiothreitol (DTT), 50 mM Tris-HCl, pH 7.4), snap-frozen in liquid nitrogen, and stored 
at -80°C until use. Following the collection of all time points, samples were heated at 
95°C for 10 min, then diluted with 1 ml of TNN buffer (0.5% NP40, 0.25 M NaCl, 5 mM 
Na-EDTA, 50 mM Tris-HCl, pH 7.4) containing 1X complete Protease Inhibitor Cocktail 
(Roche), and immunoprecipitated using 5 µl of anti-flag M2 magnetic beads (Sigma-
Aldrich). Samples were incubated with rotation at 4°C for 4 hrs, followed by three 
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washes in TNN buffer, a wash in 10 mM Tris-HCl, pH 8.5, and resuspension in 20 µl of 
SDS-sample buffer. Samples were heated at 95°C for 5 min, and fractionated SDS-10% 
PAGE, followed by autoradiography and quantification, using Typhoon-9500 Imager and 
ImageQuant (GE Healthcare).  
Reticulocyte extract-based assays in which Rec8f, its derivatives, and the 
fDHFR-ha-UbK48R reference protein were detected by immunoblotting were carried 
similarly, except that no 35S-Met/Cys labeling was involved. The 
synthesis-deubiquitylation-degradation of URT-based test fusions was allowed to proceed 
for 1 hr at 30°C either in the absence of added dipeptides, or in the presence of either 
Arg-Ala (1 mM) or Ala-Arg (1 mM), followed by SDS-PAGE and immunoblotting with 
anti-flag antibody (Fig. 5E). 
Histology and Immunohistochemistry – For histological analyses, testes and 
epididymis were fixed, after dissection, in 4% paraformaldehyde (formaldehyde, HCHO) 
(Solarbio, Beijing, China, P1110) overnight at 4°C, followed by standard procedures 
(79). Briefly, tissues were dehydrated through a series of ethanol washes and thereafter 
embedded in paraffin wax. Sections (5 µm thick) were produced using a microtome. 
Deparaffinized and rehydrated sections were stained with hematoxylin and eosin for 
histological observations. For immunohistochemical assays, deparaffinized and 
rehydrated sections were rinsed 3 times at room temperature (RT) in PBS (pH 7.4), 
followed by antigen retrieval by boiling for 15 min in 10 mM Na-citrate, pH 6.0. Sections 
were then incubated for 10 min at RT with 3% H2O2, followed by blocking of each 
section by incubating them for 30 min at RT in 5% bovine serum albumin (BSA; Sigma). 
Sections were incubated with a primary antibody at 4°C overnight, followed by 
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incubation with an HRP-conjugated secondary antibody at 37°C for 1 hr. Sections were 
then stained with 3, 3’-diaminobenzidine (DAB) according to manufacturer’s instructions 
(Zhong Shan Jin Qiao, Beijing, China, ZL1-9018), and nuclei were stained with 
hematoxylin. Negative controls were processed identically but without the primary 
antibody. Sections were examined using a Nikon 80i inverted microscope with a charge-
coupled camera. 
Spreads of Spermatocyte Nuclei – They were prepared as previously described 
(81), with modifications. Briefly, testes were washed in PBS after dissection from mice. 
The tunicae were removed and adherent extratubular tissues were removed by rinsing the 
seminiferous tubules with PBS at room temperature. The tubules were placed in a 
hypotonic extraction buffer (50 mM sucrose, 17 mM Na-citrate, 0.5mM dithiothreitol 
(DTT), 0.5mM phenylmethylsulphonyl fluoride (PMSF), 3 mM Tris-HCl, pH 8.2) for 30-
60 min. Thereafter approximately 1 inch of tubule was shredded to pieces by fine-tipped 
forceps in 20 µl of 0.1 M sucrose (pH adjusted to pH 8.2 by NaOH) on a clean glass 
slide. Another 20 µl of sucrose solution was then added, and a slightly cloudy suspension 
was prepared, using a 20-µl pipettor. Residual tubular tissues were removed. The 
suspension was transferred onto a new precoated (3-aminopropyl-triethoxysilane (Zhong 
Shan Jin Qiao, Beijing, China, ZL1-9002)) glass slides, each of them containing on the 
surface 0.1 ml of freshly made (and filtered through a 0.22 µm Rephile filter (Rephile, 
Shanghai, China, RJP3222SH)) solution of 1% paraformaldehyde (HCHO), 0.15% 
Triton-X100 (with pH adjusted to 9.2 using 10 mM Na-borate, pH 9.2). Each slide was 
gently rocked to mix the initial suspension with HCHO solution, followed by drying for 
at least 2 hr in a closed box with high humidity. To stain the resulting nuclei spreads, 
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slides were washed with 0.4% Photoflo (Kodak, Rochester, NY) 3 times and with PBS 3 
times, then blocked in 5% BSA for 1 hr, incubated with a primary antibody in 1.5% BSA 
and 0.3% Triton-X100 overnight at 4°C, then incubated with secondary antibody in PBS 
for 1 hr at 37°C. The resulting slides were washed in PBS, and nuclei were stained with 
42,6-diamidino-2-phenylindole (DAPI). Slides were examined using the LSM 780/710 
microscope (Zeiss).  
TUNEL Assays – They were carried out using the In Situ Cell Death Detection Kit 
(Roche Diagnostics, Basel, Switzerland, 11684795910) as described by us 
previously(82). Briefly, sections of testis were heated at 60°C for 2 hrs followed by 
washing in xylene and rehydration through a graded series of washes with ethanol and 
double-distilled water. Thereafter the sections were treated with proteinase K for 15 min 
at RT and rinsed twice with PBS. After adding the TUNEL reaction mixture, slides were 
incubated in a humidified atmosphere for 60 min at 37 °C in the dark, following by 
staining with DAPI (82). All experiments were repeated at least three times, with 
standard deviations shown.  
 
RESULTS 
Germ Cell-specific Ablation of the Ate1 R-transferase Strongly Decreases 
Fertility of Male Mice – Probing sections of mouse testis with affinity-purified antibody 
to mouse Ate1 indicated the presence of the Ate1 R-transferase in the testis, particularly 
in spermatocytes and spermatogonia (precursors of spermatocytes) (Fig. 2A). These 
immunohistochemical results were in agreement with in situ hybridization data about 
Ate1 expression in spermatocytes (77). To produce mouse strains in which Ate1 was 
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selectively ablated in primordial germ cells (PGCs), we mated the previously constructed 
Ate1flox/flox mice (33) with Tnap-Cre mice expressing Cre recombinase from the 
PGC-specific Tnap promoter (78) (see Experimental Procedures). Immunoblotting 
analyses of testis extracts from the resulting Tnap-Ate1-/- mice vs. Ate1flox/flox (wild-type) 
mice with anti-Ate1 antibody indicated a dramatic decrease of Ate1 in Tnap-Ate1-/- testes 
(Fig. 2B). Inasmuch as spermatogonia and spermatocytes (in which Tnap-Cre was 
selectively expressed) comprise a large fraction but not the entirety of testicular cells, 
these results (Fig. 2B) indicated that the Ate1 R-transferase was either completely or 
nearly completely absent from spermatogonia and spermatocytes of Tnap-Ate1-/- mice. 
Fertility of Tnap-Ate1-/- and “wild-type” Ate1flox/flox males was assessed by mating 
three males of each strain with Ate1flox/flox females. For each male mouse, at least six 
plugged females were collected and the pregnancy rates were recorded. Only ~9% of 
plugged Ate1flox/flox females became pregnant after mating with Tnap-Ate1-/-male mice, in 
comparison to the pregnancy rate of ~78% after mating with Ate1flox/flox males (Fig. 2D). 
In addition, the average number of pups born to Ate1flox/flox females that were mated with 
Tnap-Ate1-/-males was only ~1.3, in contrast to ~7.3 pups that were born, on average, to 
Ate1flox/flox females mated to Ate1flox/flox males (Fig. 2E).  
In agreement with low fertility of Tnap-Ate1-/-males (Fig. 2D, E), 
hematoxylin/eosin (HE)-stained sections of their epididymides contained few apparently 
mature spermatozoa (~1×106 per epididymis), in contrast to a much larger number 
(~16×106 per epididymis) of mature spermatozoa in Ate1flox/flox males (Fig. 2G, I). In 
contrast to Ate1flox/flox males, the epididymides of Tnap-Ate1-/- males contained a number 
of round-shaped cells with large nuclei, possibly immature spermatids (Fig. 2F). In 
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agreement with these results, Tnap-Ate1-/-testes were considerably smaller and lighter 
than their Ate1flox/flox counterparts (Fig. 2C, H). Histological assays also showed that the 
average diameter of seminiferous tubules in Tnap-Ate1-/-testes was ~139 µm, in contrast 
to ~204 µm for Ate1flox/flox tubules, and that Tnap-Ate1-/- tubules contained a smaller 
average number of cells per section (~93 cells vs. ~177 cells, respectively) (Fig. 2K, L). 
These results (Fig. 2) indicated that the Ate1 R-transferase was required for 
normal fertility levels in male mice. Given very low but still non-zero fertility of Ate1-/- 
males (Fig. 2D, E) as well as complete or nearly complete absence of the Ate1 R-
transferase from germ cells in Tnap-Ate1-/- testes (Fig. 2B), it is formally possible that the 
total absence of the Ate1-mediated arginylation in spermatogonia and spermatocytes is 
still compatible with a low but non-zero probability of sperm maturation. The alternative 
and a priori more likely interpretation is that the low but detectable sperm maturation that 
underlies the residual fertility of Tnap-Ate1-/- mice (Fig. 2D, E) is made possible by rare 
spermatocytes of Tnap-Ate1-/- testes that retained at least one copy of the intact Ate1flox 
gene. 
The Absence of Arginylation Is Compatible with Early Stages of Germ Cell 
Development – Using an antibody to the promyelocytic leukemia zinc finger (Plzf), a 
spermatogonia-specific marker, we observed similar levels of Plzf in presumptive 
spermatogonia in either the absence or presence of Ate1 (~56 Plzf-positive cells, on 
average, per a section of seminiferous tubule in both Tnap-Ate1−/− and Ate1flox/flox mice) 
(Fig. 3A, C). Formation of the synaptonemal complex and synapsis of chromosomes 
during the prophase of meiosis I in spermatocytes is accompanied by expression of the 
synaptonemal complex proteins 1 and 3 (Sycp1 and Sycp3) (83-85). Antibodies to Sycp1 
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and Sycp3 stained meiotic chromosomes indistinguishably in chromosome spreads of 
either Tnap-Ate1-/- or Ate1flox/flox spermatocytes (Fig. 3B). Similar immunofluorescence 
assays with Mlh1, a marker for chromosome crossovers (86-89), also showed no 
significant differences between Tnap-Ate1−/− and Ate1flox/flox spermatocytes (Fig. 3B, D, 
E).  
In addition, we could readily identify, cytologically, every major stage of the 
prophase of meiosis I in both Tnap-Ate1-/- and Ate1flox/flox spermatocytes, including 
leptotene, zygotene, pachytene and diplotene, and there were no statistical significant 
differences between the two genotypes vis-á-vis the percentages of each stage of 
prophase I (Figs. 3E, F and Fig. 4A, B). The average numbers of spermatocytes per a 
seminiferous tubule section in the prophase of meiosis I were also similar between Tnap-
Ate1-/- and Ate1flox/flox mice (~61 and ~60 spermatocytes, respectively) (Fig. 3E). These 
results indicated that (at resolution levels of our assays) pre-metaphase stages of germ-
cell development did not require the Ate1 R-transferase. 
Lack of Arginylation Causes Metaphase Arrest in Meiosis I – In contrast to the 
absence of detectable defects in the progression of Ate1-lacking Tnap-Ate1-/- 
spermatocytes through the prophase of meiosis I, we found these cells to be arrested at 
the metaphase of meiosis I, followed by their death through apoptosis (Figs. 3G, H and 
4C, D, F). In stage-XII seminiferous tubules, metaphase-I spermatocytes could be 
identified by their highly condensed (hematoxylin-stained) chromatin (74) (Fig. 3G, H). 
Both metaphase and later-stage (anaphase) spermatocytes (indicated by arrowheads and 
arrows, respectively) could be observed in Ate1-containing tubules of Ate1flox/flox testes 
(Fig. 3G). However, no anaphase spermatocytes could be detected in tubules of 
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Ate1-lacking Tnap-Ate1-/- testes, whose relative content of metaphase spermatocytes was 
~9.9%, in contrast to ~2.6% of such cells in Ate1flox/flox testes (Fig. 3G, H). In agreement 
with these results, it was easy to detect spindle bodies marked by ±-tubulin (consistent 
with the arrest of metaphase I spermatocytes) in Tnap-Ate1-/- testes (Fig. 4E). We also 
examined, by immunoblotting, the expression of cyclin B1, a marker of metaphase (90). 
The level of cyclin B1 was significantly increased in Tnap-Ate1-/- testes (Fig. 2J), yet 
another indication of metaphase arrest of Ate1-lacking spermatocytes in meiosis I. 
Apoptotic Death of Arginylation-lacking Spermatocytes in Metaphase of Meiosis I 
– The terminal deoxynucleotidyl transferase dUTP nick end labeling assay (TUNEL) was 
used to measure the extent of apoptosis of Tnap-Ate1-/- vs. Ate1flox/flox spermatocytes (Fig. 
4C, D, F). In Tnap-Ate1-/- testes, on average ~33% of spermatocytes were overtly 
apoptotic (TUNEL-positive), in comparison to ~9% of such cells in Ate1-containing 
Ate1flox/flox testes (Fig. 4C). In addition, only ~1.8 apoptotic cells per a seminiferous 
tubule section were found, on average, in Ate1flox/flox testes, vs. ~8.3 apoptotic cells in 
Tnap-Ate1-/- testes (Fig. 4F). Together, these results are likely to account for the observed 
massive decrease in the content of mature sperm cells in the testes of Ate1-lacking 
Tnap-Ate1-/- males and the resulting very low fertility of these mice (Fig. 2C-E). As 
described below, the metabolic stabilization of a natural fragment of the meiosis-specific 
Rec8 cohesin subunit is likely to be at least a significant, and possibly the major, reason 
for this functional consequence of Ate1 ablation in germ cells. 
Arginylation-mediated Degradation of the Separase-produced Rec8 Fragment – 
Rec8 is the main meiosis-specific cohesin subunit of the kleisin family. Mouse Rec8 is 
sequelogous to both yeast and mammalian kleisin-type cohesin subunits (Fig. 1C and 
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Introduction). The cleavage of mouse Rec8 by the separase would be expected to 
generate a 15-kDa C-terminal fragment bearing N-terminal Glu, a secondary 
destabilizing residue and a substrate of the Ate1 R-transferase (Fig. 1A, C). Although 
separase can cleave mouse Rec8 in vitro at more than one location, the cleavage between 
Arg-454 and Glu-455 is by far the predominant one (Fig. 1C) (76). 
To determine whether the separase-generated Rec8 fragment was a substrate of 
the Arg/N-end rule pathway, we used both steady-state and pulse-chase assays. 
Immunoblotting of extracts from wild-type and Tnap-Ate1-/- mouse testes with antibody 
to a C-terminal region of Rec8 showed the presence of both the full-length endogenous 
Rec8 protein and its fragment. The latter species migrated, upon SDS-PAGE, at a 
position close to the one expected for the 15 kDa Glu455-Rec8 fragment (Figs. 1C and 5A, 
lane 2). Strikingly, however, while this endogenous Rec8 fragment was abundant in 
extracts from Tnap-Ate1-/- testes, it was virtually absent in wild-type extracts (Fig. 5A, 
lane 1 vs. lane 2).  
A parsimonious interpretation of these results is that the separase-generated 
15 kDa Glu455-Rec8 fragment (Fig. 1C) (76) was arginylated by the Ate1 R-transferase in 
wild-type cells and thereafter rapidly destroyed by the “downstream” part of the Arg/N-
end rule pathway, whereas in Tnap-Ate1-/- cells the Glu455-Rec8 fragment was long-lived, 
as it could not be arginylated (Figs. 1A and 5A). Hence the virtual absence of the 
endogenous Glu455-Rec8 fragment in wild-type testes at steady state (Fig. 5A, lane 1) and 
its accumulation in Tnap-Ate1-/- testes (Fig. 5A, lane 2). Interestingly, the level of the 
full-length Rec8 protein was also considerably higher in Tnap-Ate1-/- testes than in wild-
type ones, at equal total protein loads (Fig. 5A and Discussion).  
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Degradation of the Glu455-Rec8 fragment was also assayed directly, using 35S-
pulse-chases and the Ub reference technique (URT), derived from the Ub fusion 
technique (Fig. 5C) (4,21,22,91,92). Cotranslational cleavage of a URT-based Ub fusion 
by deubiquitylases that are present in all eukaryotic cells produces, at the initially 
equimolar ratio, both a test protein with a desired N-terminal residue and the reference 
protein fDHFR-UbR48, a flag-tagged derivative of the mouse dihydrofolate reductase (Fig. 
5C). In URT-based pulse-chase assays, the labeled test protein is quantified by measuring 
its levels relative to the levels of a stable reference at the same time point during a chase. 
In addition to being more accurate than pulse-chases without a built-in reference, URT 
also makes it possible to detect and measure the degradation of the test protein before the 
chase, i.e., during the pulse (17,91,92).  
URT-based 35S-pulse-chases with C-terminally flag-tagged Glu455-Rec8f and its 
derivatives were performed in a transcription-translation-enabled rabbit reticulocyte 
extract, which contains the Arg/N-end rule pathway and has been extensively used to 
analyze this pathway (4,21,22). The indicated fDHFR-UbR48-X455-Rec8f URT fusions 
(X=Glu; Val; ArgGlu) were labeled with 35S-Met/Cys in reticulocyte extract for 10 min 
at 30°C, followed by a chase, immunoprecipitation with a monoclonal anti-flag antibody, 
SDS-PAGE, autoradiography, and quantification (Fig. 5B-D). The logic of these assays 
involves a comparison between the degradation rates of a protein bearing a destabilizing 
N-terminal residue and an otherwise identical protein with an N-terminal residue such as 
Val, which is not recognized by the Arg/N-end rule pathway (Fig. 1A).  
The Glu455-Rec8f fragment was short-lived in reticulocyte extract (t1/2 of 10-15 
min) (Fig. 5B, D). Moreover, ~30% of pulse-labeled Glu455-Rec8f were degraded during 
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the pulse, i.e., before the chase, in comparison to the otherwise identical Val455-Rec8f, 
which was also completely stable during the chase (Fig. 5B, D). We also constructed and 
examined Arg-Glu455-Rec8f. This protein was a DNA-encoded equivalent of the 
posttranslationally Nt-arginylated Glu455-Rec8f fragment of Rec8. As would be expected, 
given the immediate (cotranslational) availability of N-terminal Arg in the DNA-encoded 
Arg-Glu455-Rec8f, this protein was destroyed by the Arg/N-end rule pathway even more 
rapidly than the already short-lived Glu455-Rec8f. Specifically, nearly 80% of Arg-Glu455-
Rec8f was eliminated during the 10-min pulse (before the chase), in comparison to ~30% 
of Glu455-Rec8, with the long-lived Val455-Rec8f control being a part of the reference set 
(Fig. 5B, D).  
The results of pulse-chase analyses (Fig. 5B-D) were in agreement with other 
measurements, in which the synthesis-deubiquitylation-degradation of fDHFR-UbR48-X-
Rec8f fusions in reticulocyte extract was allowed to proceed for 1 hr, followed by 
detection of Glu455-Rec8f, of other test proteins, and of the fDHFR-UbR48 reference 
protein by SDS-PAGE and immunoblotting with anti-flag antibody (Fig. 5E). In these 
assays, the samples were incubated in reticulocyte extract either without added 
dipeptides, or with 1 mM Arg-Ala (RA), bearing N-terminal Arg, a type-1 primary 
destabilizing residue, or with 1 mM Ala-Arg (AR), bearing N-terminal Ala, a residue that 
is not recognized by N-recognins of the Arg/N-end rule pathway (Figs. 1A and 5E).  
Ubr1 and Ubr2, the two sequelogous (47% identical) and functionally overlapping 
200-kDa N-recognins (E3 Ub ligases) of the mammalian Arg/N-end rule pathway, have 
several substrate-binding sites. These sites recognize (bind to) specific classes of 
N-degrons and specific internal (non-N-terminal) degrons. The two substrate-binding 
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sites that recognize N-degrons are the type-1 site, which specifically binds to the N-
terminal basic residues Arg, Lys or His, and the adjacent but distinct type-2 site, which 
specifically binds to the N-terminal bulky hydrophobic residues Leu, Phe, Tyr, Trp, and 
Ile (4,6,93,94). Dipeptides bearing, for example, type-1 N-terminal residues can 
competitively and selectively inhibit the binding of Ubr1/Ubr2 to a type-1 N-degron but 
not to a type-2 N-degron in a test protein (4,6,95-97). 
In agreement with the rapid degradation of the Glu455-Rec8f fragment in 35S-
pulse-chase assays (Fig. 5B-D), the synthesis-deubiquitylation-degradation of the 
fDHFR-UbR48-Glu455-Rec8f fusion for 1 hr in reticulocyte extract either in the absence of 
added dipeptide, or in the presence of Ala-Arg (which does not bind to Ubr1/Ubr2) did 
not result in a detectable accumulation of the Glu455-Rec8f fragment, at its expected 
(roughly 15 kDa) position in SDS-PAGE-based immunoblots (Fig. 5E, lanes 8 and 10). 
In striking contrast, the same assay but in the presence of the Arg-Ala dipeptide (which 
competitively inhibits the recognition of type-1 N-degrons) resulted in a prominent 
protein band at the expected position of Glu455-Rec8f (Fig. 5E, lane 9 vs. lanes 8 and 10). 
Given the URT-based design of fDHFR-UbR48-Glu455-Rec8f (Fig. 5C), that protein band 
was inferred to be the Glu455-Rec8f fragment that had been metabolically stabilized by the 
Arg-Ala dipeptide. In contrast, the larger Met206-Rec8f fragment, corresponding to a 
putative (and at most a minor) separase cleavage site in the full-length Rec8 protein, was 
metabolically stable irrespective of the presence or absence of the Arg-Ala dipeptide 
(Fig. 5E, lanes 5-7 vs. lanes 8-10). The same was true of full-length Rec8f. It should also 
be mentioned that full-length Rec8f was not converted into a smaller fragment in 
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reticulocyte extract, indicating (as would be expected) the absence of active separase in 
that extract (Fig. 5E, lanes 2-4). 
 
DISCUSSION 
The arginyltransferase (R-transferase) Ate1 is a component of the Arg/N-end rule 
pathway of protein degradation. Ate1 utilizes Arg-tRNA as a cosubstrate to arginylate 
N-terminal Asp, Glu or (oxidized) Cys of a targeted protein substrate. The resulting 
N-terminal Arg is recognized by E3 ubiquitin ligases (N-recognins) of the Arg/N-end rule 
pathway (Fig. 1A, Introduction, and references therein). In the present study, we 
constructed an Ate1-/- mouse strain in which the ablation of Ate1 was confined to germ 
cells. We used this and other experimental tools to characterize Glu455-Rec8, a specific C-
terminal fragment of the kleisin-type, meiosis-specific Rec8 subunit of mouse cohesin. 
Rec8 is cleaved, late in meiosis I (see Introduction and references therein), by a 
nonprocessive protease called separase. The main C-terminal fragment of that cleavage, 
Glu455-Rec8, bears N-terminal Glu, a substrate of Ate1 (Fig. 1A, C). We have shown that 
the mouse Glu455-Rec8 fragment is a short-lived substrate of the Arg/N-end rule pathway 
and that the degradation of this fragment requires its Nt-arginylation by the Ate1 R-
transferase (Figs. 5).  
In S. cerevisiae, Scc1/Rad21/Mcd1 is the mitotic counterpart of the mammalian 
meiotic Rec8 subunit of cohesin. Similarly to the mouse Glu455-Rec8 fragment, the 
separase-generated C-terminal fragment of yeast Scc1 is also a short-lived substrate of 
the Arg/N-end rule pathway, and the failure to destroy this fragment in ubr1” cells 
(which lack the Arg/N-end rule pathway) results in chromosome instability (62). The 
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separase-generated C-terminal fragment of yeast Scc1 retains, in part, the physical 
affinity of Scc1 for the rest of cohesin complex (62). The mouse Glu455-Rec8 fragment 
would also be likely to interact in vivo with the rest of meiotic cohesin. If so, the failure 
to arginylate the Glu455-Rec8 fragment in arginylation-lacking spermatocytes of 
Ate1-/- mice, and hence the failure to destroy this fragment (Figs. 1A and 5) would be 
expected to interfere with cohesin mechanics. This (at present hypothetical) interference 
would account, at least in part, for the observed arrest and apoptotic death of 
Ate1-/- spermatocytes at the end of meiosis I and the resulting strong decrease in the 
fertility of Ate1-/- males (Fig. 2C-L). 
Immunoblotting analyses of the arginylation-dependent degradation of the 
endogenous Glu455-Rec8 fragment showed that this fragment was virtually absent, at 
steady state, in wild-type mouse testes but accumulated in Ate1-/- testes (Fig. 5A). 
Interestingly, the steady-state level of the full-length Rec8 protein was also significantly 
higher in Ate1-/- testes than in wild-type ones, at equal total protein loads (Fig. 5A). A 
plausible but unproven interpretation of this result is that the cleavage of the full-length 
mouse Rec8 by separase may be subject to a product-mediated inhibition of separase in 
Ate1-/- spermatocytes, if the product, Glu455-Rec8, is no longer eliminated by the 
Ate1-dependent arginylation branch of the Arg/N-end rule pathway (Figs. 1A and 5). 
Although selective ablation of Ate1 in mouse germ cells nearly abrogates the 
fertility of male mice (Fig. 2C-E), it is unlikely that specific cases of human infertility 
can be caused by unconditionally null mutations of human Ate1, inasmuch as global 
mouse Ate1-/- mutants are late embryonic lethals (29). In addition, a post-natal ablation of 
mouse Ate1, in adult mice (using cre-lox technology and a ubiquitously expressed Cre 
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recombinase), while compatible with mouse viability, causes a variety of abnormal 
phenotypes, including the loss of fat and hyperkinetic behavior (33). Nevertheless, 
partially active (hypomorphic) mutants of the human Ate1 R-transferase might underlie 
some, currently obscure, cases of human infertility.  
The same disposition would obtain if the human Arg/N-end rule pathway would 
be partially inactivated “downstream” of the Ate1 R-transferase, at the level of pathway’s 
Ub ligases (Fig. 1A). For example, unconditional Ubr1-/- mice, lacking one of two major 
N-recognins, Ubr1 and Ubr2, are viable and fertile, while exhibiting some abnormal 
phenotypes (98). The analogous Ubr2-/- mice, lacking the second major N-recognin (it is 
structurally and functionally similar to Ubr1), are also viable (in some strain 
backgrounds) but exhibit male infertility (77). This infertility is similar to the low-fertility 
phenotype of Ate1-/- mice in the present study, as in both cases the infertility is caused by 
apoptotic death, in meiosis I, of either Ubr2-/- or Ate1-/- spermatocytes (Figs. 2C-D and 
4C, D, F). A parsimonious interpretation of these results is that a failure to rapidly 
destroy the separase-generated Glu455-Rec8 fragment is a common mechanistic 
denominator of both Ate1-/- and Ubr2-/- infertility phenotypes.  
No human Ubr2-/- mutants have been identified so far. In contrast, human patients 
with the previously characterized Johansen-Blizzard Syndrome (JBS) have been shown to 
be null Ubr1-/- mutants (99). It is unknown whether or not human JBS patients are fertile, 
in part because the overall phenotype of human JBS is more severe than analogous 
phenotype of Ubr1-/- mice. Abnormal phenotypes of human JBS (Ubr1-/-) patients include 
anatomical malformations, an insufficiency and inflammation of the acinar pancreas, 
mental retardation, and deafness (4,99). 
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Although separase can cleave mouse Rec8 in vitro at more than one site, the 
cleavage between Arg-454 and Glu-455, resulting in the Glu455-Rec8 fragment, is by far 
the predominant one (Fig. 1C) (76). Mammalian Rad21, the mitosis-specific counterpart 
of the meiotic Rec8 cohesin subunit, is also cleaved by separase, late in mitosis. Similarly 
to the cleavage of the meiosis-specific Rec8, the separase-mediated cleavage of the 
mammalian mitotic Rad21 subunit also yields the C-terminal fragment of Rad21 bearing 
N-terminal Glu (75). However, in contrast to the present results with the Glu455-Rec8 
fragment of meiotic Rec8 (Fig. 4B, C), our recent analyses of the N-terminal Glu-bearing 
mitotic Rad21 fragment using 35S-pulse-chases and the URT method (Fig. 5A) indicated 
that this fragment was long-lived (B.W. and A.V., unpublished data). Further analyses of 
these unexpected (and therefore particularly interesting) results about the apparently 
stable mitotic Glu-Rad21 fragment vis-à-vis the short-lived meiotic Glu455-Rec8 fragment 
(Fig. 4) are under way. 
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Fig. 5.1. The mammalian N-end rule pathway and the separase cleavage site in 
Rec8, a meiosis-specific cohesin subunit. See Introduction for references and 
descriptions of the pathway’s mechanistic aspects and biological functions. Amino acid 
residues are denoted by single-letter abbreviations. (A) The Arg/N-end rule pathway. It 
targets proteins for degradation through their specific unacetylated N-terminal residues. 
A yellow oval denotes the rest of a protein substrate. “R-transferase” is the Ate1 
arginyltransferase. “Primary”, “secondary”, and “tertiary” refer to mechanistically 
distinct classes of destabilizing N-terminal residues. “Type 1” and “type 2” refer to two 
sets of primary destabilizing N-terminal residues, basic (Arg, Lys, His) and bulky 
hydrophobic (Leu, Phe, Trp, Tyr, Ile, and Met followed by a bulky hydrophobic residue 
($ )), respectively. These sets of N-terminal residues are recognized by two distinct 
substrate-binding sites of N-recognins, the pathway’s E3 ubiquitin ligases. (B) The Ac/N-
end rule pathway. It targets proteins through their N±-terminally acetylated 
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(Nt-acetylated) residues. Red arrow on the left indicates the cotranslational removal of 
the N-terminal Met residue by Met-aminopeptidases (MetAPs). N-terminal Met is 
retained if a residue at position 2 is larger than Val. (C) Alignments of amino acid 
sequences near the main separase cleavage site in mammalian Rec8, between Arg454 and 
Glu455 of mouse Rec8. The consensus sequence of this cleavage site (its P4-P1 residues) 
in both mitotic (Rad21) and meiotic (Rec8) kleisin-type cohesin subunits is also shown. 
Conserved residues of mammalian Rec8 near the cleavage site are in yellow. The 
conserved P4, P3, P1 and P1’ residues of mammalian Rec8 at the cleavage site are in red, 
orange, green, and blue, respectively. 
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Fig. 5.2. Tnap-Ate1-/- mice, in which the ablation of Ate1 is confined to germ cells, are 
nearly infertile. (A) Immunohistochemical detection of the Ate1 R-transferase in 
sections of wild-type (Ate1flox/flox) seminiferous tubules in adult mice, using 
affinity-purified anti-Ate1 antibody. Sub-panels on the right are enlargements of the areas 
demarcated by dashed rectangles on the left. Upper sub-panels: staining with primary 
(anti-Ate1) and secondary antibodies. Lower sub-panels: secondary antibody alone 
(control). Scale bars, 50 µm. (B) Dramatic decrease of the Ate1 R-transferase in the testes 
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of Tnap-Ate1-/- mice, as determined by immunoblotting of testes extracts with anti-Ate1 
antibody. (C) Decreased size of Tnap-Ate1-/- testes, in comparison to wild-type 
(Ate1flox/flox) ones. (D) Pregnancy rates (%) of plugged wild-type females after matings 
with Tnap-Ate1-/- vs. wild-type males. (E) Average numbers of pups per all plugged wild-
type females after matings with Tnap-Ate1-/- vs. wild-type males. (F) Histological 
appearance (hematoxylin-eosin) of sections through epididymis of Tnap-Ate1-/- vs. wild-
type males. Sub-panels on the right are enlargements of areas (indicated by dashed 
rectangles) on the left. Arrowheads indicate abnormal cells, absent in sections of wild-
type epididymis. Scale bar, 20 µm. (G) Calculated total sperm number in epididymis of 
Tnap-Ate1-/- vs. wild-type males. (H) Ratio of testis mass to mouse body mass for Tnap-
Ate1-/- vs. wild-type males. (I) Histological appearance (hematoxylin-eosin) of sectioned 
seminiferous tubules in Tnap-Ate1-/- vs. wild-type males. Scale bars, 50 µm. (J) 
Immunoblotting analyses, using antibodies to actin and to cyclin B1 (the latter a marker 
for metaphase) of extracts from Tnap-Ate1-/- vs. wild-type testes (see the main text). (K) 
Average diameters of seminiferous tubules in Tnap-Ate1-/- vs. wild-type testes. (L) 
Average numbers of cells per seminiferous tubule in Tnap-Ate1-/- vs. wild-type testes. 
Standard deviations are indicated in D, E, G, H, K and L (the corresponding assays were 
carried out in triplicate). 
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Fig. 5.3. Knockout of the Ate1 R-transferase gene does not affect the progression of 
spermatocytes through meiosis I until their arrest at metaphase. (A) Similar 
frequencies of cells (Plzf+ cells) that could be stained with antibody to Plzf, a 
spermatogonia-specific marker, in testes of Tnap-Ate1-/- vs. wild-type males. Scale bars: 
50 µm. (B) Sycp3 (green) and Sycp1 (red) proteins, the markers for synaptonemal 
complex, detected (using corresponding antibodies) on chromosomes of Tnap-Ate1-/- vs. 
wild-type spermatocytes at the pachytene stage of meiosis I. Scale bars, 5 µm. 
(C) Numbers of Plzf+ cells (presumptive spermatogonia) per section of a seminiferous 
tubule in Tnap-Ate1-/- vs. wild-type males (quantification of results in A). (D) Same as in 
B but for Sycp3 and Mlh1 (the latter a marker for chromosome crossovers) in Tnap-Ate1-
/- vs. wild-type males. Scale bars: 5 µm. (E) Numbers of prophase I (Sycp3-positive) cells 
per section of a seminiferous tubule in Tnap-Ate1-/- vs. wild-type males. (F) Percentages 
of spermatocytes at different prophase stages of meiosis I Tnap-Ate1-/- vs. wild-type 
males. (G) Sections of Tnap-Ate1-/- vs. wild-type testes were stained with 
hematoxylin/eosin. Sub-panels on the right are enlargements of the areas demarcated by 
dashed rectangles on the left. An arrow and arrowheads indicate anaphase and metaphase 
cells, respectively. Scale bars, 50 µm. (H) Percentages of spermatocytes at metaphase I of 
meiosis I (quantification of cell images in G). Standard deviations are indicated in C, E, 
F, and H (the corresponding assays were carried out in triplicate). 
178 
 
 
Fig. 5.4. Increased apoptosis in seminiferous tubules of Tnap-Ate1-/- mice. 
(A) Spermatocytes in prophase I of meiosis I, stained with DAPI for DNA and with anti-
Sycp1 antibody in sections of seminiferous tubes in Tnap-Ate1-/- vs. wild-type testes. 
Scale bar, 50 µm. (B) Stages of meiosis I in spermatocytes of Tnap-Ate1-/- vs. wild-type 
testes, detected by staining chromosome spreads with anti-Sycp3 antibody. Scale bar, 10 
µm. (C) Percentages of seminiferous tubules containing apoptotic (TUNEL-positive) 
cells in Tnap-Ate1-/- vs. wild-type testes. (D) Representative TUNEL-assay patterns 
(stained with DAPI as well) in Tnap-Ate1-/- vs. wild-type testes. Sub-panels on the right 
are enlargements of areas (indicated by dashed squares) on the left. Scale bars, 50 µm. 
(E) Staining of testes sections from Tnap-Ate1-/- vs. wild-type testes with DAPI for DNA, 
and with antibody to ±-tubulin for spindle bodies (see the main text). Scale bar, 50 µm. 
(F) Numbers of apoptotic (TUNEL-positive) cells per a section of seminiferous tubules in 
Tnap-Ate1-/- vs. wild-type testes. Standard deviations are indicated in C and F (the 
corresponding assays were carried out in triplicate). 
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Fig. 5.5. The separase-generated C-terminal fragment of Rec8 as a short-lived 
substrate of the Arg/N-end rule pathway. (A) Immunoblotting of extracts from wild-
type (lane 1) vs. Tnap-Ate1-/- (lane 2) mouse testes with antibody to a C-terminal region 
of Rec8. Note the presence of a prominent band, inferred to be the endogenous Glu455-
Rec8 fragment, in Tnap-Ate1-/- but not wild-type testes. The lower panel shows the results 
of control immunoblots using antibody to the unrelated p97 protein. (B) Quantification of 
data in D. (C) The ubiquitin reference technique (URT; see the main text). (D) Lanes 1-4, 
35S-pulse-chase of the C-terminally flag-tagged Glu455-Rec8f fragment of mouse Rec8, 
produced as the URT fusion fDHFR-UbR48-Glu455-Rec8f in reticulocyte extract (see the 
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main text). The bands of Glu455-Rec8f and the reference protein fDHFR-UbR48 are 
indicated on the left. Lanes 5-8, same as in A but with the otherwise identical Val455-
Rec8f, bearing N-terminal Val, which is not targeted by the Arg/N-end rule pathway. 
Lanes 9-12, same as in but with Arg-Glu455-Rec8f (see the main text). (E) In these assays, 
the synthesis-deubiquitylation-degradation of URT-based fDHFR-UbR48-X-Rec8f fusions 
in reticulocyte extract was allowed to proceed for 1 hr, followed by detection of 
Glu455-Rec8f, of other test proteins, and of the fDHFR-UbR48 reference protein by SDS-
PAGE and immunoblotting with anti-flag antibody. Lane 1, control extract with the 
added vector plasmid (see Experimental Procedures). Lane 2, expression of the 
fDHFR-UbR48-Rec8f fusion, which is processed by deubiquitylases in the extract to yield 
full-length Rec8f. Lane 3, same as lane 2, but in the presence of the Arg-Ala (RA) 
dipeptide at 1 mM. Lane 4, same as lane 3, but in the presence of the Ala-Arg (AR) 
dipeptide at 1 mM. Lanes 5-7, same as lanes 2-4, but expression of the fDHFR-UbR48-
Met206-Rec8f fusion, which is processed in the extract to yield fDHFR-UbR48 and Met206-
Rec8f (see the main text). Lanes 8-10, same as lanes 5-7, but expression of the 
fDHFR-UbR48-Glu455-Rec8f fusion, which is processed in the extract to yield fDHFR-
UbR48 and the Glu455-Rec8f protein, the main product of the cleavage of full-length Rec8 
by separase. Note the presence of a prominent protein band, inferred to be the 16 kDa 
flag-tagged Glu455-Rec8f protein, in the presence of the Arg-Ala dipeptide (lane 9) but 
neither in the absence of added dipeptide or in the presence of Ala-Arg (lanes 8 and 10; 
see also the main text). Also indicated, in panels D and E, are the molecular masses of 
key protein species, the C-terminally flag-tagged Rec8 fragment (16 kDa) and the N-
terminally flag-tagged reference protein DHFR-Ub (33 kDa). An asterisk denotes a 
protein band that crossreacted with anti-flag antibody. 
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ABSTRACT 
The arginyltransferase Ate1 is a component of the N-end rule pathway, which 
recognizes proteins containing N-terminal degradation signals called N-degrons, 
polyubiquitylates these proteins and thereby causes their degradation by the proteasome. 
At least six isoforms of mouse Ate1 are produced through alternative splicing of Ate1 
pre-mRNA. We identified a previously uncharacterized mouse protein, termed Liat1 
(ligand of Ate1), that interacts with Ate1 but does not appear to be its arginylation 
substrate. Liat1 has a higher affinity for the isoforms Ate11A7A and Ate11B7A. Liat1 
stimulated the in vitro N-terminal arginylation of a model substrate by Ate1. All 
examined vertebrate and some invertebrate genomes encode proteins sequelogous 
(similar in sequence) to mouse Liat1. Sequelogs of Liat1 share a highly conserved ~30-
residue region that is shown here to be required for the binding of Liat1 to Ate1. We also 
identified non-Ate1 proteins that interact with Liat1. In contrast to Liat1 genes of non-
primate mammals, Liat1 genes of primates are subtelomeric, a location that tends to 
confer evolutionary instability on a gene. Remarkably, Liat1 proteins of some primates, 
from macaques to humans, contain tandem repeats of a 10-residue sequence, whereas 
Liat1 proteins of other mammals contain a single copy of this motif. Quantities of these 
repeats are, in general, different in Liat1 of different primates. For example, there are 1, 
4, 13, 13, 17, and 17 repeats in the gibbon, gorilla, orangutan, bonobo, neanderthal, and 
human Liat1, respectively, suggesting that repeat number changes in this previously 
uncharacterized protein may contribute to evolution of primates. 
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INTRODUCTION 
The N-end rule pathway recognizes proteins containing N-terminal degradation 
signals called N-degrons, polyubiquitylates these proteins, and thereby causes their 
degradation by the proteasome (Fig. 1A, B) (1-9). The main determinant of an N-degron 
is a destabilizing N-terminal residue of a protein. Recognition components of the N-end 
rule pathway are called N-recognins. In eukaryotes, N-recognins are E3 ubiquitin (Ub) 
ligases that can target N-degrons (Fig. 1). Bacteria also contain a (Ub-independent) 
version of the N-end rule pathway (10, 11). 
Regulated degradation of proteins or their fragments by the N-end rule pathway 
mediates a strikingly broad range of functions, including the sensing of heme, nitric 
oxide, oxygen, and short peptides; control of protein quality and subunit stoichiometries, 
including the elimination of misfolded proteins; regulation of G proteins; repression of 
neurodegeneration; regulation of apoptosis, chromosome cohesion/segregation, 
transcription, and DNA repair; control of peptide import; regulation of meiosis, 
autophagy, immunity, fat metabolism, cell migration, actin filaments, cardiovascular 
development, spermatogenesis, and neurogenesis; the functioning of adult organs, 
including the brain, muscle and pancreas; and the regulation of many processes in plants 
(4-9) (Fig. 1A, B; see Supporting Information for a supplementary legend and references 
to this figure). 
In eukaryotes, the N-end rule pathway consists of two branches. One branch, 
called the Ac/N-end rule pathway, targets proteins for degradation through their N±-
terminally acetylated (Nt-acetylated) residues (Fig. 1B) (2, 3, 12). Degradation signals 
and E3 Ub ligases of the Ac/N-end rule pathway are called Ac/N-degrons and Ac/N-
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recognins, respectively. Nt-acetylation of cellular proteins is apparently irreversible, in 
contrast to acetylation-deacetylation of internal Lys residues. Approximately 90% of 
human proteins are cotranslationally Nt-acetylated by ribosome-associated Nt-acetylases 
(13). Posttranslational Nt-acetylation occurs as well. Many, possibly most, Nt-acetylated 
proteins contain Ac/N-degrons (Fig. 1B) (2-4, 12). 
The pathway’s other branch, called the Arg/N-end rule pathway, targets specific 
unacetylated N-terminal residues (Fig. 1A) (3, 14-16). The “primary” destabilizing N-
terminal Arg, Lys, His, Leu, Phe, Tyr, Trp, and Ile are directly recognized by N-
recognins. The unacetylated N-terminal Met, if it is followed by a bulky hydrophobic ($ ) 
residue, also acts as a primary destabilizing residue (Fig. 1A) (3). In contrast, 
unacetylated N-terminal Asn, Gln, Asp, and Glu (as well as Cys, under some metabolic 
conditions) are destabilizing owing to their preliminary enzymatic modifications, which 
include N-terminal deamidation (Nt-deamidation) of Asn and Gln and Nt-arginylation of 
Asp, Glu and oxidized Cys (Fig. 1A) (4, 6, 7, 17).  
Nt-arginylation is mediated by the Ate1-encoded arginyltransferase (Arg-tRNA-
protein transferase; R-transferase), a component of the Arg/N-end rule pathway and a 
subject of the present study (Fig. 1A, D) (18-23). Alternative splicing of mouse Ate1 pre-
mRNAs yields at least six R-transferase isoforms, which differ in their Nt-arginylation 
activity (Fig. 1C, D). (18, 21). R-transferases are sequelogous (similar in sequence) (24) 
throughout most of their ~60 kDa spans from fungi to mammals (4). R-transferase can 
arginylate not only N-terminal Asp and Glu but also N-terminal Cys, if it has been 
oxidized to Cys-sulfinate or Cys-sulfonate, through reactions mediated by NO, oxygen, 
and N-terminal Cys-oxidases (6, 20). The resulting circuits can act as sensors of NO and 
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oxygen in a cell through reactions that start with a conditional oxidation of N-terminal 
Cys in proteins such as the Rgs4, Rgs5, and Rgs16 regulators of G proteins in mammals 
(4, 20, 25) and specific transcriptional regulators in plants (reviewed in (4, 6, 7)). 
There are dozens of either identified Nt-arginylated proteins (including natural 
protein fragments) or proteins that are predicted to be Nt-arginylated. Many, possibly 
most, of these proteins are conditionally or constitutively short-lived substrates of the 
Arg/N-end rule pathway (Fig. 1A) ((14, 15, 20, 26) and refs. therein). In contrast, there 
were, until now, no analyzed protein ligands of R-transferase that did not appear to be its 
substrates. We describe a previously uncharacterized mouse protein, termed Liat1 (ligand 
of Ate1) that binds to the mouse Ate1 R-transferase, is apparently not arginylated by it, 
and has a higher affinity for specific splicing-derived Ate1 isoforms. We also identified 
proteins other than R-transferase that appear to interact with Liat1. Remarkably, Liat1 
proteins of some primates, from macaques to humans, contain tandem repeats of a 10-
residue sequence, in contrast to a single copy of this motif in Liat1 of other mammals. 
Quantities of repeats in Liat1 are, in general, different among different primates, 
suggesting that repeat number changes in this previously uncharacterized protein may 
contribute to evolution of primates.  
 
RESULTS 
Alternative Ate1 Exons and Their Sequelogies (Sequence Similarities). The 
59 kDa mouse R-transferase is encoded by Ate1. This gene, located on chromosome 7 
(7-F3), contains 14 protein-coding exons that encompass, together with introns, ~128 kb 
of Ate1 DNA (Fig. 1C, D) (18, 21, 23, 27). Mouse Ate1 encodes at least six splicing-
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derived Ate1 isoforms. Fig. 1D shows designations and exon compositions of the four 
major isoforms. They are enzymatically active R-transferases whose levels of expression 
vary among different mouse tissues (21). The splicing of Ate1 pre-mRNAs involves 
transcription from two distinct Ate1 promoters and the alternative utilization of two exon 
pairs: (i) either exon 1A or 1B; and (ii) either exon 7A or 7B (Fig. 1C, D). The alternative 
exons 1A and 1B encode two sequelogous (similar in sequence) (24) ~30-residue 
N-terminal regions of R-transferase (Figs. 1D and S1) (21). The alternative exons 7A and 
7B encode two sequelogous 43-residue regions of R-transferase (Figs. 1D and S1). 
Two-Hybrid Detection of a Protein That Interacts with Ate1. In a search for 
mouse proteins that specifically interact with mouse R-transferase without being 
arginylation substrates, we employed a yeast-based two-hybrid (Y2H) assay, using a 
mouse testis cDNA library and a Gal4 DNA-binding domain (DBD)-Ate11B7A fusion as 
bait. This screen identified 9 independent positive DNA clones encoding different 
(overlapping) segments of a previously uncharacterized mouse protein (LOC74230; Acc. 
NP_941039) (Fig. 2A). This 228-residue protein, encoded by a single-copy mouse gene, 
was termed Liat1 (ligand of Ate1) (Fig. 3A).  
To verify and expand these results, we expressed, in S. cerevisiae of appropriate 
genetic backgrounds, Gal4-DBD fusions to three mouse Ate1 isoforms, Ate11B7A, 
Ate11A7A, or Ate11B7B, and a Gal4 activation domain (AD) fusion to the full-length mouse 
Liat1. These strains were assayed for their ability to grow on minimal (SD) media lacking 
Leu, Trp, His, and Ade, thereby indicating the presence or absence of interactions among 
the examined protein fusions. The results were in agreement with the findings by the 
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initial two-hybrid screen in that the Ate11B7A R-transferase isoform interacted with Liat1 
(Figs. 1D and 2A). 
However, the two-hybrid assay did not detect interactions of Liat1 with the 
Ate11A7A and Ate11B7B isoforms, in contrast to the Ate11B7A isoform (Figs. 1D and 2A). 
This result was unexpected because differences among Ate1 isoforms are significant but 
not large, given sequelogies (24) between the encoded sequences of the Ate1 exons 1A 
vs. 1B (36% identity) and 7A vs. 7B (30% identity), respectively (Figs. 1D and S1). 
Although the affinity of Ate11A7A and Ate11B7B for Liat1 was too low for detection by 
two-hybrid assays (in contrast to the affinity of Ate11B7A) (Figs. 1D and 2A), an 
immunoprecipitation assay, described below, did detect a complex between Liat1 and the 
Ate11A7A isoform. One ramification of these two-hybrid results was a high likelihood that 
the interaction between Liat1 and Ate11B7A was specific, given the ability of Liat1 to 
distinguish, in its binding patterns, among three similar Ate1 isoforms (Figs. 1D, 2A, and 
S1). 
A Region of Liat1 Required for Interaction with Ate1. The yeast two-hybrid 
assay was also employed, using the mouse Ate11B7A isoform and either 
N-terminal/C-terminal truncations or internal deletions of mouse Liat1, to delineate a 
region of Liat1 that was required for the observed interaction (Figs. 2A and 3B). Liat1113-
165, a 53-residue internal segment of the 228-residue Liat1 that contained a particularly 
strongly conserved ~30-residue region (termed the Liat1 domain; see below and Fig. 
A3.S2) was sufficient for the Liat1-Ate11B7A interaction, whereas the Liat1 domain alone 
did not suffice (Fig. 3B). It was also found that only a part of the Liat1 domain was 
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required for the binding of a C-terminally truncated Liat1 to Ate11B7A, provided that a 
region immediately upstream of the Liat1 domain was present as well (Fig. 3B). 
Coimmunopreciptation Assays. We also transiently coexpressed, in mouse Ate1-
/- embryonic fibroblasts (EFs) lacking R-transferase (19), the N-terminally triple 
ha-tagged mouse Liat1 (3haLiat1) and one of the four untagged mouse R-transferases, 
Ate11A7A, Ate11B7A, Ate11A7B, or Ate11B7B (Figs. 1D and 2B). 3haLiat1 in cell extracts was 
immunoprecipitated with anti-ha antibody, followed by SDS-PAGE and immunoblotting 
with either anti-ha or the previously characterized, affinity-purified antibody to mouse 
Ate1 (20). The results of these coimmunoprecipitation (co-IP) assays were reproducible 
in independent assays and showed an efficacious co-IP of 3haLiat1 with Ate11A7A (Fig. 
2B, lanes 6 and 8). A less efficacious but still detectable co-IP with Ate11B7A was also 
observed (Fig. 2B, lane 4 vs. lanes 6 and 8), whereas co-IP with the isoforms Ate11A7B 
and Ate11B7B was negligible (Fig. 2B). 
We also carried out co-IP assays with recombinant proteins that had been 
expressed in E. coli using the Ub fusion technique and were purified by affinity 
chromatography that included the removal of Ub moiety (28, 29). These procedures 
yielded purified 3haLiat1 and purified, untagged Ate11A7A, Ate11B7A, Ate11A7B or Ate11B7B. 
Equal amounts of Ate11A7A, Ate11B7A, Ate11A7B or Ate11B7B were incubated with a ~4-
fold molar excess of purified full-length 3haLiat1, followed by immunoprecipitation with 
anti-Ate1, SDS-PAGE, and immunoblotting with either anti-ha or anti-Ate1 (Fig. 2C). 
These “carrier-free” co-IP assays with purified proteins (instead of cell extracts 
containing these proteins) detected interactions between Liat1 and all four Ate1 isoforms 
(Fig. 2C). Note, however, that co-IPs of purified 3haLiat1 with purified Ate11B7A and 
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Ate11A7A were significantly more efficacious than co-IPs with the other two isoforms, 
Ate11A7B and Ate11B7B (Fig. 2C, lanes 1, 3 vs. lanes 2, 4). These results were in 
qualitative agreement with the findings by both two-hybrid assays and co-IP assays with 
cell extracts, neither of which could detect Liat1 interactions with the isoforms Ate11A7B 
and Ate11B7B (Fig. 2B, C). In addition, co-IPs with purified Liat1 and purified Ate11B7A or 
Ate11A7A (Fig. 2C) indicated that Liat1-Ate1 interactions did not require other proteins. 
We do not understand the cause of the reproducible difference between Ate11B7A 
as the only Liat1-interacting Ate1 isoform in two-hybrid assays (Figs. 2A and 3B), in 
contrast to Ate11A7A as the apparently highest-affinity Liat1-interacting Ate1 isoform in 
co-IP assays with cell extracts (Fig. 2B). A plausible possibility is a different pattern of 
modifications (e.g., phosphorylation) of Ate11B7A vs. Ate11A7A that influences the 
outcomes of two different kinds of binding experiments (protein fusions in yeast-based 
Y2H assays in vivo vs. epitope-tagged 3haLiat1 and untagged Ate1 in co-IP assays with 
mammalian cell extracts in vitro). The other two isoforms, Ate11A7B and Ate11B7B, were 
negative in regard to interactions with Liat1 in both two-hybrid assays and co-IP assays 
with cell extracts (Figs. 2B and 3B). The non-interacting (or weakly interacting) Ate11A7B 
and Ate11B7B isoforms both contained the 7B exon, in contrast to the other two Ate1 
isoforms (Figs. 1D and S1). 
Sequence Features of the Mouse Liat1 Protein. The mouse Liat1 cDNA 
(1700016K19Rik; Acc. NM_198637) encodes a 228-residue (25.5 kDa), previously 
uncharacterized protein (NP_941039) with a deduced pI of 7.45 (Fig. 3A). The Liat1 
gene, located on the mouse chromosome 11-B5, contains a single 2,737 bp intron 
between two protein-coding exons, and no alternative mouse Liat1 cDNA isoforms could 
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be detected in databases (Figs. 3A and 4). Amino acid sequence features of mouse Liat1 
include a negatively charged 10-residue region (9 of 10 residues are Glu) and a positively 
charged 12-residue region (11 of 12 residues are basic, largely Lys) (Fig. 3A). These 
regions are present in Liat1 of all examined mammals, but Liat1 of other vertebrates can 
lack either one of the two charged regions or both of them (Fig. 4B). 
An aspect of Liat1 that is particularly conserved in evolution is a ~30-residue 
region termed the Liat1 domain (Figs. 3, 4, and S2-S4). The 32-residue mouse and human 
Liat1 domains are 96% identical (Figs. S2 and S3). Genomes of all examined vertebrates, 
and of some invertebrates as well, encode proteins sequelogous to mouse Liat1 (Figs. 4 
and S2-S4). All sequelogs of Liat1 share at least the ~30-residue Liat1 domain. In fact, 
among vertebrates other than mammals and in Liat1-containing invertebrates as well, the 
Liat1 domain is often the only region that identifies a protein as a sequelog of 
mammalian Liat1 (Figs. 3, 4, S2-S4). 
The extent of conservation of the Liat1 domain among mammals (>95%) and a 
weaker but still considerable conservation of this domain between, e.g., mammals and 
invertebrates such as sea anemone or acorn worm (Figs. 4 and S2-S4) indicate a purifying 
selection that maintained this Ate1-interacting domain (of unknown function) in the 
course of animal evolution. At the same time, large clades of organisms, including plants 
and fungi, lack proteins that can be identified as Liat1 through sequelogies (sequence 
similarities) alone, as distinguished from still possible spalogies (spatial similarities) (24). 
Tandem repeats of a 10-residue motif in Liat1 of primates. Yet another feature 
of mammalian Liat1 is a 10-residue sequence immediately downstream of the Liat1 
domain (Figs. 3, 4, and S3). This 10-residue motif is present as a single copy in non-
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primate mammalian Liat1 proteins, but in Liat1 of some primates, including humans, this 
sequence is tandemly repeated (Figs. 4 and S3). For example, there are 4, 13, 13, 17, 17, 
and 18 repeats in the, gorilla, orangutan, bonobo, neanderthal, human, and baboon Liat1, 
respectively (Figs. 4 and S3). At the same time, some primates, such as gibbon and 
bushbaby, contain just one copy of the 10-residue motif, similarly to non-primate 
mammals (Figs. 4 and S3). The specific sequences of 10-residue repeats in a tandem 
array are either identical or nearly identical to each other both within a given Liat1 and 
among Liat1 proteins of different primate species (e.g., Fig. A3.S3).  
The probability of mutations that alter the quantity of repeats in a gene can be 
orders of magnitude higher than the probability of, e.g., missense mutations (see 
Discussion) (30, 31). As a result, genetic variation that stems from repeat number 
changes in specific proteins can greatly exceed variation caused by other changes. This 
difference would be even higher if a gene in question is subtelomeric (see Discussion) 
(31). Liat1 genes are subtelomeric in all examined primates, including humans (32), and 
most (though not all) primate Liat1 proteins contain tandem repeats of the 10-residue 
motif (Figs. 4 and S3). In contrast, Liat1 genes of non-primate mammals are not 
subtelomeric, and all such Liat1 proteins contain one copy of the 10-residue motif (Fig. 
4A). 
The possibility that differences, among primates, in the quantities of their 10-
residue repeats (Fig. 4) signify a role for these repeats in primate evolution is considered 
in Discussion. In contrast to non-primate Liat1, still unresolved aspects of subtelomeric 
primate Liat1 genes are complicated enough to preclude definitive conclusions about 
expression patterns of, e.g., human Liat1 (called C17orf97 in databases) until its DNA, 
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pre-mRNAs and mature mRNAs are extensively characterized. For example, current 
descriptions of human Liat1 (C17orf97) 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db=human&l=C17orf97) 
are consistent with the existence of at least one additional intron in the region of human 
Liat1 repeats, in contrast to mouse Liat1, which lacks both a second intron and the 
tandem repeats (Figs. 3A, 4, and S3) (see Discussion). 
Expression of Liat1 in Mouse Tissues and in Mouse or Human Cell Lines. 
A commercial antibody to human C17orf97 (Liat1) was raised in rabbits against a 
93-residue internal segment that included the highly conserved 32-residue human Liat1 
domain, which is 96% identical to its counterpart in mouse Liat1 (Figs. 3A, S2, and S3). 
In immunoblots of extracts from mouse tissues or NIH-3T3 mouse cell line, this anti-
Liat1 antibody detected largely a single band at the expected ~26 kDa Mr of mouse Liat1 
in the heart, kidney, liver, spleen, testis, lung, thymus, pancreas, and brown adipose 
tissue, and in NIH-3T3 cells as well (Fig. 5B, lanes 1-5, and Fig. 5C, lanes 1-9). 
Immunoblotting with decreasing amounts of purified recombinant (untagged) mouse 
Liat1 indicated that this antibody to human Liat1 could detect down to ~50 ng of mouse 
Liat1 per lane (Fig. 5A). At this (moderate) sensitivity, little if any Liat1 was detected in 
the total mouse brain, hippocampus, cerebellum, and white adipose tissue (Fig. 5B, lane 
6, and Fig. 5C, lanes 1-3). We note that histochemical data in the Human Protein Atlas 
(HPA023583), produced through the use of the same antibody, suggested the presence of 
Liat1 (C17orf97) in the human brain 
(http://www.proteinatlas.org/ENSG00000187624/tissue). In situ hybridization of a mouse 
1700016K19Rik (Liat1) cDNA to sections of mouse brain indicated the presence of Liat1 
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mRNA at least in the cerebellum (http://mouse.brain-
map.org/experiment/show?id=69114594). 
Immunoblotting with extracts from human HeLa and HEK293T cells detected 
two Liat1 species, of ~55 kDa and ~50 kDa (Fig. 5C, lanes 10, 11). Human Liat1 is 
predicted to be 423 residues long (46.4 kDa), owing to 17 tandem repeats, in human 
Liat1, of a 10-residue sequence, in contrast to a single copy of this sequence in the 228-
residue (25.5 kDa) mouse Liat1 and other non-primate Liat1 proteins (Fig. 3, 4, and Fig. 
5C, lanes 10, 11). A smaller of two human Liat1 species in Fig. 5C (lanes 10, 11) may be 
either a cleavage product of the larger human Liat1 or a pre-mRNA splicing-derived 
Liat1 isoform. Remarkably, this human Liat1 immunoblotting pattern also contained a 
~26 kDa band that comigrated with the ~26 kDa band recognized by the same antibody in 
mouse tissues (Fig. 5C, lanes 10, 11 vs. lanes 4-9). These results are consistent with the 
existence of human Liat1 isoforms in which quantities of the 10-residue repeat can vary 
between ~17 and 1, a functionally remarkable possibility that will be followed up through 
a more detailed understanding of primate Liat1 genes.  
Effect of Liat1 on Ate1-Mediated Nt-Arginylation. The previously 
characterized in vitro Nt-arginylation assay (21) used [14C]-L-Arg, purified mouse 
Ate11A7A, Ate11B7A, Ate11A7B and Ate11B7B isoforms, an Arg-tRNA-generating system, 
and either bovine ±-lactalbumin (it bears the Nt-arginylatable N-terminal Glu residue; 
Fig. A3.S5B) or purified, C-terminally tagged recombinant reporters X-DHFRbt (X=Asp, 
Cys or Arg-Cys) based on the mouse dihydrofolate reductase (DHFR (the “bt” tag is 
described in (17)). X-DHFRbt contained the 6-residue sequence KGLAGL immediately 
after the N-terminal X residue (X=Asp, Cys or Arg-Cys), followed by the DHFRbt 
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moiety. KGLAGL is the sequence of mouse Rgs4 (a physiological Arg/N-end rule 
substrate; see Introduction) immediately after its wild-type N-terminal Cys (20). 
Initially, identical amounts of the individual purified Ate11A7A, Ate11B7A, Ate11A7B 
and Ate11B7B isoforms were incubated for 60 min at 37°C with the rest of assay’s 
components, including [14C]-L-Arg and X-DHFRbt (X=Asp, Cys, or Arg-Cys), and 
either with or without Ate1-lacking extract from mouse Ate1-/- embryonic fibroblasts 
(EFs), followed by SDS-PAGE and autoradiography (Fig. A3.S5A). As expected (21), all 
Ate1 R-transferase isoforms could Nt-arginylate the N-terminal Asp residue of Asp-
DHFRbt, with Ate11B7B being most active, and with Ate11B7A, Ate11A7A, and Ate11A7B 
exhibiting, respectively, ~66%, ~65%, and ~12% of the activity of Ate11B7B (Fig. 
A3.S5A). No Nt-arginylation of the “pre-arginylated” Arg-Asp-DHFRbt was observed 
under any conditions (Fig. A3.S5A), as expected, given the specificity of R-transferase 
(Fig. 1A) (4). There was no detectable Nt-arginylation of Cys-DHFRbt in the absence of 
extract from Ate1-/- EF cells, but this reporter was Nt-arginylated in the presence of 
extract, owing, presumably, to the oxidation of N-terminal Cys by compounds in cell 
extracts (7, 20). 
The Liat1-supplemented version of this assay (without extract from Ate1-/- EF 
cells) employed X-DHFRbt (X=Asp, Cys). Each of the Ate11A7A, Ate11B7A, Ate11A7B, and 
Ate11B7B isoforms was pre-incubated for 30 min at 37°C with a ~4-fold molar excess of 
purified untagged mouse Liat1 or with buffer alone before their addition to the 
arginylation assay. The Nt-arginylation of Asp-DHFRbt by Ate1 was reproducibly 
enhanced in the presence of Liat1, from 1.3-fold to 2.3-fold (Fig. A3.S5C). This effect is 
unlikely to stem from increased macromolecular crowding upon the addition of Liat1, 
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because the addition of equal or larger amounts of bovine serum albumin did not alter the 
efficacy of Nt-arginylation. The unknown mechanistic cause of moderate but 
reproducible effects of Liat1 on Nt-arginylation is a subject for future studies. 
Significantly, we could not detect, despite attempts to do so, the conjugation of 
14C-Arg to Liat1 itself in this assay, in either the presence or absence of test proteins such 
as ±-lactalbumin or X-DHFRbt. (Upon SDS-PAGE, the untagged mouse Liat1 migrates 
significantly below the band of X-DHFRbt.) Even overexposures of autoradiograms of 
electrophoretically fractionated proteins after 14C-arginylation in the presence of purified 
Liat1 did not reveal any significant 14C in the vicinity of the ~26 kDa Liat1 band, 
indicating that Liat1 is not an Ate1 substrate. 
Identification of Liat1-Binding Proteins Other Than Ate1. We also carried out 
a search for mouse proteins other than Ate1 that interact with mouse Liat1 (Fig. 3A), 
using a library of mouse brain cDNAs fused to the Gal4 activation domain (AD) vis-á-vis 
Liat1 cDNA fused to the Gal4 DNA-binding domain (DBD). This screen identified ~40 
different mouse proteins that appeared to bind to mouse Liat1, with the corresponding 
cDNA isolates having passed standard controls of the Y2H assay (Fig. A3.S6C). In 
addition, an independent Y2H screen for interactions among protein methyltransferases 
and proteins that bind to them (including their substrates) identified the human Jmjd6 
methyltransferase as a putative ligand of human C17orf97 (33), i.e., the human Liat1 
protein (Fig. A3.S6C). 
We also searched for protein interactions with Liat1using GST-pulldowns with 
GST-Liat1 and extracts from mouse EF cells (Fig. A3.S6A). These mass spectrometry 
(MS)-based assays added the ribosomal proteins S14 and S19 as well as three specific 
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histones to the Y2H-based list of other Liat1 ligands (Fig. A3.S6). Thus identified 
putative ligands of Liat1 encompassed a broad range of functional classes, including 
components of the translation, transcription, and Ub-proteasome systems. Our ongoing 
co-IP assays that independently verify the binding of Liat1 to its putative ligands (which 
were detected by Y2H or GST-pulldowns (Fig. A3.S6C)) have recently confirmed that 
Jmjd6 and the ribosomal protein S14 can be coimmunoprecipitated with mouse Liat1 
from a cell extract (Fig. A3.S6B). These and other binding assays with putative ligands of 
Liat1 will continue to verify the current preliminary list (Fig. A3.S6), thereby making 
possible systematic analyses of confirmed Liat1 ligands in regard to specific functions of 
their interactions with Liat1. 
 
DISCUSSION 
We identified a 26 kDa mouse protein, termed Liat1 (ligand of Ate1), by 
detecting its binding to the 59 kDa mouse Ate1 R-transferase, a component of the 
Arg/N-end rule pathway (Figs. 1-3). The Liat1-Ate1 interaction was shown to require at 
least a part of the highly conserved ~30-residue region of Liat1 (Fig. 3B). Biological 
functions of Liat1-Ate1 interactions (Figs. 2 and 3), remain to be understood, in part 
because Liat1 is a previously uncharacterized protein. (In current databases, human Liat1 
is called C17orf97.) We also identified putative Liat1-binding proteins other than Ate1 
(Fig. A3.S6), but the biological function of Liat1 remains to be discovered. 
Further analyses showed that Liat1 proteins of some primates, from macaques to 
humans, contain tandem repeats of a 10-residue sequence, in contrast to a single copy of 
this motif in Liat1 of other mammals, including rodents. Quantities of these repeats are, 
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in general, different in Liat1 of different primates. For example, there are 4, 13, 13, 17, 
and 17 repeats in the gorilla, orangutan, bonobo, neanderthal, and human Liat1, 
respectively (Figs. 4 and S3), suggesting that repeat number changes in Liat1 might play 
a role in evolution of primates. As evidence, these differences in the quantities of Liat1 
repeats do not rise above a correlational argument, and the current disposition is further 
complicated by our finding of intra-species variability in the number of repeats. For 
example, the Liat1 proteins encoded by an anonymous human genome (NM_001013672) 
and by the genome of James D. Watson 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db=human&l=C17orf97) 
were found to contain, each, 17 tandem repeats, whereas the genome of J. Craig Venter 
encodes Liat1 that contains 18 repeats (NP_001013694). 
Analyses of primate genomes have identified, so far, relatively few alterations 
that could be demonstrated to contribute to phenotypic differences among these species. 
The “causative” alterations include variants of developmental enhancer DNA sequences 
as well as specific alleles of genes that influence circadian rhythms, human brain size, 
language, other human traits, and differences in body sizes among primates (34-37). On 
evolutionary timescales, the emergence of anatomical and behavioral features that 
distinguish humans from great apes was remarkably fast, as the last common ancestor of 
humans and chimpanzees lived about 6 million years ago.  
The efficacy of selection pressure is limited by the extent of relevant genetic 
variation within a breeding population. We suggest, therefore, that the rapidity of 
evolution that led to humans may have involved proteins containing tandemly repeated 
sequences, given frequent changes in the numbers of such repeats. Analogous arguments 
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have been made both in general and to account for the strikingly rapid (in less than 1,000 
years) emergence of modern dog breeds, in response to selection pressures imposed by 
breeders (30, 38). Morphological differences among dog breeds, and even within a breed, 
were found to correlate with variations in the numbers of 1-residue or 2-residue repeats in 
proteins that regulate embryonic development and postnatal growth (30). 
Tandem repeats of amino acid sequences that range in size from 1 to more than 
100 residues are a feature of many cellular proteins (30, 36, 38, 39). Heritable changes in 
the number of repeat units are known to underlie a significant fraction of phenotypic 
variability both among different species and within a species (36, 38). The previously 
demonstrated genetic instability of repeats stems from several causes, including unequal 
crossover, DNA replication slippage, and double-strand break repair (30, 31). In an 
evolving species, genetic variation that results from repeat number changes in specific 
proteins can greatly exceed variation that is caused, for example, by missense mutations. 
This difference would be even higher if a gene in question is subtelomeric, because 
proximity to a telomere tends to increase the frequency of recombination-mediated 
changes in the quantity of repeats in a gene (31).  
Remarkably, Liat1 genes are subtelomeric in all examined primates, including 
humans, and most primate Liat1 proteins contain tandem repeats of a 10-residue motif 
(Figs. 4 and S3). Potentially telling exceptions include the gibbon and bushbaby Liat1 
proteins, which contain a single copy of the 10-residue motif that is repeated in other 
examined primates (Fig. 4B) (37). In contrast to primate Liat1 genes, their counterparts in 
other mammals, including the mouse, are not subtelomeric (Fig. 4A), and all predicted 
non-primate Liat1 proteins in databases contain one copy of the 10-residue motif. The 
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function of Liat1 repeats (Fig. 4) and their possible relevance to anatomic and phenotypic 
evolution of primates, remain to be addressed. 
One subtelomeric gene encoding a protein that contains tandem repeats is Drd4 
(40). A human dopamine receptor encoded by Drd4 contains varying numbers of tandem 
repeats of a 16-residue sequence that forms the third cytosolic loop of the receptor. Both 
the quantity of 16-residue repeats and specific sequences within each repeat are often 
altered among individual humans, with repeat numbers varying between 2 and 10 (40). 
Analogous polymorphisms of these repeats were also observed in Drd4 of other primates 
(40). Human Drdr4 receptors with different repeat numbers were reported to differ in 
functional properties, and were also differentially regulated in diseases such as 
schizophrenia. Nevertheless, there is still no definitive evidence that the observed 
frequencies of Drd4-encoded isoforms containing different quantities of repeats had been 
caused, at least in part, by positive selection, as distinguished from a quasi-neutral drift 
(41). 
In sum, a major unanswered question is whether changes in repeat quantities 
among Liat1 proteins of different primates stemmed, at least in part, from specific 
selection pressures. The alternative scenario is that most variation in Liat1 repeats (Figs. 
4 and S3) may be the result of genetic drift and unselected fixations of altered repeat 
quantities, owing to a small effective population size of an evolving species, including 
occasional population bottlenecks. A smaller population is characterized by 
correspondingly weaker forces of natural selection. Near-neutral evolution of proteins 
under such conditions is discussed by Lynch (42). Because small changes in Liat1 repeat 
numbers may have modest phenotypic effects, a near-neutral drift would be likely to at 
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least contribute to evolution of repeats in Liat1. If so, it is the selection-based, adaptation-
centered hypothesis about a functional role of repeat number changes in Liat1 that must 
be experimentally verified vis-á-vis the competing null hypothesis, in which these 
changes would be caused by a near-neutral genetic drift. 
The understanding of both Liat1 itself and the functional significance of its 
binding to specific isoforms of the Ate1 R-transferase would be advanced by answers to 
at least the following questions. What are the composition and functions of in vivo 
complexes that contain Ate1, Liat1, and other macromolecular components? (Gel 
filtration of mouse cell extracts indicates that Ate1 and Liat1 can be parts of specific but 
not necessarily identical protein complexes (data not shown).) What is the biological 
function of Liat1? How does this function relate to the known role of the Ate1 
R-transferase in the Arg/N-end rule pathway (Fig. 1A)? Does a divergent Liat1 protein, 
e.g., the one of sea anemone (it is identifiable as Liat1 solely through its ~30-residue 
Liat1 domain; Figs. S2 and S4), specifically bind to the sea anemone Ate1? (The binding 
of mouse Liat1 to mouse Ate1 requires the Liat1 domain and apparently does not involve 
the 10-residue motif that forms repeats in Liat1 of primates; Figs. 2, 3B, 4, and S2-S4.) 
Furthermore: do repeats of the 10-residue motif in, for example, human Liat1 
(Figs. 4 and S3) interact with each other? Do these repeats specifically bind to any human 
protein? If they do, does the binding of Liat1 repeats to that protein also involve other 
regions of human Liat1? Is there a counterpart of a human repeat-binding protein in, for 
example, mouse cells? (Mouse Liat1 contains one copy of the sequence that forms 
repeats in human Liat1.) As mentioned in Results, it would also be essential to 
understand, in detail, a primate (e.g., the human or macaque) Liat1 gene, given its more 
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complex organization (including the presence of Liat1 isoforms) than the structure of 
repeat-lacking Liat1 genes of non-primate mammals (Figs. 3A and 4). 
The understanding of Liat1 would also benefit from constructing and 
characterizing mouse strains that either lack Liat1 or contain its counterpart in which the 
10-residue motif had been amplified to yield primate-like tandem repeats. It would also 
be informative to determine, with a primate such as, for example, macaque, the 
phenotypic effects of strongly increased or strongly decreased quantities of 10-residue 
repeats in Liat1 (Fig. 4). (Gene-specific alterations of the macaque genome through the 
CRISPR technology have already been achieved (43).) Given the preferential binding of 
Liat1 to specific isoforms of the Ate1 R-transferase (Fig. 2), further studies of Liat1 may 
also advance the functional understanding of Ate1 isoforms. In addition, the obscurity, 
until the present study, of tandem repeats in primate Liat1, and still incomplete 
descriptions of subtelomeric loci among the sequenced metazoan genomes (owing to 
complexities of dealing with telomere-proximal microsatellite DNA repeats) suggest that 
it may be informative to further explore subtelomeric regions of the 23 human 
chromosomes for the presence of other uncharacterized genes that might encode repeats 
analogous to those of Liat1.  
 
EXPERIMENTAL PROCEDURES 
Yeast Two-Hybrid (Y2H) Assays. They were carried with S. cerevisiae, using 
the BD Matchmaker kit (BD Biosciences, Palo Alto, CA), the plasmid pCB132, which 
expressed the Gal4DBD-ATE11B7A fusion (Table S1), and a mouse testis cDNA pACT 
library (Clontech). 
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Construction and Expression of Recombinant Proteins in BL21 (DE3) E. coli. 
The untagged mouse Ate11B7A, Ate11B7B, Ate11A7A, and Ate11A7B, the untagged mouse 
Liat, and 3haLiat1 were expressed as Ub fusions in E. coli, followed by the removal of Ub 
and purification of recombinant proteins by Mono-S chromatography (see SI 
Experimental Procedures). 
In Vitro Arginylation Assay. The Nt-arginylation assay was performed 
essentially as described previously (21). 
Tissue Extracts and Immunoblotting. Extract preparation and immunoblotting 
were carried out essentially as described previously (3, 12, 21). 
GST pulldown assay and immunoprecipitations. Mouse EF cells were 
transiently transformed with a plasmid expressing either glutathione transferase (GST) or 
a GST-Liat1 fusion, and GST-pulldown assays were carried out as described in SI 
Experimental Procedures. Immunoprecipitations with anti-flag or anti-ha antibodies were 
performed as previously described (3, 12).  
Additional information regarding experimental procedures is given in SI 
Experimental Procedures. 
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Fig. 6.1. The mammalian N-end rule pathway and the Ate1 arginyltransferase 
(R-transferase). See Introduction for a summary of pathway’s mechanistic aspects and 
biological functions. N-terminal residues are denoted by single-letter abbreviations. A 
yellow oval denotes the rest of a protein substrate. (A) The Arg/N-end rule pathway. It 
recognizes proteins through their unacetylated N-terminal residues and contains the N-
terminal arginylation (Nt-arginylation) branch, mediated by the arginyltransferase (R-
transferase) Ate1 and by the Nt-amidases Ntan1 and Ntaq1 that act upstream of Ate1 (4-
6). (B) The Ac/N-end rule pathway. It recognizes proteins through their N±-terminally 
acetylated (Nt-acetylated) residues (2, 3, 12). Red arrow on the left indicates the removal 
of the N-terminal Met residue by Met-aminopeptidases (MetAPs). N-terminal Met is 
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retained if a residue at position 2 is larger than Val. (C) The bidirectional DfaPAte1 
promoter upstream of exon 1B of the mouse Ate1 gene (4, 21, 27). (D) Four major mouse 
Ate1 R-transferase isoforms and their designations (4, 21). See SI Text for a detailed 
supplementary legend and supplementary references to this figure. 
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Fig. 6.2. Detection and characterization of interactions between the mouse Ate1 R-
transferase and a previously uncharacterized mouse protein termed Liat1. (A) 
Detection of Ate1-Liat1 interactions using two-hybrid (Y2H) assay. A Gal4 
DNA-binding domain (DBD)-Ate11B7A fusion and other DBD-based fusions (e.g., a 
control DBD fusion containing the WASP protein) vs. coexpressed Gal4 activation 
domain (AD) fusions to full-length Liat1 and to other proteins, including specific Ate1 
isoforms as well as the control (WASP-interacting) Cdc42 protein. The ability to grow on 
minimal media lacking Leu, Trp, His and Ade was used to detect interactions among the 
examined protein fusions. See SI Experimental Procedures. (B) Detection of Ate1-Liat1 
interactions using coimmunoprecipitation (co-IP) assays with mouse cell extracts. 
Plasmids expressing 3haLiat1 and/or specific Ate1 isoforms were transiently expressed in 
mouse Ate1-/- EF cells, followed by immunoprecipitations with anti-ha antibody, SDS-
PAGE of immunoprecipitates, and immunoblotting with both anti-ha and anti-Ate1 
antibodies. (C) Same as in B but using purified mouse 3haLiat1 and purified mouse Ate1 
isoforms, with immunoprecipitation by anti-Ate1 antibody. 
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Fig. 6.3. Mouse Liat1 and the mapping of its Ate1-binding region. (A) Nucleotide 
sequence of mouse Liat1 cDNA and amino acid sequence features of mouse Liat1 
(NP_941039). A large black “I” after the Lys-rich region denotes the position of a single 
2,737 bp intron between two protein-coding exons in the Liat1 genomic DNA. The 
purple, green, yellow, and blue rectangles denote, respectively, the negatively charged 
region of mouse Liat1, its positively charged region, its particularly highly conserved 
~30-residue domain, termed the Liat1 domain, and a 10-residue region that becomes 
tandemly repeated in Liat1 of some primates, including humans, but is a single-copy 
sequence in Liat1 of other mammals, including mouse Liat1. The same color scheme is 
used to denote these regions of Liat1 in other figures of this paper. Black and red 
numbers on the left indicate nucleotide and amino acid residue numbers, respectively. 
See also the main text and Figs. S2-S4. (B) Mapping Liat1-Ate1 interactions using two-
hybrid (Y2H) assays. The Gal4 DNA-binding domain (DBD)-Ate11B7A fusion was 
examined, using Y2H, for interactions with the coexpressed Gal4 activation domain (AD) 
fusion to either full-length Liat1 or to the indicated AD fusions encoding Liat1 fragments. 
The results of this assay are summarized on the right, and the color coding of Liat1 
domains (the same as in A) is indicated on the left. 
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Fig. 6.4. Chromosomal locations of Liat1 genes and evolution of Liat1 proteins. (A) 
Liat1 genes are located away from telomeres in both mice (chromosome 11-B5) and 
other non-primate mammals. In contrast, Liat1 genes are subtelomeric in all examined 
primates (e.g., human chromosome 17-p13.3), indicating a translocation of Liat1 to a 
subtelomeric site in an ancestor of modern primates, from gibbons and bushbabies to 
macaques and humans. (B) Evolution of Liat1 proteins. The colors of rectangles (the 
same as in Fig. 3A) denote, respectively, the negatively charged region of Liat1 (purple), 
its positively charged region (green), its particularly highly conserved ~30-residue 
domain (the Liat1 domain) (yellow), and a 10-residue segment that becomes tandemly 
repeated in Liat1 of some primates (blue). In all examined Liat1 proteins that contain 
these regions they are present in the same (indicated) order. While each of these regions, 
in a given Liat1, is unambiguously recognizable upon inspection of its amino acid 
sequence, the “linear” distances between these regions are not identical even among 
mammals, and are particularly variable among non-mammalian Liat1 proteins (Figs. S3 
and S4). This aspect of Liat1 is largely bypassed in these diagrams, whose chief aim is to 
highlight the presence or absence of specific regions and the emergence of tandem 10-
residue repeats in Liat1 of some primates, including humans and great apes. Dashed and 
shifted rectangles in Liat1 of non-mammalian vertebrates and invertebrates signify a non-
conservation of distances between specific domains of Liat1 in the indicated organisms, 
in comparison to a significant (though incomplete) conservation of inter-region distances 
among mammalian Liat1 proteins. See also the main text and Figs. S2-S4. For the 
accession numbers of specific Liat1 proteins and for Latin names of the cited animal 
species, see the legend to Fig. A3.S2. 
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Fig. 6.5. Analyses of Liat1 proteins by immunoblotting. (A) Purified recombinant 
(untagged) mouse Liat1 was fractionated by SDS-PAGE, following by immunoblotting 
with an antibody to a highly conserved region of human Liat1 (C17orf97) (see the main 
text). Lanes 1-3: 25, 50, and 100 ng of mouse Liat1 per lane, respectively. (B) Same as in 
A but with extracts from the indicated mouse tissues that had been fractionated by SDS-
PAGE. An asterisk indicates a larger, apparently unrelated (crossreacting) protein species 
in extracts from thymus and white adipose tissue (WAT). The results of immunoblotting 
with anti-tubulin antibody are shown as well. (C) Lanes 1-8, same as in B, with extracts 
from indicated mouse tissues. Lane 9, same as in lanes 1-8 but an extract from mouse 
NIH-3T3 cells. Lanes 10, 11, same as lane 8 but extracts from human HeLa and 
HEK293T cells. Larger human Liat1 proteins, corresponding, presumably, to species 
with multiple tandem repeats (see Fig. 4 and the main text) are indicated on the right. A 
question mark denotes a putative Liat1 species from human cell lines that comigrates 
with the much smaller (26 kDa) mouse Liat1 and may contain just one copy of the 10-
residue motif that is tandemly repeated in other species of human Liat1 (see the main 
text). 
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Fig A1.S1. Degradation assays with a proteasome inhibitor and a mutant of rat 
AANAT in S. cerevisiae. A, Lane 1, wild-type S. cerevisiae were transformed with 
vector (V) alone (control). Lanes 2-5, CHX-chase was performed at 30°C for the 
indicated times in wild-type S. cerevisiae with the wild-type rat MLSrAANAT3ha. Lanes 6-
9, same as in lanes 2-5 but the CHX-chase was in the presence of the MG132 proteasome 
inhibitor (see Experimental Procedures). Lanes 10-13, same as in lanes 2-5 but in pdr5”  
S. cerevisiae lacking the efflux pump Pdr5. Lanes 14-17, same as in lanes 10-13 but in 
the presence of MG132. The bands of actin and MLSrAANAT3ha are indicated on the left. 
B, quantification of data in A. C, CHX-chases were performed in wild-type S. cerevisiae 
with the wild-type rat MLSrAANAT3ha (lanes 2-5) and with its Lys-8-to-Arg mutant 
MLSrAANAAT3haK8R (see Results). The bands of tubulin and AANAT are indicated on the 
left. An asterisk on the right denotes a band of protein that crossreacted with anti-ha 
antibody (the band is also present in lane 1, the vector-only control). 
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Fig. A1.S2. Degradation assays with wild-type and mutant human AANATs in S. 
cerevisiae. A, Lane 1, wild-type S. cerevisiae were transformed with vector (V) alone 
(control). Lanes 2-5, CHX-chase was performed at 30°C for the indicated times in 
wild-type S. cerevisiae with the wild-type human (M)SThAANAT3f. Lanes 6-9, same as in 
lanes 2-5 but with the mutant human (M)PThAANAT3f. The bands of actin and AANAT 
are indicated on the left. B, quantification of data in A. 
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Fig. A1.S3. Construction and testing of weakened derivatives of the PCMV promoter 
in HEK293T cells. A, a simplified diagram of “wild-type” (unmodified) PCMV in the 
cloning vector, with schematically illustrated binding sites for the NFº B, SP1 and CREB 
transcriptional regulators. Two 5’-terminal truncations of wild-type PCMV, denoted as 
PCMVt1 and PCMVt2, are also indicated. B, Lane 1, HEK293T cells were transformed with 
vector (V) alone (control). CHX-chases were performed at 37°C for the indicated times in 
HEK293T cells with the wild-type rat MLSrAANAT3f expressed either from the 
unmodified PCMV promoter (lanes 2-5), or from the PCMVt1 promoter (lanes 7-10), or from 
the PCMVt2 promoter (lanes 12-15). Lanes 6, 10, and 16, same as lanes 5, 9, and 15, except 
that the MG132 proteasome inhibitor was present during a 8-h CHX-chase, in each case 
(see Experimental Procedures and Results). The bands of tubulin and MLSrAANAT3f are 
indicated on the left. C, quantification of data in B. Symbols shown separately and 
framed in black squares correspond to altered levels of test proteins in the presence of 
MG132.
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Supplementary Table S1.  S. cerevisiae strains used in this study. 
Strains Relevant genotypes Sources 
BY4742 MAT± his3-1 leu2-0 lys2-0 ura3-0 can1-100 
Open 
Biosystems. 
BY15470 naa30”::kanMX6 in BY4742 
Open 
Biosystems 
BY10976 naa10”::KanMX6 in BY4742  
Open 
Biosystems 
BY17299 doa10”:KanMX6 in BY4742 
Open 
Biosystems 
CHY345 ubr1”::LEU2 in BY4742 
(Kim et al., 
2014) 
CHY346 ubr1”::LEU2 doa10”:KanMX6 in BY4742 This study 
BWY29 naa10”::kanMX6 ubr1”::LEU2 in BY4742 This study 
CHY349 naa30”::kanMX6 ubr1”::LEU2 in BY4742 (1) 
JOY487 naa30”::natNT2 in BY4742 This study 
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Supplementary Table S2.  Plasmids used in this study. 
Plasmid Description 
Source or 
Reference 
pcDNA3  Invitrogen 
pCISII-
rAANAT rAANAT in pCISII (2) 
pRS313Cup1 pRS313 containing the PCUP1 promoter 
Varshavsky Lab 
Collection 
pRS416Gal1 pRS416 containing the PGAL1 promoter 
Varshavsky Lab 
Collection 
pBW105 MLSrAANAT3f in pRS416 with PGal1 This study 
pBW106 (M)SIrAANAT3f in pRS416 with PGal1 This study 
pBW107 (M)SMLSrAANAT3f in pRS416 with PGal1 This study 
pBW135 MLSrAANAT3ha in pRS313 with PCup1 This study 
pBW173 pcDNA3(PCMVt1) This study 
pBW206 MLSrAANAT3f in pcDNA3(PCMVt1) This study 
pBW209 (M)PLSrAANAT3f in pRS416 with PGal1 This study 
pBW211 (M)SMLSrAANAT3f in pcDNA3(PCMVt1) This study 
pBW212 (M)SIrAANAT3f in pcDNA3(PCMVt1) This study 
pBW213 (M)PLSrAANAT3f in pcDNA3(PCMVt1) This study 
pBW394 MLSrAANAAT3haK8R in pRS416 with PGal1 This study 
pBW395 (M)SThAANAT3f in pRS416 with PGal1 This study 
pBW419 (M)PThAANAT3f in pRS416 with PGal1 This study 
pBW466 (M)SThAANAT3f in pcDNA3(PCMVt1) This study 
pBW467 (M)PThAANAT3f in pcDNA3(PCMVt1) This study 
pBW477 MLSrAANAT3ha in pcDNA3(PCMVt1) This study 
pBW478 MLSrAANAAT3haKzero in pcDNA3(PCMVt1) This study 
pBW481 (M)SThAANAT3f in pcDNA3(PCMVt1) This study 
pBW482 (M)SThAANAAT3haKzero in pcDNA3(PCMVt1) This study 
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Supplementary Table S3. PCR primers used in this study. 
Primer Sequence 
BW239 5'-CCTTGAATTCATACCCATGTTGAGCATCCA-3' 
BW240 5'-CCTTGAATTCATACCCATGAGCATCCA-3' 
BW241 5'-CCTTGAATTCATACCCATGAGCATGTTGAGCA-3' 
BW243 5'-CCTTTCCTTGTAGTCGGATCCACCGCAGCCACTGTT-3' 
BW244 5'-CCTTAAGCTTACTTGTCATCGTCGTCCTTGTAGTCGG-3' 
BW335 5'-TTGAATTCATGTTGAGCATCCACCCC-3' 
BW338 5'-GTATGGGTAGCAGCCACTGTTCC-3' 
BW339 5'-CAGTGGCTGCTACCCATACGATG-3' 
BW340 5'-TTCTCGAGTCAAGCGTAATCTGGAACGTC-3' 
BW352 5'-AATTGAATTCACCATGTTGAGCATCC-3' 
BW353 5'-AATTGAATTCACCATGAGCATCCACC-3' 
BW354 5'-AATTGAATTCACCATGAGCATGTTGA-3' 
BW355 5'-AATTCTCGAGTTACTTGTCATCGTCG-3' 
BW375 5'-TTAATCTAGATGCATGCTCGAGC-3' 
BW376 5'-CGTTAATCGCGACCAAAATCAACGGGACTTTC-3' 
BW412 5'-TTGAATTCATGCCCTTGAGCATCCACCCC-3' 
BW705 5'-TTGAATTCATACCCATGTCCACGCAGAGCACCCACCCCCTGAAACCTGA 
    GGCCCCACGTCTGCCACCTGGGATC-3' 
BW711 5'-CTTATAGTCACCAGAACCAGAGCAGCCGCTGTTCCTGCGCAGG-3' 
BW712 5'-CAGGAACAGCGGCTGCTCTGGTTCTGGTGACTATAAGGATG-3' 
BW771 5'-TTGAATTCATACCCATGCCAACGCAGAGCACCCACCCCCTGAAACCTG 
    AGGCCCCACGTCTGCCACCTGGGATC-3' 
BW784 5'-CTGAGTAAGTCTCTCTCTGTCCCAAAGTGAACC-3' 
BW785 5'-GGTTCACTTTGGGACAGAGAGAGACTTACTCAG-3' 
BW786 5'-CAGCAGGACGGAGCCTCTGCCCTGCTGCCGGAAG-3' 
BW787 5'-CTTCCGGCAGCAGGGCAGAGGCTCCGTCCTGCTG-3' 
BW788 5'-GGCCTGGAAACCAAATCTCTCATAGAAGGGCAC-3' 
BW789 5'-GTGCCCTTCTATGAGAGATTTGGTTTCCAGGCC-3' 
BW866 5'-TTGAATTCACCATGTCCACGCAGAGCACCCACCCCC-3' 
BW867 5'-TTGAATTCACCATGTCCACGCAGAGCACCCACCCCCTGAGACCTGA 
    GGC-3' 
BW868 5'-TTGAATTCACCATGCCAACGCAGAGCACCCACCCC-3' 
BW884 5'-TTAAGAATTCACCATGTCCACGCAGAGCACC-3' 
BW885 5'-GTCAGGAACATCGTATGGGTAGCAGCCGCTGTTCCTGCGCAGG-3' 
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MATERIALS AND METHODS 
Reagents and antibodies 
Cycloheximide, dithiobis(succinimidylpropionate) (DSP; Lomant’s reagent), 
MG132 and complete protease inhibitor cocktail tablet were from Sigma, Thermo 
Scientific, Calbiochem and Roche, respectively. Antibodies to the following antigens 
were used for immunoblotting and/or immunoprecipitation: anti-flag M2 (Sigma, F1804 
or Stratagen, 200471), anti-c-Myc-9E10 (Sigma, M5546), anti-hemaggutinin (ha) tag 
(Sigma, H9658 or H6958), anti-tubulin (Sigma, T5168), anti-Teb4 (Bethyl Laboratories, 
A304-171A), anti-ubiquitin (Stressgen, SPA-203), anti-Naa20 (Nat5) (Santa Cruz 
Biotechnology, sc-100645), anti-Naa60 (Nat15) (Abcam, ab103800), anti-phospho-
p44/42 Erk1/2 (Cell Signaling Technologies, Ab9101), anti-p44/42 Erk1/2 (Cell 
Signaling Technologies, Ab9102) and anti-Rgs2 (Abgent, AT3628a). Secondary 
antibodies for immunoblotting were HRP-conjugated goat anti-rabbit (Bio-Rad, 
170-6515) or anti-mouse (Bio-Rad, 170-6516), and either ECL Prime Western Blotting 
Detection System (GE Healthcare) or Clarity Western ECL substrate (Bio-Rad) were 
used, according to manufacturers’ protocols. The following reagents were used for 
immunoprecipitation and GST-pulldown assays: anti-flag M2 affinity gel (Sigma, 
A2220), Dynabeads Protein A and G (Life Technologies), and Glutathione Hicap 
(Qiagen). For determining the state of N±-terminal acetylation (Nt-acetylation) of Rgs2, 
human Rgs2 (purified from the HEK293 cell line) was purchased from Origene 
(TP302781) and analyzed using mass spectrometric (MS) techniques (see below). 
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Yeast strains, media, and genetic techniques 
The S. cerevisiae strains used in this study are described in Table S1. Standard 
techniques (27, 28) were employed for strain construction and transformation. S. 
cerevisiae media included YPD medium (1% yeast extract, 2% peptone, 2% glucose; 
only most relevant components are cited); SD medium (0.17% yeast nitrogen base, 0.5% 
ammonium sulfate, 2% glucose); and synthetic complete (SC) medium (0.17% yeast 
nitrogen base, 0.5% ammonium sulfate, 2% glucose), plus a drop-out mixture of 
compounds required by a given auxotrophic strain. The S. cerevisiae strain CHY367 
(naa20∆::natNT2) was constructed using PCR-mediated gene targeting (29) and the 
natNT2 module (30) in the strain JD53 (see Table S1). 
Cell culture, transfection and RNA interference 
Human HeLa cell line was grown in Dulbecco's Modified Eagle Medium 
(DMEM) (Ronza) supplemented with 10% fetal bovine serum (FBS) (HyClone) and 
penicillin (100 U/ml)/streptomycin (100 µg/ml) (HyClone) in a 5% CO2 incubator at 
37°C. Transfections with DNA plasmids or siRNA oligoribonucleotides were carried out 
using Lipofectamine-2000 (Life Technologies) according to the manufacturer’s 
instructions. For RNA interference (RNAi), HeLa cells were seeded on day 1 at 2 × 105 
cells per well in 6-well cell culture plates (SPL Life Sciences, Korea) containing DMEM 
and 10% FCS. After incubations for 24 hr, cells were transfected with 100 nM of either 
human Teb4 siRNA, or Naa20 siRNA, or Naa60 siRNA, or non-targeting (control) 
siRNA (Santa Cruz Biotechnology, sc-91789, sc-37007, sc-62662, and sc-93037, 
respectively), using Lipofectamin-2000 according to the manufacturer’s instructions. 
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DNA constructs and primers 
E. coli DH5± strain was used for cloning and maintaining plasmids (Table S1). 
Solg Pfu-X DNA polymerase (SolGent, Korea) was employed for PCR. The plasmids 
and PCR primers used in this study are described in Tables S2 and S3, respectively. To 
express human MX-Rgs2 (X=Gln, Leu, Arg) in mammalian cells, we used the pCH766, 
pCH767 and pCH768 plasmids, which expressed, respectively, MQ-Rgs2ha, ML-Rgs2ha 
and MR-Rgs2ha from the PCMV promoter and were a gift from Dr. R. Neubig (Univ. of 
Michigan Medical School, East Lansing, MI) (11). To construct pCH821, which 
expressed PQ-Rgs2ha (MPQ-Rgs2ha), the MPQ-RGS2ha-encoding DNA fragment was 
produced by PCR from the plasmid pCH766 (Table S2) using the primer pair 
OCH1091/OCH1100. This fragment was digested with KpnI/XhoI and ligated into 
KpnI/XhoI-cut pCH766.  
To construct the low copy (CEN-based) pCH5050 and pCH5051 plasmids, which 
expressed MQ-Rgs2ha and ML-Rgs2ha in S. cerevisiae from the PCUP1 promoter, the 
relevant Rgs2 DNA fragments were amplified from pCH766 using the primer pairs 
OCH5070/OCH5073 and OCH5071/OCH5073, respectively. The resulting PCR products 
were digested with BamHI/SacI and ligated into BamHI/SacI-cut pCH692, a pRS316-
based low copy plasmid containing the PCUP1 promoter.  
To construct pCH879 and pCH881, which expressed, from the PCMV promoter in 
mammalian cells, the wild-type human Teb4 and its catalytically-inactive mutant Teb4C9A 
(both of them were C-terminally tagged with triple flag plus His6), a DNA sequence 
encoding the above “double” epitope was produced by annealing the complementary 
primers OCH1265/OCH1266 (Table S3). The resulting DNA, encoding triple flag plus 
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His6, was digested with HindIII/AflII and ligated into HindIII/AflII-cut pCH759 and 
pCH760, which encoded, respectively Teb4 and Teb4C9A in the pcDNA3.1-myc-His(-) A 
vector (24). The plasmid pCH3056, which encoded full-length MQ-Rgs2 whose C-
terminus was fused to GST, was constructed by producing, at first, a DNA fragment from 
pCH766 (Table S2), using PCR and the primer pair OCH3006/OCH3013. This fragment 
was digested with NdeI/BamHI. Furthermore, a DNA fragment was produced by PCR 
from pGEX4T-3 and the primer pair OCH3015/OCH1514, followed by digestion of the 
resulting fragment with BamHI/XhoI. The above two fragments were ligated into 
NdeI/XhoI-cut pET30a, yielding the plasmid pCH3056. 
To construct the plasmid pCH3080, which expressed, from the IPTG-inducible 
T7lac promoter in E. coli, a fusion between the N-terminal 10 residues of MQ-Rgs2 and 
the GST moiety, a DNA fragment was produced by PCR using pCH3056 (Table S2) and 
the primer pair OCH3095/OCH1514 (Table S3). The resulting fragment was digested 
with NdeI/XhoI and ligated into NdeI/XhoI-cut pET30a (Table S2).  
To construct pCH3132 that expressed the human muscarinic acetylcholine 
receptor M3 from the PCMV promoter, DNA sequence encoding M3 was PCR-amplified 
from a human HEK293T cDNA library using primer pairs OCH3178/OCH3179. The 
resulting PCR fragment was digested with BamHI/XbaI and ligated into BamHI/XbaI-cut 
pCH61. To clone pCH5064 that expressed the human guanidine-nucleotide binding 
protein G(q) subunit alpha (G±q) from the PCMV promoter, DNA sequence encoding G±q 
was also PCR-amplified from HEK293T cDNA library using primer pairs 
OCH5090/OCH5091. The resulting DNA fragment was digested with KpnI/XhoI and 
ligated into KpnI/XhoI-cut pCH61, yielding pCH5064. Construction details for other 
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plasmids are available upon request. All final constructs were verified by DNA 
sequencing. 
Cycloheximide-chase assays and immunoblotting 
For immunoblotting, HeLa cells were lysed by incubating them on ice for 20 min 
in the TLB lysis buffer (1% Triton X100, 50 mM NaCl, 2 mM Na-EDTA, 50 mM Tris-
HCl, pH 7.4), containing complete protease inhibitor mixture (Roche). After precipitating 
cell debris by centrifugation at 11,200g for 10 min at 4°C, total protein concentrations in 
the supernatants were determined using Bradford or DC protein assay (Bio-Rad). 
Identical total amounts of protein in each sample were heated at 95°C for 10 min or at 
37°C for 15 min (the samples for immunoblotting of Teb4 were incubated, instead, at 
37°C for 20 min) in 1x SDS-sample buffer, followed by Tris-glycine-SDS-10% PAGE or 
Tris-glycine-4-20% PAGE. For immunoblotting analyses of Teb4, protein samples were 
fractionated by Tris-glycine-SDS-6% PAGE or by Tris-glycine-SDS-8% PAGE. 
Fractionated proteins were electroblotted to Immobilon-P membranes (Millipore) using 
mini-transblot cell (Bio-Rad), and were analyzed by immunoblotting with indicated 
antibodies, followed by secondary antibodies described in the first section above. 
Immunoblots were detected using Clarity Western ECL substrate (Bio-Rad) or ECL Plus 
Western blotting Detection System (GE Healthcare). 
Cychloheximide (CHX)-chase assays with HeLa cells were set up on day 1 at 2 × 
105 cells/well in 6- or 12-well cell culture plates (SPL Life Sciences, Korea) containing 
DMEM and 10% FCS. After 24-hr incubation at 37°C, the cells were treated with CHX 
at the final concentration of 0.1 mg/ml, harvested by centrifugation at each time point, 
and lysed in RIPA buffer (0.1% NP40, 0.15 M NaCl, 5•mM Na-EDTA, 1•mM 
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dithiothreitol (DTT), 50•mM HEPES, pH 7.5, plus the “complete protease inhibitor 
cocktail” (Roche)). Equal amounts of total protein were fractionated by Tris-glycine 
SDS-4-20 % PAGE, followed by immunoblotting with indicated antibodies. In particular, 
immunoblotting with antibody to α-tubulin was used as a loading control for all 
immunoblotting experiments.  
CHX-chases with S. cerevisiae cells were performed as previously described (13, 
15), with slight modifications. S. cerevisiae were grown to A600 of 0.8-1.0 at 30°C in 
selective media appropriate for a plasmid(s) carried by a strain. Cells were harvested by 
centrifugation at 11,200g for 1 min and thereafter resuspended in fresh YPD to a final 
concentration of A600 of 1.0, followed by the treatment with CHX at the final 
concentration of 0.2 mg/ml. At indicated times, cell samples (corresponding to 1 ml of 
cell suspension at A600 of 1) were harvested by centrifugation for 1 min at 11,200g, and 
were resuspended in 0.8 ml of 0.2 M NaOH and incubated for 20 min on ice, followed by 
centrifugation for 1 min at 11,200g. Pelleted cells were resuspended in 80 µl of HU 
buffer (8 M urea, 5% SDS, 1 mM Na-EDTA, 0.1 M DTT, 0.005% bromophenol blue, 0.2 
M Tris-HCl, pH 6.8) containing 1x protease inhibitor cocktail “for use with fungal and 
yeast extracts” (Sigma), and heated for 10 min at 70°C. After centrifugation for 5 min at 
11,200g, 10 µl of supernatant was subjected to SDS-10% PAGE, followed by 
immunoblotting with anti-ha (1:2,000) and anti-tubulin (1:2,000) antibodies. 
Quantification of immunoblotting data was carried out using GelQuantNET 
(http://biochemlabsolutions.com/GelQuantNET.html). 
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Cycloheximide-chase assays with co-expressed Rgs2ha and G±qha2 
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of a chase by rapid scraping into 0.1 ml of TSD buffer (1% SDS, 5mM DTT, 50 mM 
Tris-HCl, pH7.4) and snap-freezing in liquid nitrogen. Samples were then heated at 95°C 
for 10 min and diluted with 10 volumes of TNN buffer (0.5% NP40, 0.25M Na Cl, 5 mM 
Na-EDTA, 50 mM Tris-HCl, pH 7.4) containing the “complete protease-inhibitor 
mixture” (Roche). The amounts of 35S in the 10% CCl3COOH-insoluble fraction of each 
sample were then measured by liquid scintillation counting. For immunoprecipitation, the 
samples were adjusted to contain equal amounts of total 35S and then added to 20 µl of 
anti-ha agarose (Sigma). Suspensions of beads were incubated by rocking at 4°C for 2 hr, 
washed 3 times in TNN buffer, and once in 10 mM Tris-HCl, pH 8.5. Final samples were 
eluted by 30 µl of SDS-PAGE sample buffer, including the heating at 95°C for 5 min, 
followed by clarification through centrifugation at 11,200g for 1 min. 10 µl of each of the 
resulting samples were separated by SDS-4-20% PAGE (Bio-Rad, followed by 
autoradiography using Typhoon 9400 PhosphorImager (GE Healthcare) and 
quantification of autoradiograms with ImageQuant (GE Healthcare). 
RNA isolation and quantitative RT-qPCR 
Total RNA was isolated from HeLa cells using an RNeasy Mini kit (Qiagen), 
according to the manufacturer’s instructions. 2 µg of total RNA was reverse-transcribed 
into cDNA with oligo-dT as a primer by using Promega cDNA reverse transcription kit. 
Quantitative real-time PCR was performed in 20-µl reactions containing 10 ng of the 
cDNA sample, 50 nM forward and reverse primers, and the SYBR Green Master Mix 
(Applied Biosystems). Primers for human Rgs2 and ² -actin genes were designed using 
GenScript Real-time PCR Primer Design tool. Reaction mixtures were incubated at 95°C 
for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. No template 
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control sample was included, to enable detection of RNA and/or DNA contamination. 
Quantification of relative Rgs2 mRNA expression levels was carried out using the 
threshold-cycle difference method (ref. (31) and Applied Biosystems StepOne and 
StepOnePlus Real-Time PCR Systems Getting Started Guide for Relative Standard Curve 
and Comparative CT experiments), with ² -actin as a normalization control. The Rgs2 and 
β-actin gene primer pairs for RT-qPCR were OCH5082/OCH5083 and 
OCH5084/OCH5085, respectively (Table S3). 
In vivo ubiquitylation assay 
HeLa cells were transfected with pcDNA3.1 (control vector), or CH776 (a 
pcDNA3.1-based plasmid expressing MQ-Rgs2ha), or pCH879 (expressing Teb43f) or 
pCH881 (expressing Teb43fC9A) (Table S2). After 24 hr, transfected cells were treated with 
10•µM MG132 for 4•hr and thereafter lysed with RIPA buffer. Supernatants were 
immunoprecipitated with a monoclonal anti-ha antibody (Sigma), and were washed three 
times in RIPA buffer. Immunoprecipitates were fractionated by SDS-8% PAGE, 
followed by immunoblotting with anti-ubiquitin and/or rabbit polyclonal anti-ha 
antibodies. 
UQDl0
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plus “complete protease inhibitor cocktail” (Roche)) and incubating on ice for 20 min. 
The extracts were centrifuged at 11,200g for 20 min at 4°C and total protein 
concentrations in the supernatants were determined using Bradford assay (Bio-Rad). 
Samples containing 1 mg of total protein were incubated with anti-ha or anti-flag bound 
IgG Dynabeads (Life Technologies) at 4°C for 16 hr and the magnetic beads were 
washed 3 times in buffer A. Captured proteins were eluted in 15 µl of 0.1 M glycine-HCl 
(pH 2.8), followed by incubation in SDS-sample buffer containing 50 mM DTT for 30 
min at 37°C, SDS-10% PAGE and immunoblotting with anti-ha or anti-flag as described 
above. 
Purification of MQ-Rgs23-10-[GST] and GST-pulldown assays 
To produce and purify the conditionally N±-terminally acetylated (Nt-acetylated) 
MQ-Rgs23-10-[GST] fusion, we employed an E.coli-based expression system. “Wild-
type” E. coli very rarely Nt-acetylates heterologous eukaryotic proteins. In the resulting 
novel system, MQ-Rgs23-10-[GST] was expressed in E. coli either by itself or together 
with the cognate (Nt-acetylating the Met-Gln N-terminal sequence) NatB Nt-acetylase 
complex from the fission yeast Schizosaccharomyces pombe (32). The plasmid pCH3080, 
expressing MQ-Rgs23-10-[GST], was transformed into E. coli BL21(DE3) that carried 
either a vector plasmid (pACYCDuet (pCH15)) or pCH3025 (32), which expressed the 
Naa20 and Naa25 subunits of the S. pombe NatB Nt-acetylase in E. coli. 
Overnight cultures (5 ml) of transformed E. coli were inoculated into LB medium 
(500 ml) containing chloramphenicol (34 µg/ml) and kanamycin (50 µg/ml), followed by 
growth at 37°C to A600 of ~0.7. Expression of MQ-Rgs23-10-[GST] was then induced with 
1 mM isopropyl β-D-thiogalactoside (IPTG) at 30°C for 4 hr. Cells were harvested by 
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centrifugation and frozen at -80°C. Cell pellets were thawed and resuspended in STE 
buffer (0.1 M NaCl, 1 mM Na-EDTA, 10 mM Tris-HCl, pH 8.0) containing 1 mM DTT, 
1mM phenylmethylsulfonyl fluoride (PMSF) and 1 mg/ml of chicken egg white 
lysozyme (Sigma). Cell suspensions were incubated on ice for 20 min and thereafter 
treated by sonication for 1 min 3 times, at 1-min intervals, followed by the addition of 
Triton X100 to the final concentration of 1%. After centrifugation at 11,200g for 20 min 
at 4°C, the supernatants (~25 ml) were incubated with 1 ml of Glutathione Hicap agarose 
(50% slurry; Qiagen) at 4°C for 2 hr. The beads were washed twice in 25 ml of the STE 
buffer. Carrier-bound GST or MQ-Rgs23-10-[GST] were eluted with 1 ml of STE buffer 
containing 10 mM glutathione (GSH), followed by overnight dialysis against storage 
buffer (10% glycerol, 0.15 M NaCl, 10 mM β-mercaptoethanol, 50 mM HEPES, pH 7.5). 
The state of Nt-acetylation of the resulting MQ-Rgs23-10-[GST] fusion proteins was 
determined by MALD-TOF mass spectrometry. 
For GST-pulldown assays, 50 µg of either GST, or MQ-Rgs23-10-[GST] 
(expressed in E. coli without S. pombe NatB), or (presumably) Nt-acetylated MQ-Rgs23-
10-[GST] (coexpressed in E. coli with S. pombe NatB) were incubated with 50 µl of the 
Glutathione Hicap agarose beads in GST-loading buffer (10% glycerol, 0.5 M NaCl, 1% 
NP40, 1 mM Na-EDTA, 50 mM Tris-HCl, pH 8.0) at 4°C for 1 hr. The beads were 
washed once with 0.5 ml of the loading buffer and once with 0.5 ml GST-binding buffer 
(10% glycerol, 0.05% NP40, 50 mM NaCl, 50 mM Na-HEPES, pH 7.8). The beads in 0.2 
ml-GST binding buffer were thereafter incubated at 4°C for 2 hr with 0.25 ml extracts 
from HeLa cell (2 mg of total protein) that expressed C-terminally triple flag-tagged (plus 
His6-tagged) Teb4. The beads were washed 3 times in 0.5 ml of GST-binding buffer, 
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followed by elution of bound proteins by the addition of 15 µl of 2xSDS-sample buffer 
and incubation for 30 min at 37°C. The resulting samples were fractionated by SDS-8% 
PAGE and analyzed by immunoblotting with anti-flag antibody. The blotting membrane 
was also stained with Coomassie Brilliant Blue to verify the approximate equality of total 
protein loads vis-à-vis GST, MQ-Rgs23-10-[GST] and Ac-MQ-Rgs23-10-[GST]. 
Analysis of endogenous MQ-Rgs2 from human cells by mass spectrometry 
Purified human Rgs2 (~ 0.4 µg; see the first section of Materials and Methods) 
was treated with 8 M Urea in 25 mM NH4HCO3 (pH 8.0) and thereafter reduced with 9.5 
mM DTT in 25 mM NH4HCO3 (pH 8.0) at 25°C for 1 hr. Rgs2 was then alkylated with 
iodoacetamide (32 mM) in NH4HCO3 (pH 8.0) at 25°C for 1 hr in the dark, followed by 
quenching of excess unreacted iodoacetamide with DTT (40 mM) at 25°C for 10 min. 
The sample was diluted 10-fold with 25 mM NH4HCO3 (pH 8.0), and 1 ml of the 
resulting sample was digested with of trypsin (1.2 µg/ml) overnight at 37°C. Nt-
acetylated peptides in the digested sample were analyzed by nanoflow liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) using the LTQ Orbitrap Velos 
(Thermo Scientific) hybrid mass spectrometer. Nt-acetylation sites were assigned by 
manual inspection of MS/MS spectra and also using MaxQuant software (33). 
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Fig. A2.S1. Conditional removal of N-terminal methionine from nascent proteins, 
their N-terminal acetylation, and the N-end rule pathway. 
(A) N-terminal processing of nascent proteins by N±-terminal acetylases (Nt-
acetylases) and Met-aminopeptidases (MetAPs). “Ac” denotes the N±-terminal acetyl 
moiety. M, methionine (Met) residue. X and Z, single-letter abbreviations for any amino 
acid residue. Yellow ovals denote the rest of a protein molecule. MetAPs 
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cotranslationally remove N-terminal Met from a nascent protein unless the side chain of a 
residue at position 2 is bulkier than Val, in which case Met is retained (12, 34). 
(B) Functional complementarity between the Arg/N-end rule pathway and the 
Ac/N-end rule pathway for proteins bearing the N-terminal M$  motif, i.e., unacetylated 
N-terminal Met followed by a bulky hydrophobic ($ ) residue. This motif is targeted by 
the Arg/N-end rule pathway (16). Because the Met-$  motif is also a substrate of the 
NatC Nt-acetylase (Fig. A3.S2), Met-$  proteins are usually Nt-acetylated at least in part, 
thereby acquiring the previously characterized Ac/N-degrons (13, 16). Thus, both Nt-
acetylated and unacetylated versions of the same Met-$  protein can be destroyed, either 
by the Ac/N-end rule pathway or by the “complementary” Arg/N-end rule pathway (16). 
(C, D) The mammalian N-end rule pathway. The main determinant of an N-
degron is a destabilizing N-terminal residue of a protein. Recognition components of the 
N-end rule pathway, called N-recognins, are E3 ubiquitin ligases that can recognize N-
degrons. 
Regulated degradation of proteins or their fragments by the N-end rule pathway 
mediates a strikingly broad range of functions, including the sensing of heme, nitric 
oxide, oxygen, and short peptides; control of protein quality and subunit stoichiometries, 
including the elimination of misfolded proteins; regulation of signaling by G proteins; 
repression of neurodegeneration; regulation of apoptosis, chromosome 
cohesion/segregation, transcription, and DNA repair; control of peptide import; 
regulation of meiosis, autophagy, immunity, fat metabolism, cell migration, actin 
filaments, cardiovascular development, spermatogenesis, and neurogenesis; the 
functioning of adult organs, including the brain, muscle and pancreas; and the regulation 
of many processes in plants (references (12-14, 16, 18, 20, 35-88) and references therein). 
In eukaryotes, the N-end rule pathway consists of two branches, the Ac/N-end rule 
pathway and the Arg/N-end rule pathway. 
(C) The Ac/N-end rule pathway. This diagram illustrates the mammalian Ac/N-
end rule pathway through extrapolation from its S. cerevisiae version. As described in the 
main text, the Ac/N-end rule pathway has been identified only in S. cerevisiae (13, 15, 
16), i.e., the presence of this pathway in mammals and other multicellular eukaryotes was 
conjectural, until the present work. Red arrow on the left indicates the removal of N-
terminal Met by Met-aminopeptidases (MetAPs). N-terminal Met is retained if a residue 
at position 2 is nonpermissive (too large) for MetAPs. If the retained N-terminal Met or 
N-terminal Ala, Ser, Thr are followed by acetylation-permissive residues, the above N-
terminal residues are N±-terminally acetylated (Nt-acetylated) by ribosome-associated Nt-
acetylases (21, 89, 90). Nt-terminal Val and Cys are Nt-acetylated relatively rarely, while 
N-terminal Pro and Gly are almost never Nt-acetylated. (N-terminal Gly is often N-
myristoylated.) N-degrons and N-recognins of the Ac/N-end rule pathway are called 
Ac/N-degrons and Ac/N-recognins, respectively (12). The term “secondary” refers to 
Nt-acetylation of a destabilizing N-terminal residue before a protein can be recognized by 
a cognate Ac/N-recognin. As described in the main text, the human Teb4 E3 ubiquitin 
ligase was identified, in the present study, as an Ac/N-recognin of the mammalian Ac/N-
end rule pathway. Natural Ac/N-degrons are regulated at least in part by their reversible 
steric shielding in protein complexes (15, 16). 
(D) The Arg/N-end rule pathway. The prefix “Arg” in the pathway’s name refers 
to N-terminal arginylation (Nt-arginylation) of N-end rule substrates by the Ate1 
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arginyltransferase (R-transferase), a significant feature of this proteolytic system. The 
Arg/N-end rule pathway targets specific unacetylated N-terminal residues. In the yeast S. 
cerevisiae, the Arg/N-end rule pathway is mediated by the Ubr1 N-recognin, a 225 kDa 
RING-type E3 ubiquitin ligase and a part of the targeting apparatus comprising a 
complex of the Ubr1-Rad6 and Ufd4-Ubc4/5 holoenzymes (12, 14, 18). In multicellular 
eukaryotes several functionally overlapping E3 ubiquitin ligases (Ubr1, Ubr2, Ubr4, 
Ubr5) function as N-recognins of this pathway. An N-recognin binds to the “primary” 
destabilizing N-terminal residues Arg, Lys, His, Leu, Phe, Tyr, Trp and Ile. In contrast, 
the N-terminal Asn, Gln, Asp, and Glu residues (as well as Cys, under some metabolic 
conditions) are destabilizing owing to their preliminary enzymatic modifications. These 
modifications include the Nt-deamidation of N-terminal Asn and Gln by the Ntan1 and 
Ntaq1 Nt-amidases, respectively, and the Nt-arginylation of N-terminal Asp and Glu by 
the Ate1 R-transferase, which can also Nt-arginylate oxidized Cys, either Cys-sulfinate or 
Cys-sulfonate. They can form in animal and plant cells through oxidation of Cys by nitric 
oxide (NO) and oxygen, and also by N-terminal Cys-oxidases (19, 44, 52, 59, 61, 91-93). 
In addition to its type-1 and type-2 binding sites that recognize, respectively, the basic 
and bulky hydrophobic unacetylated N-terminal residues, an N-recognin such as Ubr1 
contains other substrate-binding sites as well. These sites recognize substrates that are 
targeted through their internal (non-N-terminal) degrons, as indicated on the diagram 
(12). Hemin (Fe3+-heme) binds to the Ate1 R-transferase, inhibits its Nt-arginylation 
activity and accelerates its in vivo degradation. Hemin also binds to Ubr1 (and apparently 
to other N-recognins as well) and alters its functional properties, in ways that remain to 
be understood (43). As shown in the diagram, the unacetylated Met of the N-terminal 
M$  motif is recognized by both yeast and mammalian Ubr1; this capability greatly 
expands the substrate range of the Arg/N-end rule pathway (16).  
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Fig. A2.S2. Specificities and subunit compositions of N±-terminal acetylases 
(Nt-acetylases). 
(A) Substrate specificities of S. cerevisiae Nt-acetylases. “Ac” denotes the N±-
terminal acetyl moiety. The bulk of Nt-acetylases are associated with ribosomes (94, 95). 
The specificities of mammalian Nt-acetylases are similar to those of their yeast 
counterparts, but an individual mammalian genome encodes more than ten Nt-acetylases, 
in contrast to four in S. cerevisiae. Some mammalian Nt-acetylases, such as NatF (its 
catalytic subunit is called Naa60 (see fig. A3.S4H, I)) (22), can Nt-acetylate N-terminal 
motifs that include Met-Lys or Met-Arg, which are rarely if ever Nt-acetylated in S. 
cerevisiae. This compilation of Nt-acetylases and their specificities is derived from data 
in the literature ((21, 89, 90, 96-108) and references therein). 
(B) Subunits of S. cerevisiae Nt-acetylases. This paper employs the revised 
nomenclature for subunits of Nt-acetylases (109) and cites older names of these subunits 
in parentheses. 
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Fig. A2.S3. The targeting of MX-Rgs2 proteins by the yeast and human Ac/N-end 
rule and Arg/N-end rule pathways. 
(A) CHX chases with the hypertension-associated mutant human ML-Rgs2ha in 
wild-type, naa30”, ubr1”, and naa30” ubr1” S. cerevisiae.  
(B) As in A but in human HeLa cells with wild-type human MQ-Rgs2ha and 
hypertension-associated mutants MR-Rgs2ha and ML-Rgs2ha. 
(C) HeLa cells expressing MQ-Rgs2ha or PQ-Rgs2ha together with Teb43f were 
treated with a cell-penetrating crosslinker, followed by immunoprecipitations with 
anti-flag, reversal of crosslinks, SDS-PAGE, and immunoblotting with anti-ha and anti-
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flag (see also Fig. 2H and Materials and Methods). Note the coimmunoprecipitation of 
MQ-Rgs2ha with Teb43f, and the absence of coimmunoprecipitation of PQ-Rgs2ha. 
(D) Quantification of data in A. 100% corresponded to the zero-time level of 
ML-Rgs2ha in naa30” ubr1” S. cerevisiae. 
(E) Quantification of data in B. 100% corresponded to the zero time level of 
PQ-Rgs2ha in HeLa cells.  
In every set of degradation curves shown in this figure and in the main Figs. 1 and 
3, 100% at zero time was chosen to correspond to the relative initial level of the most 
slowly degraded test protein in a given set. Panel A (quantified in D) and panel B 
(quantified in E) show the results of CHX-chases that were independently carried out 
counterparts of CHX-chases that are shown in the main Fig. 1B (quantified in D) and 1F 
(quantified in E), respectively. These comparisons illustrate qualitative reproducibility of 
independently generated data (particularly the robustly reproduced order of metabolic 
stabilities of specific test proteins in specific genetic backgrounds), which differed in 
relatively minor aspects of corresponding degradation curves. In our extensive experience 
with repeated CHX-chases and 35S-pulse-chases in either S. cerevisiae or HeLa cells, a 
strictly quantitative reproducibility of independently produced and measured chase-
degradation patterns remains the aim to be reached. 
(F) Extracts from HeLa cells expressing MQ-Rgs2ha in the presence or absence of 
coexpressed Teb43f or Teb43fC9A and in the presence of the MG132 proteasome inhibitor, 
as indicated. MQ-Rgs2ha was immunoprecipitated from extracts using anti-ha antibody, 
followed by SDS-PAGE and immunoblotting with anti-ubiquitin antibody to detect 
polyubiquitin chains linked to MQ-Rgs2, and with anti-flag, anti-ha and anti-tubulin 
antibodies as well, as shown. 
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Fig. A2.S4. Degradation assays with MX-Rgs2 proteins in HeLa cells subjected to 
RNAi of specific Nt-acetylases and Teb4. 
(A) CHX-chases with endogenous (not overexpressed) MQ-Rgs2 in HeLa cells 
subjected to RNAi-mediated knockdowns of endogenous Teb4 or Naa20 (NatB). 
(B) Same as in A but CHX-chases with transiently expressed (exogenous) MQ-
Rgs2ha. 
(C) Relative steady-state levels of exogenous wild-type MQ-Rgs2ha and its 
MR-Rgs2ha and ML-Rgs2ha mutants in HeLa cells transfected with equal amounts of 
MX-Rgs2ha plasmids. 
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(D) ML-Rgs2ha expressed in HeLa cells in the presence of the coexpressed wild-
type Teb43f or Teb43fC9A. Note a strong decrease of ML-Rgs2ha in the presence of wild-
type Teb43f but not in the presence of its inactive missense mutant Teb43fC9A. Note also a 
much lower steady-state level of active Teb43f (in comparison to the inactive Teb43fC9A), 
owing to the previously described self-targeting of active Teb4 for degradation (24). 
(E) Same as in D but with MR-Rgs2ha. 
(F) Quantification of data in C (relative levels of the three MX-Rgs2ha proteins). 
(G) Same as in F but quantification, using qRT-PCR, of the relative levels of 
mRNAs encoding the three MX-Rgs2ha proteins. Standard errors of means (SEMs), with 
qRT-PCR assays in triplicate for each sample, are indicated as well. 
(H) Steady-state levels of transiently expressed (exogenous) MR-Rgs2ha in HeLa 
cells subjected to RNAi-mediated knockdowns of either endogenous Naa60, the cognate 
(for MR-Rgs2ha) NatF Nt-acetylase, or endogenous Naa20, the non-cognate (for MR-
Rgs2ha) NatB Nt-acetylase. Note the increase in MR-Rgs2ha in response to RNAi of 
Naa60 but not of Naa20. 
(I) Same as in H but with MK-Rgs2ha, a derivative of wild-type MQ-Rgs2ha not 
encountered, thus far, among human patients, that contained another basic residue at 
position 2.  
(J) 35S-pulse-chases with MX-Rgs2ha (X=R, Q, L) in HeLa cells.  
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Fig. A2.S5. Mass spectrometric analyses of Nt-acetylation of MQ-Rgs2 and 
MQ-Rgs21-10-[GST].  
(A) Wild-type MQ-Rgs2ha purified from human HEK293 cells is Nt-acetylated. 
(B) Non-Nt-acetylated (upper panel) and Nt-acetylated MQ-Rgs21-10-[GST] fusion 
(lower panel) purified from E. coli that either lacked or expressed, respectively, the 
Schizosaccharomyces pombe NatB Nt-acetylase (see Materials and Methods). 
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Fig. A2.S6. Rgs2, Teb4, N-terminal acetylation, and the N-end rule pathway. Rgs2 and 
Teb4 are, respectively, a substrate and Ac/N-recognin of the mammalian Ac/N-end 
pathway. Only some Rgs2-regulated processes (including the G±q-mediated activation of 
Erk1/2 kinase) are shown. Both wild-type MQ-Rgs2 and its hypertension-associated 
mutant MR-Rgs2 (the latter is not shown) are Nt-acetylated and conditionally destroyed 
by the Teb4-mediated Ac/N-end rule pathway. In contrast, another hypertension-associated 
mutant, ML-Rgs2, is targeted by both the Ac/N-end rule pathway and the Arg/N-end rule 
pathway (see the main text) (fig. A3.S1C, D). Some abbreviations: IP3, inositol 
trisphosphate. DAG, diacyglycerol. 
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Fig. A2.S7. Mammalian RGS proteins as identified or predicted N-end rule 
substrates. Human RGS proteins as identified or possible (predicted) substrates of either 
the Ac/N-end rule pathway, or the Arg/N-end rule pathway, or both pathways at the same 
time, depending on the Nt-acetylation status of a specific RGS protein. See also the main 
text. 
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Table S1.  S. cerevisiae strains used in this study. 
Strains Relevant genotypes Sources 
JD53 MATα trp1- 63 ura3-52 his3- 200 leu2-3112. lys2-801 (110) 
BY4742 MATα his3-1 leu2-0 lys2-0 ura3-0 can1-100 Open Biosystems, Inc. 
CHY223 doa10∆::kanMX6 in JD53 (13) 
CHY272 naa30∆::kanMX4 in BY4742 Open Biosystems, Inc. 
CHY345 ubr1∆::LEU2 in BY4742 (16) 
CHY349 naa30∆::kanMX4 ubr1∆::LEU2 in BY4742 (16) 
CHY367 naa20∆::natNT2 in JD53 This study 
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Table S2. Plasmids used in this study. 
Plasmids Descriptions Sources 
pCH12 pET30a Novagen, Inc. 
pCH15 pACYCDuet Novagen, Inc. 
pCH61 pcDNA3.1(+) with ha2 Hwang’s lab collection 
pCH692 p316CUP1 Hwang’s lab collection 
pCH759 Teb4 in pcDNA3.1 myc/His (-) (24) 
pCH760 Teb4C9A in pcDNA3.1 myc/His(-) (24) 
pCH766 MQ-Rgs2ha in pcDNA3(+) (11) 
pCH767 ML-Rgs2ha in pcDNA3(+) (11) 
pCH768 MR-Rgs2ha in pcDNA3(+) (11) 
pCH821 MPQ-Rgs2ha in pcDNA3(+) This study 
pCH879 Teb4f3h in pcDNA3.1 This study 
pCH881 Teb4C9Af3h in pcDNA3.1 This study 
pCH3002 MQ-Rgs2-GST in pACYCDuet This study 
pCH3015 pET30a Qiagen, Inc. 
pCH3025 S. pombe Naa20+-NAA25+ in pACYCDuet (32) 
pCH3056 MQ-Rgs2-GST in pET30a This study 
pCH3080 MQ-Rgs21-10-GST in pET30a This study 
pCH3132 M3ha2 in pcDNA3.1(+) This study 
pCH5050 MQ-Rgs2ha in pRS316, with PCUP1 This study 
pCH5051 ML-Rgs2ha in pRS316, with PCUP1 This study 
pCH5064 G±qha2 in pcDNA3.1(+) This study 
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Table S3. Some PCR primers used in this study. 
Name Primer sequences 
OCH1091 5’-CTTGGTACCATG CCA CAAAGTGCTATGTTCTTGGCTGTT-3’ 
OCH1100 
5’-
AACCTCGAGCTAAGCGTAATCTGGAACATCGTATGGGTAAGAACC
TGTAGCATGAGGCTCTGTGGTGAT-3’ 
OCH1265 
5’-
GGTAAGCTTGACTATAAAGACCATGACGGTGATTATAAAGATCAT
GATATCGATTACAAG-3’ 
OCH1266 
5’-
AATCTTAAGTTAATGATGGTGATGGTGATGAGAACCCTTGTCATC
GTCATCCTTGTAATC-3’ 
OCH1514 5'-TATCTCGAGTCATTTTGGAGGATGGTCGCCACCACC -3' 
OCH3006 5’-TCCCATATGCAAAGTGCTATGTTCTTGGCTGTT-3’ 
OCH3013 5’-CGCGGATCCTGTAGCATGAGGCTCTGTGGTGAT-3’ 
OCH3015 5’-CGCGGATCCATGTCCCCTATACTAGGTTATTGG-3’ 
OCH3095 
5'-
TCCCATATGCAAAGTGCTATGTTCTTGGCTGTTCAATCCCCTATAC
TAGGTTATTGG-3' 
OCH3178 5’-ACAGGATCCATGACCTTGCACAATAACAGTAC-3’ 
OCH3179 5’-ACATCTAGACAAGGCCTGCTCGGGTGCGCGCTTG-3’ 
OCH5070 5’-CCCGGATCCATGCAAAGTGCTATGTTCTTGGCT-3’ 
OCH5071 5’-CCCGGATCCATGTTAAGTGCTATGTTCTTGGCTGTTCAA-3’ 
OCH5073 
5’-
CCCGAGCTCCTAAGCGTAATCTGGAACATCGTATGGGTAGCTAGC
TGTAGCATGAGG CTCTGTGGTGAT-3’ 
OCH5090 5’-GTCGGTACCATGACTCTGGAGTCCATCATGGCG-3’ 
OCH5091 5’-GCTCTCGAGGACCAGATTGTACTCCTTCAGGTT-3’ 
 
  
263 
 
REFERENCES 
1. R. J. Lefkowitz, A brief history of G-protein coupled receptors. Angew. Chem. 
52, 6366-6378 (2013). 
2. B. Kobilka, The structural basis of G-protein-coupled receptor signaling. Angew. 
Chem. 52, 6380-6388 (2013). 
3. B. Sjögren, L. L. Blazer, R. R. Neubig, Regulators of G protein signaling proteins 
as targets for drug discovery. Prog. Mol. Biol. Transl. Sci. 91, 81-119 (2010). 
4. A. J. Kimple, D. E. Bosch, P. M. Giguère, D. P. Siderovski, Regulators of G-
protein signaling and their G± substrates: promises and challenges in their use as 
drug discovery targets. Pharmacol. Rev. 63, 728-749 (2011). 
5. P. Chidiac, A. J. Sobiesiak, K. N. Lee, R. Gros, C. H. Nguyen, The eIF2B-
interacting domain of RGS2 protects against GPCR agonist-induced hypertrophy 
in neonatal rat cardiomyocytes. Cell Signal. 26, 1226-1234 (2014). 
6. M. Matsuo, S. L. Coon, D. C. Klein, RGS2 is a feedback inhibitor of melatonin 
production in the pineal gland. FEBS Lett. 587, 1392-1398 (2013). 
7. M. R. Nance et al., Structural and functional analysis of the regulator of G protein 
signaling 2-(G±)q complex. Structure 21, 438-448 (2013). 
8. K. M. Tang et al., Regulator of G-protein signaling-2 mediates vascular smooth 
muscle relaxation and blood pressure. Nat. Med. 12, 1506-1512 (2003). 
9. S. P. Heximer et al., Hypertension and prolonged vasoconstrictor signaling in 
Rgs2-deficient mice. J. Clin. Investig. 111, 1259 (2003). 
264 
 
10. J. Yang et al., Genetic variations of regulator of G-protein signaling 2 in 
hypertensive patients and in the general population. J. Hypertens. 8, 1497-1505 
(2005). 
11. J. Bodenstein, R. K. Sunahara, R. R. Neubig, N-terminal residues control 
proteasomal degradation of Rgs2, Rgs4, and Rgs5 in human embryonic kidney 
293 cells. Mol. Pharmacol. 71, 1040-1050 (2007). 
12. A. Varshavsky, The N-end rule pathway and regulation by proteolysis. Prot. Sci. 
20, 1298-1345 (2011). 
13. C.-S. Hwang, A. Shemorry, A. Varshavsky, N-terminal acetylation of cellular 
proteins creates specific degradation signals. Science 327, 973-977 (2010). 
14. C.-S. Hwang, A. Shemorry, A. Varshavsky, The N-end rule pathway is mediated 
by a complex of the RING-type Ubr1 and HECT-type Ufd4 ubiquitin ligases. Nat. 
Cell Biol. 12, 1177-1185 (2010). 
15. A. Shemorry, C.-S. Hwang, A. Varshavsky, Control of protein quality and 
stoichiometries by N-terminal acetylation and the N-end rule pathway. Mol. Cell 
50, 540-551 (2013). 
16. H.-K. Kim et al., The N-terminal methionine of cellular proteins as a degradation 
signal. Cell 156, 158-169 (2014). 
17. J. M. Kim, C. S. Hwang, Crosstalk between the Arg/N-end and Ac/N-end rule. 
Cell Cycle 13, 1366-1367 (2014). 
18. T. S. Tasaki, S. M. Sriram, K. S. Park, Y. T. Kwon, The N-end rule pathway. 
Annu. Rev. Biochem. 81, 261-289 (2012). 
265 
 
19. D. J. Gibbs, J. Bacardit, A. Bachmair, M. J. Holdsworth, The eukaryotic N-end 
rule pathway: conserved mechanisms and diverse functions. Trends Cell Biol. 24, 
603-611 (2014). 
20. A. Mogk, R. Schmidt, B. Bukau, The N-end rule pathway of regulated 
proteolysis: prokaryotic and eukaryotic strategies. Trends Cell Biol. 17, 165-172 
(2007). 
21. K. K. Starheim, K. Gevaert, T. Arnesen, Protein N-terminal acettyltransferases: 
when the start matters. Trends Biochem. Sci. 37, 152-161 (2012). 
22. P. Van Damme et al., NatF contrutes to an evolutionary shift in protein N-
terminal acetylation and is is important for normal chromosome segregation. 
PLoS Genet. 7, e1002169 (2011). 
23. S. G. Kreft, L. H.-C. Wang, M. Hochstrasser, Membrane topology of the yeast 
endoplasmic reticulum-localized ubiquitin ligase Doa10 and comparison with its 
human ortholog TEB4 (MARCH-VI). J. Biol. Chem. 281, 4646-4653 (2006). 
24. G. Hassink et al., TEB4 is a C4HC3 RING-finger containing ubiquitin ligase of 
the endoplasmic reticulum. Biochem. J. 388, 647-655 (2005). 
25. J. K. Monda et al., Structural conservation of distinctive N-terminal acetylation-
dependent interactions across a family of mammalian NEDD8 ligation enzymes. 
Structure 21, 1-12 (2012). 
26. N. Zelcer et al., The E3 ubiquitin ligase MARCH6 degrades squalene 
monooxygenase and affects 3-hydroxy-3-methyl-glutaryl coenzyme A reductase 
and the cholesterol synthesis pathway. Mol. Cell. Biol. 34, 1262-1270 (2014). 
266 
 
27. F. M. Ausubel et al., Current Protocols in Molecular Biology.,  (Wiley-
Interscience, New York, 2010). 
28. F. Sherman, Getting started with yeast. Meth. Enzymol. 194, 3-21 (1991). 
29. A. Baudin, O. Ozier-Kalogeropolous, A. Denoel, A. Lacroute, C. Cullin, A simple 
and efficient method for direct gene deletion in Saccharomyces cerevisiae. Nucl. 
Ac. Res. 21, 3329-3330 (1993). 
30. C. Janke et al., A versatile toolbox for PCR-based tagging of yeast genes: new 
fluorescent proteins, more markers and promoter substitution cassettes. Yeast 21, 
947-962 (2004). 
31. T. D. Schmittgen, K. J. Livak, Analyzing real-time PCR data by the comparative 
CT method. Nature Protocols 5, 1101-1108 (2008). 
32. M. Johnson, A. T. Coulton, M. A. Geeves, D. P. Mulvihill, Targeted amino-
terminal acetylation of recombinant proteins in E. coli. . PLoS One 5, e15801 
(2010). 
33. J. Cox, M. Mann, MaxQuant enables high peptide identification rates, 
individualized p.p.b.-range mass accuracies and proteome-wide protein 
quantification. Nat. Biotechnol. 26, 1367-1372. 
34. Q. Xiao, F. Zhang, B. A. Nacev, J. O. Liu, D. Pei, Protein N-terminal processing: 
substrate specificity of Escherichia coli and human methionine aminopeptidases. 
Biochemistry 49, 5588-5599 (2010). 
35. F. Eisele, D. H. Wolf, Degradation of misfolded proteins in the cytoplasm by the 
ubiquitin ligase Ubr1. FEBS Lett. 582, 4143-4146 (2008). 
267 
 
36. J. W. Heck, S. K. Cheung, R. Y. Hampton, Cytoplasmic protein quality control 
degradation mediated by parallel actions of the E3 ubiquitin ligases Ubr1 and 
San1. Proc. Natl. Acad. Sci. USA 107, 1106-1111 (2010). 
37. E. Graciet, F. Wellmer, The plant N-end rule pathway: structure and functions. 
Trends Plant Sci. 15, 447-453 (2010). 
38. D. A. Dougan, D. Micevski, K. N. Truscott, The N-end rule pathway: from 
recognition by N-recognins to destruction by AAA+ proteases. Biochim. Biophys. 
Acta 1823, 83-91 (2011). 
39. A. Varshavsky, The N-end rule: functions, mysteries, uses. Proc. Natl. Acad. Sci. 
USA 93, 12142-12149 (1996). 
40. C.-S. Hwang, A. Shemorry, A. Varshavsky, Two proteolytic pathways regulate 
DNA repair by co-targeting the Mgt1 alkylguanine transferase. Proc. Natl. Acad. 
Sci. USA 106, 2142-2147 (2009). 
41. C.-S. Hwang, A. Varshavsky, Regulation of peptide import through 
phosphorylation of Ubr1, the ubiquitin ligase of the N-end rule pathway. Proc. 
Natl. Acad. Sci. USA 105, 19188-19193 (2008). 
42. Z. Xia et al., Substrate-binding sites of UBR1, the ubiquitin ligase of the N-end 
rule pathway. J. Biol. Chem. 283, 24011-24028 (2008). 
43. R.-G. Hu, H. Wang, Z. Xia, A. Varshavsky, The N-end rule pathway is a sensor 
of heme. Proc. Natl. Acad. Sci. USA 105, 76-81 (2008). 
44. R.-G. Hu et al., The N-end rule pathway as a nitric oxide sensor controlling the 
levels of multiple regulators. Nature 437, 981-986 (2005). 
268 
 
45. C.-S. Hwang et al., Ubiquitin ligases of the N-end rule pathway: assessment of 
mutations in UBR1 that cause the Johanson-Blizzard syndrome. PLoS One 6, 
e24925 (2011). 
46. H. Wang, K. I. Piatkov, C. S. Brower, A. Varshavsky, Glutamine-specific N-
terminal amidase, a component of the N-end rule pathway. Mol. Cell 34, 686-695 
(2009). 
47. C. S. Brower, A. Varshavsky, Ablation of arginylation in the mouse N-end rule 
pathway: loss of fat, higher metabolic rate, damaged spermatogenesis, and 
neurological perturbations. PLoS ONE 4, e7757 (2009). 
48. M. Zenker et al., Deficiency of UBR1, a ubiquitin ligase of the N-end rule 
pathway, causes pancreatic dysfunction, malformations and mental retardation 
(Johanson-Blizzard syndrome). Nat. Genet. 37, 1345-1350 (2005). 
49. R. Prasad, S. Kawaguchi, D. T. W. Ng, A nucleus-based quality control 
mechanism for cytosolic proteins. Mol. Biol. Cell 21, 2117-2127 (2010). 
50. S. Kurosaka et al., Arginylation-dependent neural crest cell migration is essential 
for mouse development. PLoS Genet. 6, e1000878 (2010). 
51. F. Zhang, S. Saha, S. A. Shabalina, A. Kashina, Differential arginylation of actin 
isoforms is regulated by coding sequence-dependent degradation. Science 329, 
1534-1537 (2010). 
52. M. J. Lee et al., RGS4 and RGS5 are in vivo substrates of the N-end rule 
pathway. Proc. Natl. Acad. Sci. USA 102, 15030-15035 (2005). 
269 
 
53. K. I. Piatkov, C. S. Brower, A. Varshavsky, The N-end rule pathway counteracts 
cell death by destroying proapoptotic protein fragments. Proc. Natl. Acad. Sci. 
USA 109, E1839-E1847 (2012). 
54. K. I. Piatkov, L. Colnaghi, M. Bekes, A. Varshavsky, T. T. Huang, The auto-
generated fragment of the Usp1 deubiquitylase is a physiological substrate of the 
N-end rule pathway. Mol. Cell 48, 926-933 (2012). 
55. Y. T. Kwon et al., An essential role of N-terminal arginylation in cardiovascular 
development. Science 297, 96-99 (2002). 
56. M. J. Lee et al., Characterization of arginylation branch of the N-end rule pathway 
in G-protein-mediated proliferation and signaling of cardiomyocytes. J. Biol. 
Chem. 287, 24043-24052 (2012). 
57. W. S. Choi et al., Structural basis for the recognition of N-end rule substrates by 
the UBR box of ubiquitin ligases. Nat. Struct. Mol. Biol. 17, 1175-1181 (2010). 
58. E. Matta-Camacho, G. Kozlov, F. F. Li, K. Gehring, Structural basis of substrate 
recognition and specificity in the N-end rule pathway. Nat. Struct. Mol. Biol. 17, 
1182-1188 (2010). 
59. F. Licausi et al., Oxygen sensing in plants is mediated by an N-end rule pathway 
for protein destabilization. Nature 479, 419-422 (2011). 
60. R. Sasidharan, A. Mustroph, Plant oxygen sensing is mediated by the N-end rule 
pathway: a milestone in plant anaerobiosis. Plant Cell 23, 4173-4183 (2011). 
61. D. J. Gibbs et al., Homeostatic response to hypoxia is regulated by the N-end rule 
pathway in plants. Nature 479, 415-418 (2011). 
270 
 
62. H. Rao, F. Uhlmann, K. Nasmyth, A. Varshavsky, Degradation of a cohesin 
subunit by the N-end rule pathway is essential for chromosome stability. Nature 
410, 955-960 (2001). 
63. S. T. Kim et al., The N-end rule proteolytic system in autophagy. Autophagy 9, 
1100-1103 (2013). 
64. G. Zhang, R. K. Lin, Y. T. Kwon, Y. P. Li, Signaling mechanism of tumor cell-
induced up-regulation of E3 ubiquitin ligase UBR2. FASEB J. 27, 2893-2901 
(2013). 
65. T. Tasaki et al., UBR box N-recognin-4 (UBR4), an N-recognin of the N-end rule 
pathway, and its role in yolk sac vascular development and autophagy. Proc. Natl. 
Acad. Sci. USA 110, 3800-3805 (2013). 
66. H. Fujiwara, N. Tanaka, I. Yamashita, K. Kitamura, Essential role of Ubr11, but 
not Ubr1, as an N-end rule ubiquitin ligase in Schizosaccharomyces pombe. Yeast 
30, 1-11 (2013). 
67. K. Kitamura, H. Fujiwara, The type-2 N-end rule peptide recognition activity of 
Ubr11 ubiquitin ligase is required for the expression of peptide transporters. 
FEBS Lett. 587, 214-219 (2013). 
68. J. Y. An et al., UBR2 mediates transcriptional silencing during spermatogenesis 
via histone ubiquitination. Proc. Natl. Acad. Sci. USA 107, 1912-1917 (2010). 
69. J. Y. An et al., UBR2 of the N-end rule pathway is required for chromosome 
stability via histone ubiquitylation in spermatocytes and somatic cells. PLoS One 
7, e37414 (2012). 
271 
 
70. R. Sultana, M. A. Theodoraki, A. J. Caplan, UBR1 promotes protein kinase 
quality control and sensitizes cells to Hsp90 inhibition. Exp. Cell Res. 18, 53-60 
(2012). 
71. P. Lee, M. E. Sowa, S. P. Gygi, J. W. Harper, Alternative ubiquitin 
activation/conjugation cascades interact with N-end rule ubiquitin ligases to 
control degradation of RGS proteins. Mol. Cell 43, 392-405 (2011). 
72. G. Román-Hernández, J. Y. Hou, R. A. Grant, R. T. Sauer, T. A. Baker, The ClpS 
adaptor mediates staged delivery of N-end rule substrates to the AAA+ ClpAP 
protease. Mol. Cell 43, 217-228 (2011). 
73. F. Yang et al., The ubiquitin ligase Ubr2, a recognition E3 component of the N-
end rule pathway, stabilizes Tex.19.1 during spermatogenesis. PLoS One 5, 
e14017 (2010). 
74. R. L. Ninnis, S. K. Spall, G. H. Talbo, K. N. Truscott, D. A. Dougan, 
Modification of PATase by L/F-transferase generates a ClpS-dependent N-end 
rule substrate in Escherichia coli. EMBO J. 28, 1732-1744 (2009). 
75. R. Schmidt, R. Zahn, B. Bukau, A. Mogk, ClpS is the recognition component for 
Escherichia coli substrates of the N-end rule degradation pathway. Mol. 
Microbiol. 72, 506-517 (2009). 
76. T. J. Holman et al., The N-end rule pathway promotes seed germination and 
establishment through removal of ABA sensitivity in Arabidopsis. Proc. Natl. 
Acad. Sci. USA 106, 4549-4554 (2009). 
272 
 
77. H. Cai, M. Hauser, F. Naider, J. M. Becker, Differential regulation and substrate 
preferences in two peptide transporters of Saccharomyces cerevisiae. Eukaryot. 
Cell 6, 1805-1813 (2007). 
78. P. Schnupf, J. Zhou, A. Varshavsky, P. D.A., Listeriolysin O secreted by Listeria 
monocytogenes into the host cell cytosol is degraded by the N-end rule pathway. 
Inflammation & Immunity 75, 5135-5147 (2007). 
79. R.-G. Hu et al., Arginyl-transferase, its specificity, putative substrates, 
bidirectional promoter, and splicing-derived isoforms. J. Biol. Chem., 32559-
32573 (2006). 
80. E. Graciet et al., Aminoacyl-transferases and the N-end rule pathway of 
prokaryotic/eukaryotic specificity in a human pathogen. Proc. Natl. Acad. Sci. 
USA 103, 3078-3083 (2006). 
81. S. Kurosaka et al., Arginylation regulates myofibrils to maintain heart function 
and prevent dilated cardiomyopathy. J. Mol. Cell. Cardiol. 53, 333-341 (2012 ). 
82. J. Wang et al., Arginyltransferase is an ATP-independent self-regulating enzyme 
that forms distinct functional complexes in vivo. Chem. Biol. 18, 121-130 (2011). 
83. M. B. Decca et al., Post-translational arginylation of calreticulin: a new isospecies 
of calreticulin component of stress granules. J. Biol. Chem. 282, 8337-8345 
(2007). 
84. J. W. Tobias, T. E. Shrader, G. Rocap, A. Varshavsky, The N-end rule in bacteria. 
Science 254, 1374-1377 (1991). 
85. G. Boso, T. Tasaki, Y. T. Kwon, N. V. Somia, The N-end rule and retroviral 
infection: no effect on integrase. Virology J. 10, 233 (2013). 
273 
 
86. S. Saha, A. Kashina, Posttranslational arginylation as a global biological 
regulator. Dev. Biol. 358, 1-8 (2011). 
87. C. Belzil et al., A Ca2+-dependent mechanism of neuronal survival mediated by 
the microtubule-associated protein p600. J. Biol. Chem. 288, 24452-24464 
(2013). 
88. K. Yamano, R. J. Youle, PINK1 is degraded through the N-end rule pathway. 
Autophagy 9, 1758-1769 (2013)10.4161/auto.24633). 
89. T. Arnesen et al., Proteomics analyses reveal the evolutionary conservation and 
divergence of N-terminal acetyltransferases from yeast to humans. Proc. Natl. 
Acad. Sci. USA 106, 8157-8162 (2009). 
90. P. Van Damme et al., N-terminal acetylome analyses and functional insights of 
the N-terminal acetyltransferase NatB. Proc. Natl. Acad. Sci. USA 109, 12449-
12454 (2012). 
91. D. J. Gibbs et al., Nitric oxide sensing in plants is mediated by proteolytic control 
of group VII ERF transcription factors. Mol. Cell 53, 369-379 (2014). 
92. F. Licausi, C. Pucciariello, P. Perata, New role for an old rule: N-end rule-
mediated degradation of ethylene responsive factor proteins governs low oxygen 
response in plants. J. Integr. Plant Biol. 55, 31-39 (2013). 
93. D. A. Weits et al., Plant cysteine oxidases control the oxygen-dependent branch of 
the N-end-rule pathway. Nat Commun. 5, 3425 (2014). 
94. M. Gautsch et al., The yeast N-alpha-acetyltransferase NatA is quantitatively 
anchored to the ribosome and interacts with nascent polypeptides. Mol. Cell. Biol. 
23, 7403-7414 (2003). 
274 
 
95. B. Polevoda, S. Brown, T. S. Cardillo, S. Rigby, F. Sherman, Yeast N(alpha)-
terminal acetyltransferases are associated with ribosomes. J. Cell. Biochem. 103, 
492-508 (2008). 
96. B. Polevoda, F. Sherman, N-terminal acetyltransferases and sequence 
requirements for N-terminal acetylation of eukaryotic proteins. J. Mol. Biol. 325, 
595-622 (2003). 
97. A. O. Helbig et al., Profiling of N-acetylated protein termini provides in-depth 
insights into the N-terminal nature of the proteome. Mol Cell Proteom. 9, 928-939 
(2010). 
98. J. R. Mullen et al., Identification and characterization of genes and mutants for an 
N-terminal acetyltransferase from yeast. EMBO J. 8, 2067-2075 (1989). 
99. E. C. Park, J. W. Szostak, ARD1 and NAT1 proteins form a complex that has N-
terminal acetyltransferase activity. EMBO J. 11, 2087-2093 (1992). 
100. S. Goetze et al., Identification and functional characterization of N-terminally 
acetylated proteins in Drosophila melanogaster. PLoS Biol. 7, e1000236 (2009). 
101. T. Arnesen, Toward a functional understanding of protein N-terminal acetylation. 
PLoS Biol. 9, e1001074 (2011). 
102. K. K. Starheim, D. Gromyko, R. Velde, J. E. Varhaug, T. Arnesen, Composition 
and biological significance of the human N-alpha terminal acetyltransferases. 
BMC Proceedings 3 (Suppl 6), S3 (2009). 
103. K. Hole et al., The human N-alpha-acetyltransferase 40 (hNaa40p/hNatD) is 
conserved from yeast and N-terminally acetylates histones H2A and H4. PLoS 
One 6, e24713 (2011). 
275 
 
104. K. Helsens et al., Bioinformatics analysis of a Saccharomyces cerevisiae N-
terminal proteome provides evidence of alternative translation initiation and post-
translational N-terminal acetylation. J. Proteome Res. 10, 3578-3589 (2011). 
105. B. Polevoda, J. Hoskins, F. Sherman, Properties of Nat4, an N-alpha-
acetyltransferase of Saccharomyces cerevisiae that modifues N-termini of 
histones H2A and H4. Mol. Cell. Biol. 29, 2913-2924 (2009). 
106. W. V. Bienvenut et al., Comparative large scale characterization of plant versus 
mammalian proteins reveals similar and idiosyncratic N-±-acetylation features. 
Mol. Cell. Proteomics 111, M111.015131 (2012). 
107. P. Van Damme et al., Proteome-derived peptide libraries allow detailed analysis 
of the substrate specificities of N(alpha)-acetyltransferases and point to hNaa10p 
as the post-translational actin N(alpha)-acetyltransferase. Mol. Cell. Proteomics 
10, M110.004580 (2011). 
108. M. Perrot, A. Massoni, H. Boucherie, Sequence requirements for Nalpha-terminal 
acetylation of yeast proteins by NatA. Yeast 25, 513-527 (2008). 
109. B. Polevoda, T. Arnesen, F. Sherman, A synopsis of eukaryotic N-terminal 
acetyltransferases: nomenclature, subunits and substrates. BMC Proceedings 3, S2 
(2009). 
110. M. Ghislain, R. J. Dohmen, F. Levy, A. Varshavsky, Cdc48p interacts with 
Ufd3p, a WD repeat protein required for ubiquitin-mediated proteolysis in 
Saccharomyces cerevisiae. EMBO. J. 15, 4884-4899 (1996).  
 
 
 
 
APPENDIX 3: 
SUPPLEMENTAL MATERIAL FOR CHAPTER 6 
  
277 
 
Detailed (extended) legend to Fig. 1 of the main text: 
Fig. 1. The mammalian N-end rule pathway and the Ate1 arginyltransferase 
(R-transferase). The main determinant of an N-degron is a destabilizing N-terminal 
residue of a protein. N-terminal residues are indicated by single-letter abbreviations for 
amino acids. A yellow oval denotes the rest of a protein substrate. Recognition 
components of the N-end rule pathway are called N-recognins. In eukaryotes, the N-end 
rule pathway consists of two branches, the Arg/N-end rule pathway (A) and the Ac/N-end 
rule pathway (B) (refs. (1-60) and refs. therein). 
(A) The Arg/N-end rule pathway targets specific unacetylated N-terminal 
residues. In the yeast S. cerevisiae, the Arg/N-end rule pathway is mediated by the Ubr1 
N-recognin, a 225 kDa RING-type E3 Ub ligase and a part of the targeting apparatus 
comprising a complex of the Ubr1-Rad6 and Ufd4-Ubc4/5 holoenzymes (1, 5, 10). In 
multicellular eukaryotes several functionally overlapping E3 Ub ligases (Ubr1, Ubr2, 
Ubr4, and Ubr5) function as N-recognins of this pathway. An N-recognin binds to the 
“primary” destabilizing N-terminal residues Arg, Lys, His, Leu, Phe, Tyr, Trp and Ile. In 
contrast, the N-terminal Asn, Gln, Asp, and Glu residues (as well as Cys, under some 
metabolic conditions) are destabilizing owing to their preliminary enzymatic 
modifications. These modifications include the Nt-deamidation of N-terminal Asn and 
Gln by the Ntan1 and Ntaq1 Nt-amidases, respectively, and the Nt-arginylation of N-
terminal Asp and Glu by the Ate1 R-transferase, which can also Nt-arginylate oxidized 
Cys, either Cys-sulfinate or Cys-sulfonate. These derivatives can form in animal and 
plant cells through oxidation of N-terminal Cys by nitric oxide (NO) and oxygen, and 
also by N-terminal Cys-oxidases (15, 23, 30, 32, 61-64). In addition to its type-1 and 
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type-2 binding sites that recognize, respectively, the basic and bulky hydrophobic 
unacetylated N-terminal residues, an N-recognin such as Ubr1 contains other substrate-
binding sites as well. These sites recognize substrates that are targeted through their 
internal (non-N-terminal) degrons, as indicated on the diagram (1). Hemin (Fe3+-heme) 
binds to the Ate1 R-transferase, inhibits its Nt-arginylation activity and accelerates its in 
vivo degradation. Hemin also binds to Ubr1 and alters its functional properties, in ways 
that remain to be understood (14). As shown in the diagram, the unacetylated Met of the 
N-terminal Met-hydrophobic residue (M$ ) motif was found to be recognized by both 
yeast and mammalian Ubr1, thereby greatly expanding the substrate range of the Arg/N-
end rule pathway (60).  
(B) The Ac/N-end rule pathway. This diagram illustrates the mammalian Ac/N-
end rule pathway through extrapolation from its S. cerevisiae version. Red arrow on the 
left indicates the removal of N-terminal Met by Met-aminopeptidases (MetAPs). N-
terminal Met is retained if a residue at position 2 is nonpermissive (too large) for 
MetAPs. If the retained N-terminal Met or N-terminal Ala, Ser, Thr are followed by 
acetylation-permissive residues, the above N-terminal residues are N±-terminally 
acetylated (Nt-acetylated) by ribosome-associated Nt-acetylases (65-67). Nt-terminal Val 
and Cys are Nt-acetylated relatively rarely, while N-terminal Pro and Gly are almost 
never Nt-acetylated. (N-terminal Gly is often N-myristoylated.) N-degrons and 
N-recognins of the Ac/N-end rule pathway are called Ac/N-degrons and Ac/N-recognins, 
respectively (1). The term “secondary” refers to Nt-acetylation of a destabilizing N-
terminal residue before a protein can be recognized by a cognate Ac/N-recognin. As 
described in the main text, the human Teb4 E3 ubiquitin (Ub) ligase was identified, in the 
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present study, as the first Ac/N-recognin of the previously unexamined mammalian 
Ac/N-end rule pathway. Natural Ac/N-degrons are regulated by their reversible steric 
shielding in protein complexes (60, 68). 
(C) The bidirectional DfaPAte1 promoter upstream of exon 1B of mouse Ate1 (1, 50, 
69).  
(D) Four major mouse Ate1 R-transferase isoforms and their designations (1, 50). 
 
SI EXPERIMENTAL PROCEDURES 
Yeast Two-Hybrid (Y2H) Assays. Two-hybrid (Y2H) assays were carried out using the 
BD Matchmaker kit (BD Biosciences, Palo Alto, CA). Briefly, S. cerevisiae AH109 
(MATa trp1-901 leu2-3, 112 ura3-52 his3-200 gal4•  gal80, LYS2::GAL1UAS-GAL1TATA-
HIS3 GAL2UAS-GAL2TATA-ADE2 URA3::MEL1UAS-MEL1TATA-lacZ, MEL1) was 
transformed with pCB132, which expressed the Gal4DBD-ATE11B7A fusion protein (Table 
S1). The resulting strain (AH109-Ate11B7A) were mated with S. cerevisiae Y187 (MAT± 
ura3-52 his3-200 ade2-101 trp1-90 leu2-3, 112, gal4•  gal80•  met- URA3::GAL1UAS-
GAL1TATA-lacZ MEL1) that had been pre-transformed with a mouse testis cDNA pACT 
library (Clontech). The resulting diploids were incubated on plates with synthetic-
complete (SC) medium containing 5 mM 3-aminotriazole (Sigma) and lacking His, Trp 
and Leu. [Trp+ Leu+ His+ ] isolates (~1.5 × 106 cells) were further assayed for their 
growth on His-lacking, Ade-lacking media, and also for their ² -galactosidase (² gal) 
activity. Colonies that were both [Trp+ Leu+ His+ Ade+] and exhibited ² gal activity were 
then grown in Leu-lacking, Trp-containing media to facilitate the loss of pCB132. The 
pA6 plasmid was recovered from one strongly positive colony (called “A6”). The 
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sequencing of pA6 insert identified full-length mouse Liat1 as a potential Ate11B7A-
binding protein. 
Vector-swapping experiments to verify detected interactions were then carried out 
by excising (using BamHI and SalI) the Ate11B7A open reading frame (ORF) from 
pCB132, and by excising (using NdeI and XhoI) the Liat1 ORF from the pA6 plasmid. 
The Ate11B7A ORF was then subcloned into pACT2 (Table S1) to yield pCB135, the Liat1 
ORF was subcloned into pAS2 to yield pCB239, and two-hybrid assays were repeated as 
described above. 
Additional two-hybrid assays with Liat1 and its derivatives were carried out by 
cotransformation of S. cerevisiae AH109 with plasmids expressing Gal4DBD-Liat1 
(pCB239) and either Gal4AD-Ate11B7B (pCB165) or Gal4AD-Ate11A7A (pCB167), as well 
as with pCB432 (expressing Gal4AD-Liat1) and either pCB164 (expressing Gal4DBD-
Ate11B7B) or pCB166 (expressing Gal4DBD-Ate11A7A). The mapping of Ate1-Liat1 
interactions was carried out by cotransformation of S. cerevisiae AH109 with pCB132 
(expressing Gal4DBD-ATE11B7A) and plasmids that expressed various (indicated in Fig. 
3B) segments of mouse Liat1 fused to the Gal4AD (the plasmids pCB432, pCB433, 
pCB434, pCB435, pCB436, pCB437, pCB438, pCB439, pCER-020, pCER-21, pCER-
022) (Table S1). Positive two-hybrid controls employed plasmids expressing Gal4DBD-
WASP (pCB142) and Gal4AD-Cdc42 (pCB141) (Table S1).  
A separate two-hybrid screen for Liat1-binding proteins was carried out by 
mating S. cerevisiae AH109 (pre-transformed with pCB239 (Table S1)) to S. cerevisiae 
Y187 (pre-transformed with a mouse brain cDNA library (Clontech)), and by carrying 
out two-hybrid assays as described above. 
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In Vitro Arginylation Assay. The N-terminal arginylation (Nt-arginylation) 
assay was performed as described previously (50), with slight modifications. Briefly, the 
untagged mouse Liat1, Ate11A7A, Ate11A7B, Ate11B7A, and Ate11B7B were expressed as 
described below, using the Ub fusion/deubiquitylase-based pH10UE expression system 
(71). The Nt-arginylation reporter X-DHFRbt (X=Asp, Cys or Arg-Cys) was prepared by 
expressing His10-Ub-X-DHFRbt (X = Asp, Cys, or Arg-Cys) using the pH10UE 
expression/purification system and pre-cleaved with the Usp2cc deubiquitylase (71) as 
described above, except that the cleaved reporter protein was not purified further before 
Nt-arginylation assays. For Nt-arginylation, purified Liat1 and specific Ate1 isoforms 
were mixed (as indicated in the main text and the legend to Fig. A3.S5) together with 5.8 
µM 14C-Arg (Perkin Elmer NEC267E050UC; 346 mCi/mmol)), E. coli tRNA (0.6 
mg/ml), E. coli aminoacyl-tRNA synthetases (800 U/ml) (Sigma) in 5 mM ATP, 0.15 M 
KCl, 10 mM MgCl2, 1 mM dithiothreitol (DTT), 50 mM Tris-HCl (pH 8.0), and 
preincubated for 15 min at 37°C. A sample of (deubiquitylase-cleaved) reporter (10 µg) 
was then added, followed by incubation for 60 min at 37°C. Reactions were stopped by 
the addition of a concentrated SDS-sample buffer to the final concentration of 1x and 
heating at 95°C for 3 min, followed by SDS-4-12% PAGE, electroblotting to Immobilon-
P membrane (Millipore, Billerica, MA), and 14C-autoradiography, with quantification 
using PhosphorImager. 
Tissue Extracts and Immunoblotting. Animal care and related procedures were 
carried out according to relevant NIH guidelines, and were approved (Protocol #1328) by 
the Institutional Animal Care and Use Committee, the Office of Laboratory Animal 
Research (OLAR) at the California Institute of Technology. Specific mouse tissues were 
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harvested and lysed in 0.05% NP40, 10% glycerol, 0.15 M NaCl, 2 mM EDTA, 1 mM 
dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), 50 mM HEPES (pH 
7.5) containing freshly dissolved “Complete EDTA-Free Protease Inhibitors” (Roche), 
using the MP FastPrep-24 instrument and Lysing Matrix D (MP Biomedicals), with 2 or 
3 runs at 6.5 m/s for 25 sec each, and with 5-min incubations on ice between the runs. 
The lysates were centrifuged at 10,000g for 20 min at 4°C. The supernatants were 
fractionated by SDS-12.5% PAGE, transferred to Immobilon-P PVDF membranes, and 
analyzed by immunoblotting with a rabbit polyclonal anti-C17orf97 antibody (Sigma; 
HPA023583). Immunoblots were visualized using the Odyssey (Li-Cor) system, with 
donkey anti-rabbit IgG conjugated to an infrared dye (Li-Cor; #926-32213) as secondary 
antibody. 
Construction and Expression of Recombinant Proteins in BL21 (DE3) E. coli. 
Untagged mouse Liat1 and Ate1 cDNAs were amplified by PCR using primers flanked 
by the SacII and HindIII sites. The resulting DNA fragments were subcloned into 
SacII/HindIII-cut pH10UE, yielding the plasmids pCER-006 (Liat1), pCB407(Ate11B7A), 
pCB408 (Ate11B7B), pCB409 (Ate11A7A), and pCB410 (Ate11A7B), which expressed His10-
Ub-tagged fusions of the Ub fusion technique (71) (Table S1). A cDNA encoding the N-
terminally triply ha-tagged mouse Liat1 (3haLiat1) was constructed using a multi-step 
PCR protocol. In particular, Liat1 ORF was amplified from the plasmid pA6 (Table S1). 
The plasmid pCB403, expressing the N-terminally triple ha-tagged mouse Liat1 
(3haLiat1), was constructed by subcloning the above 3haLiat1-encoding DNA fragment 
into SacII/HindIII-cut pH10UE, yielding pCB403 (Table S1).  
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Either 2-liter cultures (for Ate1 production) or 4-liter cultures (for Liat1 
production) of E. coli BL21(DE3) expressing one of the above-cited plasmids were 
grown at 37°C to an A600 of ~0.6 in Luria Broth (LB) containing ampicillin (50 µg/ml). 
The cultures were placed on ice for 45 min, followed by the addition of isopropyl-² 0G0
wklr j dodfwr vlgh (IPTG) to the final concentration of 0.25 mM and incubation, with 
shaking, for 6 hr at room temperature (RT). Cells were harvested by centrifugation at 
2,000g for 10 min at 4°C. Cell pellets were resuspended in either 15 ml or 30 ml of 
phosphate-buffered saline containing 30% glycerol, 0.3 M NaCl, 12 mM imidazole, 20 
mM ² -mercaptoethanol, and lysozyme at 1 mg/ml, followed by freezing in liquid 
nitrogen. Samples were then thawed slowly on ice and centrifuged at 27,000g for 30 min 
at 4°C. N-terminally His10-tagged Ub fusions of specific Ate1 isoforms, of untagged 
Liat1 and of 3haLiat1 in the soluble fraction were purified by Ni-NTA chromatography, 
with elution of resin-bound proteins by 0.3 M imidazole. The resulting samples were 
dialyzed overnight at 4°C against 5% glycerol, 0.3 M NaCl, 2 mM ² -mercaptoethanol, 
and 50 mM Na2HPO4-NaH2PO4 (pH 8.0), containing EDTA-free protease inhibitor 
cocktail (Roche). The N-terminal His10-tagged Ub moiety was then cleaved off by 
incubating dialyzed samples for 1 hr at 37°C with the purified Usp2cc deubiquitylase 
(71) (added at 1:10 molar ratio). The resulting samples were dialyzed against 5% 
glycerol, 0.15 M NaCl, 10 mM ² -mercaptoethanol, 50 mM Tris (pH 7.4), followed by 
purification of (untagged) Ate1 and either Liat1 or 3haLiat1 using Mono-S 
chromatography (Pharmacia Biotech: Id #9723125), with the elution gradient between 
0.15 M and 1 M NaCl in the above buffer. Peak fractions were pooled and dialyzed 
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overnight at 4°C against 30% glycerol 0.15 M NaCl, 10 mM ² -mercaptoethanol, 50 mM 
Tris (pH 7.4). 
Coimmunoprecipitation of Mouse Liat1 and Ate1 Isoforms. As indicated in 
the legend to Fig. 2, mouse Ate1-/- embryonic fibroblasts (EFs) were transfected with 
either pCB245, or pCB246, or pCB247, or pCB248 (expressing specific Ate1 isoforms) 
in the presence or absence of pCB179, expressing mouse 3haLiat1 (Table S1). 
Transfections were carried out using BioT reagent according to the manufacturer’s 
protocol. 48 hrs after transfection, cell extracts were prepared in lysis buffer (10% 
glycerol, 0.5% Triton X-100, 0.15 M NaCl, 40 mM HEPES (pH7.6) containing 
“complete EDTA-free protease inhibitors” (Roche). Centrifugation-clarified extracts 
were incubated with anti HA-EZ View beads (Sigma E6799) for 3 hrs at 4°C, with 
rotation. Beads were then washed 3 times in lysis buffer. Immunoprecipitated proteins 
were eluted in 2xSDS-PAGE sample buffer, followed by SDS-12% PAGE, 
electroblotting of proteins onto PVDF membrane, and the detection of 3haLiat1 and Ate1 
using anti-ha and anti-Ate1, respectively. 
For “carrier-free” coimmunoprecipitation (co-IP) of purified recombinant 3haLiat1 
and Ate1 isoforms, 1 µg of purified Ate1 isoforms were incubated for 1 hr at 4ºC in the 
presence or absence of 2 µg of purified Liat1 (~4-fold molar excess) in 10% glycerol, 
0.5% Triton-X100, 0.15 M NaCl, 40 mM HEPES (pH 7.6) containing “complete EDTA-
free protease inhibitors” (Roche). The mixture was then incubated for one more 1 hr in 
the presence of anti-Ate1 antibody (0.4 µg) and for 3 more hrs in the presence of 10 µl 
(settled bead volume) of Protein A-agarose (Replicon; IAP300; Lot#RN040321). The 
beads were then washed 3 times in the above buffer. The proteins were eluted in 2xSDS-
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PAGE sample buffer and heated at 95ºC for 5 min, followed by SDS-12% PAGE and 
immunoblotting as described above. 
Coimmunoprecipitation assays with Liat1 and putative Liat1 ligands. A 
cDNA encoding the N-terminally triply ha-tagged mouse Liat1 (3haLiat1) was constructed 
as briefly described in a section above. The final ORF, encoding mouse 3haLiat1, was 
subcloned into NheI/XhoI-cut pcDNA3.1 (Invitrogen), yielding pCB179 (Table S1). 
Untagged mouse Ate1 cDNAs were amplified by PCR using primers flanked by the 
BamHI and XhoI sites. The resulting DNA fragments were subcloned into BamHI/XhoI-
cut pcDNA-Neo, yielding the plasmids pCB245 (Ate11B7A), pCB246 (Ate11B7B), pCB247 
(Ate11A7A), and pCB248 (Ate11A7B) (Table S1). DNA fragments (cDNAs) encoding 
mouse Jmjd6 and the 40S ribosomal protein S14 were amplified by PCR from a 
preparation of total RNA (isolated from pooled mouse tissues). DNA encoding a triple-
flag epitope was added to the 3’ end of these cDNAs using a multi-step PCR protocol 
with primers flanked with HindIII and ApaI, followed by subcloning into HindIII/ApaI-
cut pcDNA-Neo, a step that yielded pCB447 (expressing the 40S ribosomal protein S14) 
and pCB458 (expressing Jmjd6). Coimmunoprecipitation assays with 3haLiat1 vis-á-vis 
Jmjd63f and S143f were carried similarly to Liat1-Ate1 co-IPs described above, except 
that mouse EFs were transfected with pCB179 (expressing 3haLiat1) and either pCB447 
(S143f) or pCB458 (Jmjd63f) and proteins were immunoprecipitated from cell extracts 
using magnetic anti-FLAG beads (Sigma), followed by SDS-12% PAGE, and 
immunoblotting with anti-ha and anti-flag. 
GST pulldowns. A cDNA encoding untagged mouse Liat1 cDNA was amplified 
by PCR using primers flanked by EcoRI sites and subcloned into EcoRI-cut pGEX-2t, 
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yielding pCB404 (Table S1). The GST-Liat1 ORF was amplified from pCB404 by PCR 
using primers flanked by NheI and EcoRI sites, and the resulting DNA fragment was 
subcloned into NheI/EcoRI digested pcDNA3.1 (Invitrogen), yielding pCB405 (Table 
S1). For expression of GST alone in mammalian cells, cDNA encoding GST was 
amplified from pGEX-2t using primers flanked by NheI and XhoI sites, and the resulting 
DNA fragment was subcloned into NheI/XhoI-cut pcDNA3.1, yielding pCB406. 
Wild-type mouse embryonic fibroblasts (EFs) were transiently transfected with pCB405 
and pCB406 using BioT (Bioland Scientific) according to the manufacturers protocol. 
Cells were lysed 48 hr after transfection in 10% glycerol, 0.5% Triton-X100, 0.15 M 
NaCl, 40 mM HEPES (pH 7.6) containing “complete EDTA-free protease inhibitors” 
(Roche). Clarified cell lysates were then incubated with Glutathione Superflow Agarose 
(Qiagen) for 3 hrs at 4°C, followed by affinity chromatography in a glutathione-agarose 
mini-column. Proteins retained on the column were washed 3 times in lysis buffer, and 
proteins were eluted in lithium-dodecyl sulfate-PAGE sample buffer, followed by SDS-4-
12% PAGE. Fractionated proteins were silver-stained, and a separate set of the same 
samples was fractionated identically but stained with Coomassie. Specific Coomassie-
stained bands were excised from the gel and proteins in gel slices were analyzed (using 
tryptic digestion and LC-MS/MS) at the Columbia University Protein Core Facility (New 
York, NY). 
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Fig. A3.S1. Mouse Ate1 arginyltransferase (R-transferase), its gene organization 
and its alternative exons. (A) Ate1 exons, including alternative exons (1A/1B and 
7A/7B), with deduced lengths of the corresponding polypeptide segments indicated on 
top. (B) The deduced amino acid sequences of the alternative mouse Ate1 exons 1A (29 
residues) and 1B (36 residues), with identical residues in red and similar residues marked 
by asterisks. (C) Same as in B, but the 43-residue alternative exons 7A and 7B. 
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Fig. A3.S2. Sequelogies (sequence similarities; see Introduction and ref. (70)) among 
the Liat1 domains of different animals. This particularly highly conserved ~30-residue 
region of mouse Liat1, termed the Liat1 domain (it is highlighted in yellow in Figs. 3 and 
4B), is aligned with Liat1 domains of other mammals, two non-mammalian vertebrates, 
and two invertebrates. At every position, a residue that is either identical or non-identical 
to the majority of residues at that position is either in red or in black, respectively. The 
numbers of last residues in each row are indicated on the right. Specific Liat1 proteins: 
Mouse (Mus musculus) (NP_941039). Rat (Rattus norvegicus) (NP_001103625.1). Dog 
(Canis lupus) (XP_537762.4). Rabbit (Oryctolagus cuniculus) (XP_002719100). 
Manatee (Trichechus manatus) (XP_004376319.1). Cow (Bos taurus) (DAA19029). Yak 
(Bos grunniens) (ELR61882). Dolphin (Delphinus capensis) (XP_004312659.1). Whale 
(Balaenoptera musculus) (XP_004267289.1). Rhinoceros (Diceros bicornis) 
(XP_004433508.1). Macaque (Macaca mulatta) (XP_001083490.1). Baboon (Papio 
ursinus) (XP_003912083). Bushbaby (Otolemur garnettii) (XP_003799182). Gibbon 
(Hylobates lar lar) (XP_003280369). Orangutan (Pongo pygmaeus) (XP_002826835). 
Gorilla (Gorilla beringei beringei) (XP_004058251.1). Chimpanzee (Pan trogloditus) 
(XP_001174024). Bonobo (Pan paniscus) (XP_003816870). Human (Homo sapiens) 
(NP_001013694.4). Dove (Columba livia) (EMC80592). Frog (Xenopus tropicalis) 
(XP_004911734). Sea anemone (Nematostella vectensis) (XP_001639507.1). Acorn 
worm (Saccoglossus kowalewskii) (XP_002738466). 
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Fig. A3.S3. Sequence alignment of the full-length mouse and human Liat1 proteins. 
Note that significant sequelogies between mouse and human Liat1 are also present 
outside the nearly identical Liat1 domains (yellow rectangle). The tandem repeats in 
human Liat1 (they are absent in the mouse and other non-primate Liat1 proteins) are 
highlighted by their arrangement in a column. At every position, a residue that is either 
identical or non-identical to a majority-residue in this alignment is either in red or in 
black, respectively. The colors of the negatively charged region (purple), of the positively 
charged region (green), and of the Liat1 domain (yellow) (see also Figs. 4 and S2) are the 
same as in the corresponding regions of mouse Liat1 in Fig. 3A. The numbers of last 
residues in each row are indicated on the right. 
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Fig. A3.S4. Sequence alignment of the full-length mouse (vertebrate) and sea 
anemone (invertebrate) Liat1 proteins. Note the near-absence of sequelogies outside 
the Liat1 domain (in yellow) and the positively charged region (in green). A 10-residue 
sequence of mouse Liat1 that becomes tandemly repeated in Liat1 of primates (see Figs. 
4 and S3) is in blue. The numbers of last residues in each row are indicated on the right. 
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Fig. A3.S5. Purified Liat1 enhances the Ate1-mediated N-terminal arginylation in 
vitro. (A) Lane 1, purified mouse Ate11B7A R-transferase was incubated with Asp-
DHFRbt, a test protein, and with other components of a 14C-Arg-based Nt-arginylation 
system (see the main text and SI Experimental Procedures) followed by SDS-PAGE and 
autoradiography. Lane 2, same as in lane 1 but with Arg-Asp-DHFRbt. Same as in lane 1 
but with Cys-DHFRbt. Lane 4, same as in lane 3 but in the presence of Ate1-lacking 
extract from Ate1-/- EF cells. Lanes 5-8, same as in lanes 1-4, respectively, but with 
purified mouse Ate11B7B R-transferase. Lanes 9-12, same as in lanes 1-4, respectively, but 
with purified mouse Ate11A7A R-transferase. Lanes 13-16, same as in lanes 1-4, 
respectively, but with purified mouse Ate11A7B R-transferase. Relative levels of 
Nt-arginylation of X-DHFRbt are plotted above the autoradiogram. (B) Lane 1, 14C-Arg-
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based Nt-arginylation of lactalbumin (a model Nt-arginylation substrate bearing N-
terminal Glu; see Fig. 1A). Lane 2, same as in lane 1 but in the absence of added 
Ate11B7A R-transferase. (C) Lane 1, same as in A, lane 1 (an independent assay). Lane 2, 
same as in lane 1 but in the presence of a ~4-fold molar excess (relative to Ate1) of the 
purified mouse Liat protein. Lanes 3 and 4, same as in lanes 1 and 2, respectively, but 
with Cys-DHFRbt. Lanes 5-8, same as in lanes 1-4, respectively, but with purified mouse 
Ate11B7B R-transferase. Lanes 9-12, same as in lanes 1-4, respectively, but with purified 
mouse Ate11A7A R-transferase. Lanes 13-16, same as in lanes 1-4, respectively, but with 
purified mouse Ate11A7B R-transferase. Lane 17, same as in lane 2 but no added Ate1 (in 
the presence of Liat1). Lane 18, same as in lane 17, but with Cys-DHFRbt. 
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Fig. A3.S6. Putative Liat1-binding proteins other than Ate1.  
(A) GST-Liat1 pulldown with an extract from mouse EF cells expressing N-terminally 
tagged GST-Liat1, which was selectively retained, together with associated proteins, 
using glutathione-beads. Proteins were detected by silver staining after. Regions of a 
Coomassie-stained counterpart of the silver-stained gel shown here (lane 2) containing 
proteins co-isolated with GST-Liat1 were cut out (see SI Experimental Procedures) and 
analyzed using trypsin digestion and mass spectrometry (MS-MS). An indicated Liat1-
binding large protein (>>250 kDa) could not be identified. (B) Coimmunoprecipitation of 
mouse 3haLiat1 (lane 1) with mouse Jmjd63f and the ribosomal protein S143f (see the main 
text). IP (in red), immunoprecipitation (with anti-flag). IB, immunoblotting (with anti-
flag and anti-ha). (C) Putative Liat1-binding proteins (besides the independently 
characterized Ate1, in red) that have been identified through a separate Y2H screen using 
mouse Liat1 and mouse brain cDNA library. Five Liat1 ligands identified using GST-
pulldowns (panel A) are cited last (before Jmjd6). 
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Table S1. Plasmids used in this study. 
Plasmid Description Source or Reference 
pcDNA3.0-Neo Amp
R; NeoR; Expression vector for 
cloning a gene of interest. 
Invitrogen 
pcDNA3.1-Hyg AmpR; HygR; Expression vector for 
cloning a gene of interest. 
Invitrogen 
pACT2 AmpR; LEU2 selectable marker in yeast.  
Yeast two-hybrid expression vector with 
PADH1 promoter. Produces ha-tagged Gal4 
Activation Domain (AD) fusion. 
Clontech 
pAS2 AmpR; (also called pAS1-CYH2); CYH 
selectable marker in yeast. Yeast two-
hybrid expression vector with PADH1 
promoter. Produces ha-tagged Gal4 DNA 
binding domain (DBD) fusion. 
Clontech 
pGEX-2t AmpR; Bacterial expression vector for 
expression of fusion proteins containing an 
N-terminal glutathione S-transferase 
(GST) moiety. 
GE Healthcare Life 
Sciences 
pH10UE AmpR; Bacterial expression vector for 
expression of fusion proteins containing an 
N-terminal His10-ubiquitin moiety. 
(1) 
pA6 AmpR; pACT2-based plasmid encoding 
Gal4-activation domain (AD) fused to 
mouse 3haLiat1 under the control of the 
yeast PADH1 promoter. 
This study 
pCB132 AmpR; pAS2-based plasmid encoding 
Gal4-DNA-binding domain (DBD) fused 
to mouse haAte11B7A under the control of 
the yeast PADH1 promoter. 
This study 
pCB135 AmpR; pACT2-based plasmid encoding 
Gal4-activation domain (AD) fused to 
haAte11B7A under the control of the yeast 
PADH1 promoter. 
This study 
pCB141   AmpR; pACT2-based plasmid encoding 
Gal4-activation domain (AD) fused to 
Cdc42 under the control of the yeast PADH1 
promoter. 
This study 
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pCB142 AmpR; pAS2-based plasmid encoding 
Gal4-DNA-binding domain (DBD) fused 
to WASP under the control of the yeast 
PADH1 promoter. 
This study 
pCB164 AmpR; pAS2-based plasmid encoding 
Gal4-DNA-binding domain (DBD) fused 
to haATE11B7B under the control of the 
yeast PADH1 promoter. 
This study 
pCB165 AmpR; pACT2-based plasmid encoding 
Gal4-activation domain (AD) fused to 
haATE11B7B under the control of the yeast 
PADH1 promoter. 
This study 
pCB166 AmpR; pAS2-based plasmid encoding 
Gal4-DNA-binding (DBD) domain fused 
to haATE11A7A under the control of the 
yeast PADH1 promoter. 
This study 
pCB167 AmpR; pACT2-based plasmid encoding 
Gal4-activation domain (AD) fused to 
haATE11A7A under the control of the yeast 
PADH1 promoter. 
This study 
pCB179 AmpR; pcDNA3.1-based plasmid encoding 
mouse 3haLiat1 under the control of the 
mammalian PCMV promoter 
This study 
pCB239 AmpR; pAS2-based plasmid encoding 
Gal4-DNA-binding (DBD) domain fused 
to 3haLiat1 under the control of the yeast 
PADH1 promoter. 
This study 
pCB245 AmpR; pcDNA-Neo-based plasmid 
encoding mouse Ate11B7A (untagged) 
under the control of the mammalian PCMV 
promoter. 
This study 
pCB246 AmpR; pcDNA-Neo-based plasmid 
encoding mouse Ate11B7B (untagged) 
under the control of the mammalian PCMV 
promoter. 
This study 
pCB247 AmpR; pcDNA-Neo-based plasmid 
encoding mouse Ate11A7A (untagged) 
under the control of the mammalian PCMV 
promoter. 
This study 
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pCB248 AmpR; pcDNANeo-based plasmid 
encoding mouse Ate11A7B (untagged) 
under the control of the mammalian PCMV 
promoter. 
This study 
pCB403 AmpR; pH10UE-based vector used for the 
bacterial expression of a fusion between 
His10-ubiquitin and 3haLiat1. 
This study 
pCB404 AmpR; Bacterial expression vector for 
expression of GST-Liat1. 
This study 
pCB405 AmpR; pcDNA3.1-based plasmid encoding 
GST-Liat1 under the control of the 
mammalian PCMV promoter. 
This study 
pCB406 AmpR; pcDNA3.1-based plasmid encoding 
GST under the control of the mammalian 
PCMV promoter. 
This study 
pCB407 
 
 
pCB408 
AmpR; pH10UE-based vector used for the 
bacterial expression of a fusion between 
His10-ubiquitin and Ate11B7A. 
AmpR; pH10UE-based vector used for the 
bacterial expression of a fusion between 
His10-ubiquitin and Ate11B7B. 
This study 
 
 
This study 
pCB409 
 
AmpR; pH10UE-based vector used for the 
bacterial expression of a fusion between 
His10-ubiquitin and Ate11A7A. 
This study 
pCB410 AmpR; pH10UE-based vector used for the 
bacterial expression of a fusion between 
His10-ubiquitin and Ate11A7B. 
This study 
pCB432 AmpR; pACT2-based plasmid encoding 
Gal4-activation domain (AD) fused to 
haLiat1(1-228) under the control of the yeast 
PADH1 promoter. 
This study 
pCB433 AmpR; pACT2-based plasmid encoding 
Gal4-activation domain (AD) fused to 
haLiat1(61-228) under the control of the yeast 
PADH1 promoter. 
This study 
pCB434 AmpR; pACT2-based plasmid encoding 
Gal4-activation domain (AD) fused to 
haLiat1(113-228) under the control of the yeast 
PADH1 promoter. 
This study 
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pCB435 AmpR; pACT2-based plasmid encoding 
Gal4-activation domain (AD) fused to 
haLiat1(135-228) under the control of the yeast 
PADH1 promoter. 
This study 
pCB436 AmpR; pACT2-based plasmid encoding 
Gal4-activation domain (AD) fused to 
3haLiat1(135-165) under the control of the 
yeast PADH1 promoter.  
This study 
pCB437 AmpR; pACT2-based plasmid encoding 
Gal4-activation domain (AD) fused to 
HAmLiat1(1-165) under the control of the 
yeast PADH1 promoter. 
 
This study 
pCB438 AmpR; pACT2-based plasmid encoding 
Gal4-activation domain (AD) fused to 
haLiat1(• 135-165) under the control of the 
yeast PADH1 promoter. 
This study 
pCB439 AmpR; pACT2-based plasmid encoding 
Gal4-activation domain (AD) fused to 
haLiat1(95-228) under the control of the yeast 
PADH1 promoter. 
This study 
pCB447 AmpR; pcDNA-Neo-based plasmid 
encoding 40S ribosomal protein S143f 
under the control of the mammalian PCMV 
promoter. 
This study 
pCB458 AmpR; pcDNA-Neo-based plasmid 
encoding Jmjd63f under the control of the 
mammalian PCMV promoter. 
This study 
pCER006 AmpR; pH10UE-based vector used for the 
bacterial expression of a fusion between 
His10-ubiquitin and mouse Liat1.  
This study 
pCER019 AmpR; pACT2-based plasmid encoding 
Gal4-activation domain (AD) fused to 
haLiat1(• 1-117) under the control of the yeast 
PADH1 promoter. 
This study 
pCER020 AmpR; pACT2-based plasmid encoding 
Gal4-activation domain (AD) fused to 
haLiat1(• 1-124) under the control of the yeast 
PADH1 promoter. 
This study 
pCER021 AmpR; pACT2-based plasmid encoding 
Gal4-activation domain (AD) fused to 
This study 
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haLiat1(113-165) under the control of the yeast 
PADH1 promoter. 
pCER022 AmpR; pACT2-based plasmid encoding 
Gal4-activation domain (AD) fused to 
haLiat1(• 153-228) under the control of the 
yeast PADH1 promoter. 
This study 
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